sbbp_Current Folio_6K

0001558370-17-008889.txt : 20171114 0001558370-17-008889.hdr.sgml : 20171114 20171114081317 ACCESSION NUMBER: 0001558370-17-008889 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 68 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171114 DATE AS OF CHANGE: 20171114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Strongbridge Biopharma plc CENTRAL INDEX KEY: 0001634432 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981130690 STATE OF INCORPORATION: L2 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37569 FILM NUMBER: 171198415 BUSINESS ADDRESS: STREET 1: 900 NORTHBROOK DRIVE, SUITE 200 CITY: TREVOSE STATE: PA ZIP: 19053 BUSINESS PHONE: (610) 254-9200 MAIL ADDRESS: STREET 1: 900 NORTHBROOK DRIVE, SUITE 200 CITY: TREVOSE STATE: PA ZIP: 19053 FORMER COMPANY: FORMER CONFORMED NAME: Cortendo AB DATE OF NAME CHANGE: 20150219 6-K 1 sbbp-20170930x6k.htm 6-K sbbp_Current Folio_6K_10Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For the month of November 2017

Commission file number 001-37569

Strongbridge Biopharma plc

(Exact name of Registrant as specified in its charter)

900 Northbrook Drive

Suite 200

Trevose, PA 19053

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Introduction

As used herein, “Strongbridge Biopharma”, the “Company” and “we”, “our” or “us” refer to Strongbridge Biopharma plc and its consolidated subsidiaries, unless the context requires otherwise.

Strongbridge Biopharma plc’s unaudited consolidated financial statements contained in this Report on Form 6-K are presented in United States dollars (“$”) and are prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”).

Cautionary Statement Regarding Forward-Looking Statements

This Report on Form 6-K contains forward‑looking statements that involve substantial risks and uncertainties. The forward‑looking statements are contained principally in the sections of this Report on Form 6-K titled “Business,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” All statements, other than statements of historical facts, contained in this Report on Form 6-K, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, size of market or patient population, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and anticipated products, are forward‑looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward‑looking statements. Forward-looking statements can be identified by words such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “potential,” “predict,” “project,” “positioned,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or other similar expressions, although not all forward‑looking statements contain these identifying words. Forward‑looking statements are based on our current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management’s beliefs and assumptions. They are not guarantees of future results, performance or developments and are subject to known and unknown risks, uncertainties and other factors. Factors that may cause our actual results or developments to differ materially from the expectations contained in the forward-looking statements include, but are not limited to:

our ability to successfully commercialize Keveyis® (dichlorphenamide) and any other product candidates we receive approval for;

the timing, progress and results of clinical and preclinical trials for our product candidates;

our ability to obtain and maintain regulatory approval for our product candidates;

our ability to secure additional financing when needed on acceptable terms;

our ability to effectively manage our anticipated growth;

our ability to develop our commercial organization and recruit and retain qualified sales representatives;

our ability to successfully implement our business model, as well as strategic plans for our business, product candidates and technology;

our ability to implement and execute our business strategy to in‑license, acquire and develop new product candidates;

our ability to retain our key personnel and our ability to recruit, retain and motivate additional qualified personnel;

our ability to develop and maintain relationships with manufacturers, clinical research organizations and other important contractors and consultants;

potential product liability claims and our ability to obtain adequate insurance;

our ability to expand, protect and enforce our intellectual property rights;

our ability to obtain and maintain orphan drug exclusivity for Keveyis or our product candidates; and

the impact of government laws and regulations in the United States and foreign countries.

Actual results could differ materially from the plans, intentions and expectations disclosed in the forward‑looking statements we make. As a result, any or all of our forward‑looking statements in this Report on Form 6-K may turn out to be inaccurate. We have included important factors in the cautionary statements included in this Report on Form 6-K and the reports we file from time to time with the U.S. Securities and Exchange Commission, including our annual report on Form 20-F, that we believe could cause actual results or events to differ materially from the forward‑looking statements that we make. We may not actually achieve the plans, intentions or expectations disclosed in our forward‑looking statements, and you should not place undue reliance on our forward‑looking statements. Moreover, we operate in a highly competitive and rapidly changing environment in which new risks often emerge. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward‑looking statements we may make. Our forward‑looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. Any forward-looking statement made by us in this report is based only on information currently available to us and speaks only as of the date of this report. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made by us, from time to time, whether as a result of new information, future developments or otherwise.

Business

We are a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs.

Our first commercial product is Keveyis® (dichlorphenamide), the first and only treatment approved by the U.S. Food and Drug Administration (“FDA”) for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (“PPP”). Keveyis has orphan drug exclusivity status in the United States through August 7, 2022. Since acquiring the U.S. marketing rights for Keveyis in December 2016, we have established sales, marketing, market access and patient service capabilities. We believe, based on our market research, that there are approximately 4,000 to 5,000 patients in the United States diagnosed with PPP. In April 2017, we launched and recorded our initial sales of Keveyis.

In addition to this neuromuscular disease product, we have two clinical-stage product candidates for rare endocrine diseases, Recorlev™ and veldoreotide. Recorlev (levoketoconazole) is a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome. Veldoreotide is a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both Recorlev and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency (“EMA”).

Given the well-identified and concentrated prescriber base addressing our target markets, we intend to use a small, focused sales force to effectively market Keveyis and our other products and product candidates, if approved, in the United States, the European Union and other key global markets. We believe that our ability to execute on this strategy is enhanced by the significant commercial and clinical development experience of key members of our management team. We will continue to identify and evaluate the potential acquisition of other products and product candidates that would be complementary to our existing rare neuromuscular and endocrine franchises or that would form the basis for new rare disease franchises. We believe this approach will enable us to maximize our commercial potential by further leveraging our existing resources and expertise.

Recent Developments

On October 6, 2017, we sold 4,000,000 ordinary shares in a public offering at a price to the public of $6.25 per ordinary share for net proceeds of approximately $23.4 million, after deducting underwriting discounts and commissions and offering expenses payable by us.

STRONGBRIDGE BIOPHARMA plc

Consolidated Balance Sheets

(In thousands, except share and per share data)

(unaudited)


	September 30,		December 31,
	2017		2016
ASSETS
Current assets:
Cash and cash equivalents	$	44,366	$	66,837
Accounts receivable		979		—
Inventory		1,003		—
Prepaid expenses and other current assets		1,687		764
Total current assets		48,035		67,601
Property and equipment, net		17		25
Deferred tax asset		—		1,599
Intangible assets, net		36,410		60,900
Goodwill		7,256		7,256
Other assets		387		150
Total assets	$	92,105	$	137,531
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
Current liabilities:
Accounts payable	$	1,422	$	1,089
Accrued liabilities		8,793		14,868
Total current liabilities		10,215		15,957
Long-term debt		37,195		18,434
Warrant liability		39,284		11,090
Supply agreement liability, noncurrent		25,063		25,078
Total liabilities		111,757		70,559
Commitments and contingencies (Note 8)
Stockholders’ (deficit) equity:
Deferred shares, $1.098 par value, 40,000 shares authorized, issued and outstanding at September 30, 2017 and December 31, 2016		44		44
Ordinary shares, $0.01 par value, 600,000,000 shares authorized at September 30, 2017 and December 31, 2016; 35,812,344 and 35,335,026 shares issued and outstanding at September 30, 2017 and December 31, 2016		358		353
Additional paid-in capital		204,081		195,975
Accumulated deficit		(224,135)		(129,400)
Total stockholders’ (deficit) equity		(19,652)		66,972
Total liabilities and stockholders’ (deficit) equity	$	92,105	$	137,531

The accompanying notes are an integral part of these unaudited consolidated financial statements.

STRONGBRIDGE BIOPHARMA plc

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

(unaudited)


	Three Months Ended				Nine Months Ended
	September 30				September 30
	2017		2016		2017		2016
Revenues:
Net product sales	$	2,533	$	—	$	4,062	$	—
Total revenues		2,533		—		4,062		—

Cost and expenses:
Cost of sales (excluding amortization of intangible asset)	$	591	$	—	$	968	$	—
Selling, general and administrative		8,484		3,117		26,068		11,260
Research and development		4,504		4,516		12,113		15,882
Amortization of intangible asset		1,256		—		3,767		—
Impairment of intangible asset		20,723		—		20,723		5,228
Total cost and expenses		35,558		7,633		63,639		32,370
Operating loss		(33,025)		(7,633)		(59,577)		(32,370)
Other income (expense), net:
Unrealized gain (loss) on fair value of warrants		1,953		—		(28,194)		—
Interest expense		(1,364)		—		(2,838)		—
Foreign exchange loss		(11)		(20)		(36)		(64)
Loss on early extinguishment of debt		(3,545)		—		(3,545)		—
Other income (expense), net		82		35		107		(1,211)
Total other income (expense), net		(2,885)		15		(34,506)		(1,275)
Loss before income taxes		(35,910)		(7,618)		(94,083)		(33,645)
Income tax (expense) benefit		850		—		(652)		926
Net loss		(35,060)		(7,618)		(94,735)		(32,719)
Net loss attributable to non-controlling interest		—		17		—		122
Net loss attributable to Strongbridge Biopharma	$	(35,060)	$	(7,601)	$	(94,735)	$	(32,597)

Net loss attributable to ordinary shareholders:
Basic and diluted	$	(35,060)	$	(7,601)	$	(94,735)	$	(32,597)
Net loss per share attributable to ordinary shareholders:
Basic and diluted	$	(0.98)	$	(0.36)	$	(2.67)	$	(1.54)
Weighted-average shares used in computing net loss per share attributable to ordinary shareholders:
Basic and diluted		35,716,247		21,205,382		35,463,496		21,205,382

The accompanying notes are an integral part of these unaudited consolidated financial statements.

STRONGBRIDGE BIOPHARMA plc

Consolidated Statement of Stockholders’ (Deficit) Equity

(In thousands, except share amounts)

(unaudited)


							Additional				Total
	Ordinary Shares			Deferred Shares			Paid-In		Accumulated		Shareholders’
	Shares	Amount		Shares	Amount		Capital		Deficit		Equity
Balance—December 31, 2016	35,335,026	$	353	40,000	$	44	$	195,975	$	(129,400)	$	66,972
Net loss	—		—	—		—		—		(94,735)		(94,735)
Stock-based compensation	—		—	—		—		3,864		—		3,864
Issuance of shares, net of offering costs	429,799		4	—		—		2,977		—		2,981
Issuance of shares in connection with at-the-market facility, net of costs	10,300		*	—		—		73		—		73
Exercise of warrants	37,219		1	—		—		*		—		1
Issuance of warrants related to loan agreement, net	—		—	—		—		1,192		—		1,192
Balance—September 30, 2017	35,812,344	$	358	40,000	$	44	$	204,081	$	(224,135)	$	(19,652)

* Represents an amount less than $1.

The accompanying notes are an integral part of these unaudited consolidated financial statements.

STRONGBRIDGE BIOPHARMA plc

Consolidated Statements of Cash Flow

(In thousands)

(unaudited)


	Nine Months Ended
	September 30,
	2017		2016
Cash flows from operating activities:
Net loss	$	(94,735)	$	(32,719)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liability		28,194		—
Impairment of intangible asset		20,723		5,228
Stock-based compensation		3,864		3,521
Amortization of intangible asset		3,767		—
Loss on early extinguishment of debt		3,545		—
Interest paid in kind		408		—
Amortization of debt discounts and debt issuance costs		371		—
Deferred income tax expense (benefit)		804		(926)
Depreciation		8		8
Impairment/loss on investment in Antisense Therapeutics		—		550
Changes in operating assets and liabilities:
Accounts receivable		(979)		—
Inventory		(1,003)		—
Prepaid expenses and other current assets		(923)		(97)
Other assets		(237)		931
Accounts payable		333		(1,781)
Accrued liabilities and other liabilities		1,410		543
Net cash used in operating activities		(34,450)		(24,742)
Cash flows from investing activities:
Payment for acquisition		(7,500)		—
Net cash used in investing activities		(7,500)		—
Cash flows from financing activities:
Proceeds from long-term debt		38,686		—
Payment of long-term debt		(22,261)		—
Proceeds from issuance of ordinary shares		2,981		—
Proceeds from issuance of ordinary shares in connection with at-the-market offering		73		—
Acquisition of non-controlling interest		—		(1,412)
Net cash provided by (used in) financing activities		19,479		(1,412)
Net decrease in cash and cash equivalents		(22,471)		(26,154)
Cash and cash equivalents—beginning of period		66,837		51,623
Cash and cash equivalents—end of period	$	44,366	$	25,469
Supplemental disclosures of cash flow information
Cash paid during the year for:
Interest	$	2,059	$	—
Income taxes other, net of refunds	$	255	$	—

The accompanying notes are an integral part of these unaudited consolidated financial statements.

STRONGBRIDGE BIOPHARMA plc

Notes to Unaudited Consolidated Financial Statements

1. Organization

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Our first commercial product is Keveyis® (dichlorphenamide), the first and only treatment approved by the U.S. Food and Drug Administration ("FDA") for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Keveyis has orphan drug exclusivity status in the United States through August 7, 2022. In addition to this neuromuscular disease product, we have two clinical-stage product candidates for rare endocrine diseases, Recorlev™ and veldoreotide. Recorlev (levoketoconazole) is a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome. Veldoreotide is a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both Recorlev and veldoreotide have received orphan designation from the FDA and the European Medicines Agency ("EMA").

Liquidity

As of September 30, 2017, we held cash and cash equivalents of $44.4 million.

On April 28, 2017, we entered into an equity distribution agreement with JMP Securities LLC (“JMP”), pursuant to which we may sell, at our option, from time to time, up to an aggregate of $40 million in ordinary shares of the Company through JMP, as the sales agent (the “ATM Facility”).

On July 14, 2017, we entered into a $50 million senior credit facility with CRG LP (“CRG”), a healthcare-focused investment firm, to retire our prior credit facility with Oxford Finance LLC and Horizon Technology Finance Corporation and provide additional capital to us. We initially borrowed $40 million under the term loan agreement and have the option to borrow an additional $10 million based upon the achievement of a certain revenue milestone on or prior to June 30, 2018. Concurrent with the initial borrowing, CRG purchased $3 million of our ordinary shares at a price of $6.98 per share. The loan and security agreement contains financial and non-financial covenants including minimum amounts of net revenue we must achieve in 2017 and beyond. Failure to comply with the covenants could result in the lenders declaring the loan immediately due and payable. Our liquidity requirements are predicated on maintaining compliance with the debt covenants and repaying outstanding borrowings in accordance with the loan agreement.

requirements will also increase to the extent we pursue potential in-licenses, acquisitions or similar transactions as part of our strategy. These expenses may be offset only in part by sales of Keveyis. To the extent our sales of Keveyis are less than we anticipate, or our expenses are higher than we anticipate, we may be required to fund our operations and capital needs through additional equity or debt financings. There can be no assurances, however, that additional funding will be available on terms acceptable to us.

2. Summary of significant accounting policies and basis of presentation

Basis of presentation

These unaudited consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (U.S. GAAP). The unaudited consolidated financial statements reflect all adjustments, which include only normal recurring adjustments that are, in the opinion of management, necessary to present a fair statement of the operating results and financial position for the periods presented.

The preparation of the unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures in the consolidated financial statements. Actual results could differ from those estimates.

These unaudited consolidated financial statements should be read in conjunction with the accounting policies and notes to the audited consolidated financial statements included in our 2016 Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2017. Operating results for the nine months ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.

Revenue recognition

Prior to the April 2017 launch of Keveyis, we did not generate any revenue. Therefore, we adopted Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers, effective April 1, 2017. Topic 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We apply the five-step model to contracts only when it is probable that we will collect the consideration we are entitled to receive in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For a complete discussion of accounting for net product revenue, see Note 3, "Revenue Recognition".

Inventory

Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Our inventory consists of only finished goods.

Foreign currency translation

these transactions are remeasured into our functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded in foreign exchange loss in our consolidated statements of operations.

Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. We must apply significant judgment in this process. Actual results could materially differ from those estimates.

Net loss per share

Basic net loss per share is calculated by dividing the net loss attributable to shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted net loss per share is calculated by dividing the net loss attributable to shareholders by the weighted‑average number of ordinary shares outstanding for the period, including any dilutive effect from outstanding stock options or other equity-based awards. Shares used in the diluted net loss per share calculations exclude anti‑dilutive ordinary share equivalents, which currently consist of outstanding stock options, unvested restricted stock units and warrants.

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of September 30, 2017 and 2016, as they would be anti-dilutive:


	Nine Months Ended
	September 30,
	2017		2016
Warrants		7,764,569		—
Stock options issued and outstanding		6,176,647		3,264,927
Unvested restricted stock units		274,250		170,000

Recent accounting pronouncements

In January 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-04, Intangibles - Goodwill and Other: Simplifying the Accounting for Goodwill Impairment. ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. This standard, which will be effective for the us beginning in the first quarter of fiscal year 2021, is required to be applied prospectively. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact this standard will have on our financial statements.

In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments, which clarifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows in order to reduce diversity in practice. The guidance is effective for us beginning in the first quarter of fiscal year 2018. Early adoption is permitted. We are currently evaluating the impact of adopting this guidance on its consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Improvements to Employee Share-Based Payment Accounting, which affects all entities that issue share-based payment awards to their employees. The amendments in this ASU cover such areas as the recognition of excess tax benefits and deficiencies, the classification of those excess tax benefits on the statement of cash flows, an accounting policy election for forfeitures, the amount an employer can withhold to cover income taxes and still qualify for equity classification and the classification of those taxes paid on the statement of cash flows. This ASU is effective for annual and interim periods beginning after December 15, 2016. This guidance can be applied either prospectively, retrospectively or using a modified retrospective transition method. Early adoption is permitted. We have adopted the standard effective January 1, 2017 and have elected

to account for forfeitures as they occur as opposed to estimating forfeitures. The adoption of this standard did not have a material impact on our financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, that discusses how an entity should account for lease assets and lease liabilities. The guidance specifies that an entity who is a lessee under lease agreements should recognize lease assets and lease liabilities for those leases classified as operating leases under previous FASB guidance. Accounting for leases by lessors is largely unchanged under the new guidance. The guidance is effective for the us beginning in the first quarter of fiscal year 2019. Early adoption is permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. We are currently evaluating the impact of adopting this guidance on our consolidated financial statements.

In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, that modifies certain aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The accounting standard update is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, and early adoption is permitted. We are currently assessing the impact that adopting this new accounting guidance will have on our consolidated financial statements.

In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU No. 2015-11 applies only to inventory for which cost is determined by methods other than last in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. We adopted this standard on April 1, 2017. The adoption of this standard had no impact on the Company’s consolidated financial statements, there was no accounting impact to previously issued financial statements based on our adoption.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The new guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. We adopted this new standard on April 1, 2017 in conjunction with the launch of Keveyis. As we did not record revenue prior to adopting this standard, there was no accounting impact to previously issued financial statements based on our adoption of ASC Topic 606.

3. Revenue recognition

Product Revenue, Net

We sell Keveyis to one specialty pharmacy provider (the “Customer”), who is the exclusive distributor of Keveyis in the United States. The Customer subsequently resells Keveyis to patients, which are covered by payors that may provide for government-mandated or privately negotiated rebates with respect to the purchase of Keveyis.

Revenues from sales of Keveyis are recognized when we satisfy a performance obligation by transferring control of Keveyis to the Customer. Transfer of control occurs upon receipt of Keveyis by the Customer. We expense incremental costs related to the set-up of the contract with the Customer when incurred, as these costs did not meet the criteria for capitalization.

Reserves for Variable Consideration

Revenues from sales of Keveyis are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from rebates, co-pay assistance and other allowances that are offered between us and the patients’ payors. There is no variable consideration reserve for returns as

we do not accept returns of Keveyis. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than the Customer). Where appropriate, these estimates may take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. We reassess our estimates on an ongoing basis. If actual results in the future vary from our estimates, we will adjust our estimates. Any such adjustments would affect net product revenue and earnings in the period such variances become known.

Trade Discount: We provide the Customer with a discount that is explicitly stated in our contract and is recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from the Customer. To the extent, the services received are distinct from our sale of Keveyis to the Customer, these payments are classified in selling, general and administrative expenses in our consolidated statement of operations and comprehensive loss.

Funded Co-pay Assistance Program: We contract with a third-party to manage the co-pay assistance program intended to provide financial assistance to qualified insured patients. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that we expect to receive associated with Keveyis that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. These payments are consideration payable to the customer and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet.

Government Rebates: We are subject to discount obligations under state Medicaid programs and Medicare. We estimate our Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated patient mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet. For Medicaid, accruals are based on estimates of future Medicaid beneficiary utilization applied to the Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. Effective January 1, 2011, manufacturers of pharmaceutical products are responsible for 50% of the patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap. In order to estimate the cost to us of this Medicare coverage gap responsibility, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program. Our liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for Keveyis that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.

Temporary Supply and Patient Assistance Programs: We provide free Keveyis to uninsured patients who satisfy pre-established criteria for either the Temporary Supply Program or the Patient Assistance Program. Patients who meet the Temporary Supply Program eligibility criteria may receive a temporary supply of free Keveyis for no more than sixty days while we are determining the patient’s third-party insurance, prescription drug benefit or other third-party coverage for Keveyis. The Patient Assistance Program provides free Keveyis for up to twelve months to patients that satisfy pre-established criteria for financial need. We do not recognize any revenue related to these free products and the associated costs are classified in selling, general and administrative expenses in our consolidated statements of operations and comprehensive loss.

4. Fair value measurement

We follow FASB accounting guidance on fair value measurements for financial assets and liabilities measured on a recurring basis. Because of their short-term nature, the amounts reported in the balance sheet for cash and cash equivalents, and accounts payable approximate fair value.

The guidance requires fair value measurements to maximize the use of “observable inputs.” The three-level hierarchy of inputs to measure fair value are as follows:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Because of their short-term nature, the amounts reported in the balance sheet for cash and cash equivalents, and accounts payable approximate fair value.

Level 2: Significant observable inputs other than Level 1 prices such as quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). The fair values of the outstanding warrants were measured using the Black-Scholes option-pricing model. Inputs used to determine estimated fair value of the warrant liabilities include the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends and the expected volatility of the underlying stock. The significant unobservable inputs used in the fair value measurement of the warrant liabilities were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement.

The following table presents our assets and liabilities that are measured at fair value on a recurring basis for the periods presented (in thousands):


	As of September 30, 2017
	Level I		Level II		Level III		Total
Cash equivalents		43,756		—		—		43,756
Total assets	$	43,756	$	—	$	—	$	43,756
Warrant liability		—		—		39,284		39,284
Total liabilities	$	—	$	—	$	39,284	$	39,284


	As of December 31, 2016
	Level I		Level II		Level III		Total
Warrant liability		—		—		11,090		11,090
Total liabilities	$	—	$	—	$	11,090	$	11,090

5. Intangible assets and goodwill

The gross carrying amount of in‑process research and development (IPR&D), acquired developed product rights and goodwill is as follows (in thousands):


	As of September 30, 2017
	Beginning of Period		Additions		Amortization/Impairment		End of Period
IPR&D	$	20,723	$	—	$	(20,723)	$	—
Acquired developed product rights		40,177		—		(3,767)		36,410
Goodwill		7,256		—		—		7,256
Total	$	68,156	$	—	$	(24,490)	$	43,666


	As of December 31, 2016
	Beginning of Period		Additions		Impairment		End of Period
IPR&D	$	36,551	$	—	$	(15,828)	$	20,723
Acquired developed product rights		—		40,177		—		40,177
Goodwill		7,256		—		—		7,256
Total	$	43,807	$	40,177	$	(15,828)	$	68,156

Our finite lived intangible asset consists of acquired developed product rights obtained from the asset acquisition of Keveyis® (dichlorphenamide) from a subsidiary of Taro Pharmaceutical Industries Ltd. (“Taro”). Keveyis is approved in the United States to treat hyperkalemic, hypokalemic and related variants of primary periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis. Keveyis has received orphan drug exclusivity status in the United States through August 7, 2022. In connection with the Asset Purchase Agreement and Supply Agreement we entered into with Taro, we paid Taro an upfront payment in two installments of $1 million in December 2016 and $7.5 million in March 2017. We concluded that the supply price payable by us exceeds fair value and, therefore, used a discounted cash flow method with a probability assumption to value the payments in excess of fair value at $29.3 million, for which we have recorded an intangible asset and corresponding liability. This liability will be reduced as we purchase inventory over the term of the Supply Agreement. In addition, we incurred transaction costs of $2.4 million, which were recorded in our Statement of Operations during the year ended December 31, 2016. The overall recording of the transaction resulted in the recording of an intangible asset of $40.2 million. This asset is being amortized over an eight-year period using the straight-line method.

We recorded amortization expense of $3.8 million and $0 for the nine months ended September 30, 2017 and 2016, respectively.

We recorded a $20.7 million impairment charge related to the in-process research and development of veldoreotide, which we acquired from Aspireo Pharmaceuticals, Ltd. in 2015. The factors considered in determining the fair value measurement were future revenues expected to be generated, estimated development timeline, increased costs and, an appropriate risk-adjusted discount rate. The decrease in the valuation of our intangible asset related to veldoreotide is due to a longer estimated development timeline, as well as increased costs above those previously estimated.

6. Accrued liabilities

Accrued liabilities consist of the following (in thousands):


	September 30,		December 31,
	2017		2016
Consulting and professional fees	$	3,202	$	1,110
Accrued payable due Taro Pharmaceuticals Industries Ltd.		—		7,500
Supply agreement - current portion		3,432		4,207
Employee compensation		2,006		1,554
Other		153		497
Total accrued liabilities	$	8,793	$	14,868

7. Long-Term debt

On July 14, 2017, we entered into a $50 million senior credit facility with CRG LP (“CRG”), a healthcare-focused investment firm, to retire our prior credit facility with Oxford Finance LLC and Horizon Technology Finance Corporation and provide additional capital to us. We initially borrowed $40 million under the term loan agreement and have the option to borrow an additional $10 million based upon the achievement of a certain revenue milestone on or prior to June 30, 2018. Concurrent with the initial borrowing, CRG purchased $3 million of our ordinary shares at a price of $6.98 per share. As a condition to the new credit facility, we issued warrants with a seven-year term to CRG to purchase 394,289 of our ordinary shares at an exercise price of $7.37 per share

The term loan agreement has a six-year term with three years of interest-only payments. The interest-only period may be extended to six years based upon the achievement of certain milestones during the first three years of the loan term. The loan agreement provides for interest payable at an annual rate of 12.5% and a final payment fee of 5% of the principal balance. The loan agreement includes a payment-in-kind (PIK) provision, which allows us to defer 4.0% of the 12.5% annual interest payable under the loan during the first three years of the term of the loan (which may be extended for the entire term of the loan, subject to the satisfaction of certain conditions) by adding such amount to the principal loan amount. We have granted a security interest in substantially all of our existing assets and assets acquired by us in the future, including intellectual property. The loan agreement contains facility and prepayment fees, and customary affirmative and negative covenants, including a financial covenant regarding minimum amounts of net revenue and restrictions on our ability to pay cash dividends, and a list of events that will constitute “events of default” under the loan agreement, and permit the lenders to declare all amounts under the loan agreement immediately due and payable, including a material adverse change in our business, operations or financial condition. We incurred $2.5 million in debt discounts and $0.8 million of debt issuance costs relating to this loan agreement which have been recorded as a reduction to the long-term debt. These amounts will be amortized over the outstanding period of the debt to interest expense using the effective interest rate method.

In connection with the retirement of our prior credit facility we incurred a final payment fee of $1.6 million and a loss on early extinguishment of debt of $3.5 million.

Future principal payments due under the loan agreement are as follows (in thousands):


	Principal
	Payments

2017	$	—
2018		—
2019		—
2020		6,765
2021		13,530
2022		13,530
2023		6,522
Total future payments	$	40,347

8. Commitments and contingencies

(a) Lease obligations

In March 2015, we entered into a 52‑month building sublease agreement for 14,743 square feet of office space in Trevose, Pennsylvania. The lease has annual rent escalations and is recognized on a straight‑line basis over the term of the lease.

As of September 30, 2017, future minimum commitments under facility operating leases were as follows (in thousands):


	Operating
	leases

2017	$	80
2018		319
2019		184
Total minimum lease payments	$	583

Rent expense recognized under our operating lease, including additional rent charges for utilities, parking, maintenance and real estate taxes, was approximately $226,000 and $206,000 for the nine months ended September 30, 2017 and 2016, respectively.

(b) Commitments to Taro Pharmaceuticals Industries Ltd.

In December 2016, we acquired the United States marketing rights to Keveyis® (dichlorphenamide) from a subsidiary of Taro. Keveyis is approved in the United States to treat hyperkalemic, hypokalemic and related variants of primary periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis. Keveyis has received orphan drug exclusivity status in the United States through August 7, 2022. Under the terms of the asset purchase agreement, we paid Taro an upfront payment in two installments of $1 million in December 2016 and $7.5 million in March 2017, and will pay an aggregate of $7.5 million in potential milestones upon the achievement of certain product sales targets. Taro has agreed to continue to manufacture Keveyis for us under an exclusive supply agreement through the orphan exclusivity period. We are obligated to purchase certain annual minimum amounts of product totaling approximately $29 million over a six-year period. The supply agreement may extend beyond the orphan exclusivity period unless terminated by either party pursuant to the terms of the agreement. If terminated by Taro at the

conclusion of the orphan exclusivity period, we have the right to manufacture the product on our own or have the product manufactured by a third party on our behalf.

9. Income taxes

Deferred tax assets and liabilities are recognized for the future tax consequences of differences between the carrying amounts and tax bases of assets and liabilities and operating loss carryforwards and other attributes using enacted rates expected to be in effect when those differences reverse. Valuation allowances are provided against deferred tax assets that are not more likely than not to be realized.

We assess our ability to realize deferred tax assets. Changes in future earnings projections, among other factors, may cause us to adjust our valuation allowance on deferred tax assets. Any such adjustments would impact our income tax expense in the period in which it is determined that these factors have changed.

For the nine months ended September 30, 2017, we recorded full valuation allowances against our deferred tax asset and deferred tax liability, resulting in income tax expense of $0.7 million.

10. Ordinary shares

Equity Transactions

Concurrent with the CRG credit facility, CRG purchased 429,799 shares of our ordinary shares at a price of $6.98 per share for total proceeds to us of approximately $3.0 million.

We entered into an equity distribution agreement with JMP on April 28, 2017, pursuant to which we may sell, at our option, from time to time, up to an aggregate of $40 million in ordinary shares of the Company through JMP, as sales agent. We will pay JMP a commission equal to 3% of the gross proceeds from the sale of ordinary shares under the ATM Facility. Pursuant to the terms of the equity distribution agreement, we reimbursed JMP for certain out-of-pocket expenses, including the fees and disbursements of counsel to JMP, incurred in connection with establishing the ATM Facility and have provided JMP with customary indemnification rights. During the three months ended September 30, 2017, we sold an aggregate of 10,300 ordinary shares under the ATM Facility for net proceeds of approximately $73,000 and paid fees to JMP of $2,000.

Warrants

During the three months ended September 30, 2017, in connection with the CRG credit facility, we issued warrants with a seven-year term to CRG to purchase 394,289 of our ordinary shares at an exercise price of $7.37. In addition, during the three months ended September 30, 2017, we issued 37,219 ordinary shares pursuant to the exercise of warrants that were previously issued in connection with our retired credit facility.


		Exercise		Expiration	Warrants	Warrants	September 30,
	Classification	Price		Date	Issued	Exercised	2017
Warrants in connection with private equity placement	Liability	$	2.50	6/28/2022	7,000,000	—	7,000,000
Warrants in connection with Horizon and Oxford loan agreement	Equity	$	2.45	12/28/2026	428,571	(58,291)	370,280
Warrants in connection with CRG loan agreement	Equity	$	7.37	7/14/2024	394,289	—	394,289
					7,822,860		7,764,569

11. Stock‑based compensation

Our board of directors has adopted the 2017 Inducement Plan (the “Inducement Plan”). The Inducement Plan provides for the grant of equity-based awards to new employees. The purpose of the Inducement Plan is to attract valued employees by offering them a greater stake in our success and a closer identity with us, and to encourage ownership of our ordinary shares by such employees. The Inducement Plan is effective as of February 23, 2017. As of September 30, 2017, 52,850 shares are available for issuance pursuant to the Inducement Plan.

Our board of directors has adopted, and our shareholders have approved, the 2015 Equity Compensation Plan (the “2015 Plan”). The 2015 Plan provides for the grant of incentive stock options to our employees and any parent or subsidiary corporations’ employees, and for the grant of nonstatutory stock options, stock awards, and restricted stock units to our employees, directors and consultants and our parent or subsidiary corporations’ employees and consultants. The 2015 Plan is effective as of September 3, 2015. As of September 30, 2017, 374,289 shares are available for issuance pursuant to the 2015 Plan.

Our board of directors has adopted, and our shareholders have approved, the Non‑Employee Director Equity Compensation Plan (the “Non‑Employee Director Plan”). The Non‑Employee Director Plan provides for the grant of nonstatutory stock options, stock awards, and restricted stock units to our non‑employee directors. The Non‑Employee Director Plan is effective as of September 3, 2015. As of September 30, 2017, 792 shares are available for issuance pursuant to the Non‑Employee Director Plan.

A summary of our outstanding stock options as of September 30, 2017 is as follows:


	Options Outstanding
				Weighted-
				Average
		Weighted-		Remaining
		Average		Contractual
	Number of	Exercise		Term	Aggregate
	Shares	Price		(Years)	Intrinsic Value
					(in thousands)
Outstanding—January 1, 2017	3,249,784	$	11.00	6.89	$	—
Granted	2,991,850	$	3.50
Forfeited and cancelled	(64,987)	$	7.37
Exercised	—		—
Outstanding—September 30, 2017	6,176,647	$	7.41	7.78	$	13,287
Vested and exercisable—September 30, 2017	2,034,974	$	10.38	5.61	$	2,249

Included in the stock options outstanding at September 30, 2017 are unvested stock options to purchase 88,908 shares at a weighted average exercise price of $18.80 per share for which the vesting of certain tranches will accelerate if the fair value per share of our stock reaches $31.46. In addition, the options outstanding include 97,652 shares that vest upon a market appreciation event, so long as it occurs prior to the date specified in the applicable award agreement and 97,652 shares that will vest upon the one year anniversary of the market appreciation event. The market appreciation event, which had not yet occurred as of September 30, 2017, is defined as the last trading day in the period in which our closing stock price on each of 20 consecutive trading days reported on NASDAQ has been at least $30.14 or $33.66 for the respective grantee.

Stock‑based compensation expense

We recognized stock‑based compensation expense for employees and directors for stock options and RSUs in the accompanying unaudited consolidated statements of operations as follows (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Selling, general and administrative	$	1,007	$	897	$	3,042	$	3,120
Research and development		324		205		822		401
Total stock-based compensation	$	1,331	$	1,102	$	3,864	$	3,521

As of September 30, 2017, the total unrecognized compensation expense related to unvested stock options, net of estimated forfeitures, is $10.3 million, which we expect to recognize over an estimated weighted‑average period of 2.77 years.

In determining the estimated fair value of our service-based awards, we use the Black‑Scholes option‑pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment.

The fair value of our service-based awards that were granted during the years was estimated with the following assumptions:


	Nine Months Ended
	September 30,
	2017	2016
Expected term (in years)	5.96	5.87
Risk-free interest rate	1.78% - 2.26%	1.3% - 1.6%
Expected volatility	78.2% - 105.9%	78.1% - 83.6%
Dividend rate	—%	—%

Restricted Stock Units

On February 26, 2016, our board of directors approved grants of restricted stock units (“RSUs”) to employees. These RSUs vest two years from the date of issuance, provided that the employee is employed by us on such vesting date. All RSUs will fully vest upon a change of control of our company. If and when the RSUs vest, we will issue one ordinary share for each whole RSU that has vested, subject to satisfaction of the executive’s tax withholding obligations. The RSUs will cease to be outstanding upon such issuance of ordinary shares. We recorded expense, which is included in the stock-based compensation table above, of $124,000 and $84,000 for the three months ended September 30, 2017 and 2016, respectively, and $309,000 and $197,000 for the nine months ended September 30, 2017 and 2016, respectively. As of September 30, 2017, the total unrecognized compensation expense related to unvested RSUs is $0.6 million, which we expect to recognize over an estimated weighted‑average period of 1.49 years.

A summary of our unvested RSUs as of September 30, 2017 is as follows:


		Number of
		Shares
Unvested—January 1, 2017		184,000
Granted		92,250
Forfeited		(2,000)
Vested		—
Unvested—September 30, 2017		274,250

12. Subsequent Events

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion summarizes the significant factors affecting our operating results, financial condition, liquidity and cash flows as of and for the periods presented below. The following discussion and analysis should be read in conjunction with the unaudited financial statements for the nine months ended September 30, 2017 and the related notes thereto included elsewhere in this Report on 6-K. The statements in this discussion regarding industry outlook, our expectations regarding our future performance, liquidity and capital resources and all other non‑historical statements in this discussion are forward‑looking statements and are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially from those discussed in or implied by forward‑looking statements as a result of various factors, including those discussed below and elsewhere in this Report on 6-K.

Overview

We are a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs.

Our first commercial product is Keveyis® (dichlorphenamide), the first and only treatment approved by the U.S. Food and Drug Administration (“FDA”) for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (“PPP”), a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis. Keveyis has orphan drug exclusivity status in the United States through August 7, 2022. We believe, based on our market research, that there are approximately 4,000 to 5,000 patients in the United States diagnosed with PPP.

In addition to this neuromuscular disease product, we have two clinical-stage product candidates for rare endocrine diseases, Recorlev™ and veldoreotide. Recorlev (levoketoconazole) is a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome. Veldoreotide is a next-generation somatostatin analog (“SSA”) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both Recorlev and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency (“EMA”).

We have never been profitable and have incurred net losses since our inception in 1996. Our operations to date have been focused on identifying, in‑licensing, acquiring and developing our product candidates, organizing and staffing our company, business planning and raising capital. We have funded our operations primarily through equity offerings and debt financings. We incurred a net loss attributable to Strongbridge Biopharma plc of $94.7 million and $32.6 million for the nine months ended September 30, 2017 and 2016, respectively. At September 30, 2017, our accumulated deficit was $224.1 million.

Financial Operations Overview

The following discussion sets forth certain components of our statements of operations as well as factors that impact those items.

Net Revenue

We recognize revenues from sales of Keveyis when we satisfy a performance obligation by transferring control of Keveyis to the Customer. Transfer of control occurs upon receipt of Keveyis by the Customer. We expense incremental costs related to the set-up of the contract with the Customer when incurred, as these costs did not meet the criteria for capitalization.

Cost of Sales

Cost of sales includes third-party acquisition costs, third-party warehousing and product distribution charges.

Research and Development Expenses

Our research and development expenses consist primarily of costs incurred in connection with the development of our product candidates, including:

personnel‑related costs, such as salaries, bonuses, benefits, travel and other related expenses, including stock‑based compensation;

expenses incurred under our agreements with contract research organizations (“CROs”), clinical sites, contract laboratories, medical institutions and consultants that plan and conduct our preclinical studies and clinical trials, including, in the case of consultants, stock‑based compensation;

costs associated with regulatory filings;

upfront and milestone payments under in‑license or acquisition agreements with third parties;

costs of acquiring preclinical study and clinical trial materials, and costs associated with formulation and process development; and

depreciation, maintenance and other facility‑related expenses.

We expense all research and development costs as incurred. Clinical development expenses for our product candidates are a significant component of our current research and development expenses as we progress our product candidates into and through clinical trials. Product candidates in later stage clinical development generally have higher research and development costs than those in earlier stages of development, primarily due to increased size and duration of the clinical trials. We recognize costs for each grant project, preclinical study or clinical trial that we conduct based on our evaluation of the progress to completion, including the use of information and data provided to us by our external research and development vendors and clinical sites.

We expect our research and development expenses to increase in absolute dollars in the future as we continue to in‑license or acquire product candidates and as we advance our existing and any future product candidates into and through clinical trials and pursue regulatory approval of our product candidates. The process of conducting the necessary clinical research to obtain regulatory approval of a product candidate is costly and time consuming. The probability that any of our product candidates receives regulatory approval and eventually is able to generate revenue depends on a variety of factors, including the quality of our product candidates, early clinical data, investment in our clinical program,

competition, manufacturing capability and commercial viability. As a result of these uncertainties, we are unable to determine the duration and completion costs of our research and development projects or if, when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates, if approved. We may never succeed in achieving regulatory approval for any of our product candidates.

We do not allocate personnel‑related research and development costs, including stock‑based compensation or other indirect costs, to specific programs, as they are deployed across multiple projects under development.

Selling, General and Administrative Expenses

Selling, general and administrative expenses include personnel costs, costs for outside professional services and other allocated expenses. Personnel costs consist of salaries, bonuses, benefits, travel and stock‑based compensation. Outside professional services consist of legal, accounting and audit services, commercial evaluation and strategy services, sales, marketing and other consulting services. We expect to incur additional selling, general and administrative costs as a result of our initial and on-going commercial activities in support of Keveyis.

Amortization of Intangible Asset

Amortization of intangible asset relates to the amortization of our product rights to Keveyis, which we acquired in December of 2016. This intangible asset is being amortized over an eight-year period using the straight-line method.

Other Income (Expense), Net

Other income (expense), net, consists of unrealized (loss)/gain on the remeasurement of the fair value of warrant liability, interest expense recognized on our long-term debt, the loss on the early extinguishment of our pre-existing long-term debt, interest income generated from our cash and cash equivalents, foreign exchange gains and losses and gains and losses on investments.

Our consolidated financial statements are reported in U.S. dollars, which is also our functional currency. Transactions in foreign currencies are remeasured into our functional currency at the rate of exchange prevailing at the date of the transaction. Any monetary assets and liabilities arising from these transactions are remeasured into our functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded in foreign currency loss in other income (expense) in our consolidated statements of operations.

Critical Accounting Policies and Significant Judgments and Estimates

This management’s discussion and analysis operating and financial review of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

In addition to our critical accounting policies described in the “Operating and Financial Review and Prospects” section included in our Annual Report on Form 20-F for the year ended December 31, 2016, which was filed with the Securities and Exchange Commission on April 4, 2017, we have adopted our Revenue Recognition policy. See Note 3 – Revenue Recognition.

Results of Operations

Comparison of the Three and Nine Months Ended September 30, 2017 and 2016

The following table sets forth our results of operations for the three and nine months ended September 30, 2017 and 2016.


	Three Months Ended						Nine Months Ended
	September 30,				Change		September 30,				Change
	2017		2016		$		2017		2016		$
	(in thousands)						(in thousands)
Revenues:
Net product sales	$	2,533	$	—	$	2,533	$	4,062	$	—	$	4,062
Total revenues		2,533		—		2,533		4,062		—		4,062

Cost and operating expenses:
Cost of sales (excluding amortization of intangible asset)	$	591	$	—	$	591	$	968	$	—	$	968
Selling, general and administrative		8,484		3,117		5,367		26,068		11,260		14,808
Research and development		4,504		4,516		(12)		12,113		15,882		(3,769)
Amortization of intangible asset		1,256		—		1,256		3,767		—		3,767
Impairment of intangible asset		20,723		—		20,723		20,723		5,228		15,495
Total cost and expenses		35,558		7,633		27,925		63,639		32,370		31,269
Operating loss		(33,025)		(7,633)		(25,392)		(59,577)		(32,370)		(27,207)
Other income (expense), net		(2,885)		15		(2,900)		(34,506)		(1,275)		(33,231)
Loss before income taxes		(35,910)		(7,618)		(28,292)		(94,083)		(33,645)		(60,438)
Income tax (expense) benefit		850		—		850		(652)		926		(1,578)
Net loss		(35,060)		(7,618)		(27,442)		(94,735)		(32,719)		(62,016)
Net loss attributable to non‑controlling interest		—		17		(17)		—		122		(122)
Net loss attributable to Strongbridge	$	(35,060)	$	(7,601)	$	(27,459)	$	(94,735)	$	(32,597)	$	(62,138)

Net Revenue and Cost of Sales

Net revenue of $2.5 and $4.1 million for the three and nine months ended September 30, 2017 and cost of sales of $0.6 million and $1.0 million for the three and nine months ended September 30, 2017, resulted from commercial sales of Keveyis following our product launch in April 2017.

Selling, General and Administrative Expenses

The following table summarizes our selling, general and administrative expenses during the three and nine months ended September 30, 2017 and 2016:


	Three Months Ended						Nine Months Ended
	September 30,				Change		September 30,				Change
	2017		2016		$		2017		2016		$
	(in thousands)						(in thousands)
Outside professional and consulting services	$	3,365	$	902	$	2,463	$	12,904	$	4,139	$	8,765
Compensation and other personnel costs		4,013		1,227		2,786		9,840		3,736		6,104
Stock-based compensation expense		1,007		898		109		3,042		3,120		(78)
Facility costs		99		90		9		282		265		17
Total general and administrative expenses	$	8,484	$	3,117	$	5,367	$	26,068	$	11,260	$	14,808

Selling, general and administrative expenses were $8.5 million for the three months ended September 30, 2017, an increase of $5.4 million compared to the three months ended September 30, 2016. The $2.5 million increase in outside professional and consulting services was primarily due to costs incurred for the launch and subsequent commercialization of Keveyis. Compensation and related personnel costs increased by $2.8 million during the three months ended September 30, 2017 primarily due to increased headcount of commercial personnel.

Selling, general and administrative expenses were $26.1 million for the nine months ended September 30, 2017, an increase of $14.8 million compared to the nine months ended September 30, 2016. The $8.8 million increase in outside professional and consulting services was primarily due to costs incurred for the launch and subsequent commercialization of Keveyis. Compensation and related personnel costs increased by $6.1 million during the nine months ended September 30, 2017 primarily due to increased headcount of commercial personnel.

Research and Development Expenses

The following table summarizes our research and development expenses during the three and nine months ended September 30, 2017 and 2016:


	Three Months Ended						Nine Months Ended
	September 30,				Change		September 30,				Change
	2017		2016		$		2017		2016		$
	(in thousands)						(in thousands)
Product development and supporting activities	$	3,290	$	3,577	$	(287)	$	8,735	$	12,952	$	(4,217)
Compensation and other personnel costs		890		734		156		2,556		2,529		27
Stock-based compensation expense		324		205		119		822		401		421
Total research and development expenses	$	4,504	$	4,516	$	(12)	$	12,113	$	15,882	$	(3,769)

Research and development expenses were $4.5 million for each of the three months ended September 30, 2017 and three months ended September 30, 2016. The $0.3 million decrease in expenses for product development and supporting activities was primarily due to a planned $0.6 million decrease in expenses for veldoreotide development activity and a $0.1 million decrease in development expenses related to programs we discontinued during 2016 (COR-004 and BioPancreate), partially offset by a $0.4 million increase in expenses relating to the ongoing clinical trials for Recorlev. Compensation and other personnel costs increased by $0.2 million for the three months ended September 30, 2017 as compared to the same period in 2016 due to increased headcount in research and development. Stock-based

compensation expense increased by $0.1 million, for the three months ended September 30, 2017 as compared to the same period in 2016 due to the granting of new awards to newly hired employees during the 2017 period.

Research and development expenses were $12.1 million for the nine months ended September 30, 2017, a decrease of $3.8 million compared to the nine months ended September 30, 2016. The $4.2 million decrease in expenses for product development and supporting activities was primarily due to a planned $1.9 million decrease in expenses for veldoreotide development activity, a $1.6 million decrease in development expenses related to programs we discontinued during 2016 (COR-004 and BioPancreate), and a $0.7 million decrease in expenses relating to the ongoing clinical trials for Recorlev and other supporting activities. Stock-based compensation expense increased by $0.4 million, for the nine months ended September 30, 2017 as compared to the same period in 2016 due to the granting of new awards to newly hired employees during the 2017 period.

Amortization of Intangible Asset

Amortization of intangible asset increased by $1.3 million and $3.8 million for the three and nine months ended September 30, 2017 compared to $0 for the three and nine months ended September 30, 2016, as we began amortizing the Keveyis product rights acquired in December 2016.

Impairment of Intangible Asset

Impairment of intangible asset increased by $20.7 million and $15.5 million for the three and nine months ended September 30, 2017 compared to $0 and $5.2 million for the three and nine months ended September 30, 2016 respectively, due to a $20.7 million impairment charge recorded in the third quarter of 2017 related to the in-process research and development recorded from our 2015 acquisition of veldoreotide from Aspireo Pharmaceuticals, Ltd.

Other Income (Expense), Net

The following table summarizes our other expense, net, during the nine months ended September 30, 2017 and 2016:


	Three Months Ended						Nine Months Ended
	September 30,				Change		September 30,				Change
	2017		2016		$		2017		2016		$
	(in thousands)						(in thousands)
Unrealized gain (loss) on fair value of warrants	$	1,953	$	—	$	1,953	$	(28,194)	$	—	$	(28,194)
Interest expense		(1,364)		—		(1,364)		(2,838)		—		(2,838)
Foreign exchange loss		(11)		(20)		9		(36)		(64)		28
Loss on early extinguishment of debt		(3,545)		—		(3,545)		(3,545)		—		(3,545)
Other income (expense), net		82		35		47		107		(1,211)		1,318
Total other income (expense), net	$	(2,885)	$	15	$	(2,900)	$	(34,506)	$	(1,275)	$	(33,231)

Other income (expense), net, increased by $2.9 million for the three months ended September 30, 2017 as compared to the three months ended September 30, 2016. The increase was primarily due to $3.5 million of expense relating to the loss on the early extinguishment of debt, and $1.4 million in interest expense, partially offset by a $2.0 million change in the fair value of our warrant liability, resulting primarily from a decrease in our stock price.

Other income (expense), net, increased by $33.2 million for the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016. The increase was primarily due to change of $28.2 million in the fair value of our warrant liability, resulting primarily from an increase in our stock price, a loss of $3.5 million relating to the early extinguishment of debt, and $2.8 million in interest expense. Other income (expense), net, decreased

by $1.3 million due to a one-time $1.1 million charge incurred in March 2016 relating to the termination of our license agreement with Antisense Therapeutics.

Income Tax

We recorded income tax expense of $0.7 million for the nine months ended September 30, 2017 as a result of recording full valuation allowances against our deferred tax asset and deferred tax liability, and a benefit of $0.9 million for the nine months ended September 30, 2016 due to impairment of intangible assets held by a since-dissolved subsidiary.

Cash Flows

Comparison for the Nine Months Ended September 30, 2017 and 2016


	Nine Months Ended
	September 30
	2017		2016
	(in thousands)
Net cash provided by (used in):
Operating activities	$	(34,450)	$	(24,742)
Investing activities		(7,500)		—
Financing activities		19,479		(1,412)
Net decrease in cash and cash equivalents	$	(22,471)	$	(26,154)

Operating Activities

Net cash used in operating activities was $34.5 million for the nine months ended September 30, 2017, compared to $24.7 million for the nine months ended September 30, 2016. The increase in net cash used in operating activities resulted primarily from investments during 2017 to support the commercialization of Keveyis.

Investing Activities

The increase in net cash used in investing activities resulted from our scheduled payment of $7.5 million to Taro Pharmaceutical Industries Ltd. in connection with our acquisition of the U.S. marketing rights of Keveyis.

Financing Activities

Net cash provided by financing activities was $19.5 million for the nine months ended September 30, 2017, an increase of $20.9 million from the nine months ended September 30, 2016. The increase in net cash provided by financing activities resulted primarily from our receipt of $38.7 million in proceeds from our senior credit facility with CRG LP and $3.1 million in proceeds from share issuances, offset by our $22.3 million repayment of our prior credit facility.

Liquidity

As of September 30, 2017, we held cash and cash equivalents of $44.4 million.

have the option to borrow an additional $10 million based upon the achievement of a certain revenue milestone on or prior to June 30, 2018. Concurrent with the initial borrowing, CRG purchased $3 million of our ordinary shares at a price of $6.98 per share. The loan and security agreement contains financial and non-financial covenants including minimum amounts of net revenue we must achieve in 2017 and beyond. Failure to comply with the covenants could result in the lenders declaring the loan immediately due and payable. Our liquidity requirements are predicated on maintaining compliance with the debt covenants and repaying outstanding borrowings in accordance with the loan agreement.

We may never achieve profitability, and unless and until we do, we will continue to need to raise additional capital. We believe the combination of our existing cash resources as of September 30, 2017 and the net proceeds from our October 2017 public offering, will provide us with sufficient resources under our current operating plan, which includes the potential regulatory approval and launch of Recorlev, to achieve consistent positive cash flows from operating activities. We expect our funding requirements for operating expenses to increase due to expenses associated with the commercialization of Keveyis, the execution of the Recorlev SONICS and LOGICS Phase 3 clinical trials, and our selling, general and administrative expenses. Our funding requirements will also increase to the extent we pursue potential in-licenses, acquisitions or similar transactions as part of our strategy. These expenses may be offset only in part by sales of Keveyis. To the extent our sales of Keveyis are less than we anticipate, or our expenses are higher than we anticipate, we may be required to fund our operations and capital funding needs through additional equity or debt financings. There can be no assurances, however, that additional funding will be available on terms acceptable to us.

Contractual Obligations and Other Commitments

The following table summarizes our future minimum commitments at September 30, 2017:


	Payments due by period
	Less than						More than
	1 year		1 to 3 years		3 to 5 years		5 years		Total
	(in thousands)

Minimum contract purchases pursuant to supply agreement	$	2,463	$	5,018	$	10,835	$	7,835	$	26,151
Debt payments	$	—	$	3,700	$	26,828	$	9,819	$	40,347
Operating leases	$	80	$	503	$	—	$	—	$	583
Total contractual obligations	$	2,543	$	9,221	$	37,663	$	17,654	$	67,081

We enter into agreements in the normal course of business with vendors for clinical trials, preclinical studies, and other services and products for operating purposes. Future payment obligations under these agreements, which are cancelable at any time by us, generally upon 30 days prior written notice, are not included in this table of contractual obligations.

We are obligated to make future payments to third parties due to payments that become due and payable upon the achievement certain commercialization milestones. As the amount and timing of these milestones are not probable and estimable, such commitments have not been included on our consolidated balance sheets or in the contractual obligations table above.

Off‑Balance Sheet Arrangements

We do not have variable interests in variable interest entities or any off‑balance sheet arrangements.

Quantitative and Qualitative Disclosures About Market Risk

At September 30, 2017, we had cash and cash equivalents of $44.4 million, which consists of bank deposits in the United States. As part of our cash and investment management processes, we perform periodic evaluations of the credit standing of the financial institutions with which we deposit our cash or purchase cash equivalents, and we have not sustained any credit losses from instruments held at these financial institutions.

Inflation

We believe the effects of inflation generally do not have a material adverse impact on our operations or financial condition.

Legal Proceedings

We are not party to any litigation or other legal proceedings that we believe could reasonably be expected to have a material adverse effect on our business, results of operations and financial condition.

EXHIBITS

EXHIBIT INDEX

10.6*		Amended and Restated Employment Agreement, dated as of October 13, 2017, by and between Strongbridge U.S. Inc. and Matthew Pauls.
10.7*		Form of Amended and Restated Employment Agreement, dated as of October 13, 2017, by and between Strongbridge U.S. Inc. and certain of its officers
10.21*		Strongbridge Biopharma plc 2017 Inducement Plan
101.INS*		XBRL Instance Document
101.SCH*		XBRL Taxonomy Extension Schema Document
101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*		XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*		XBRL Taxonomy Extension Definitions Linkbase Document

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



	STRONGBRIDGE BIOPHARMA PLC

	By:		/s/ A. BRIAN DAVIS
	Name:		A. Brian Davis
	Title:		Chief Financial Officer

Date: November 14, 2017

EX-10.21 2 sbbp-20170930ex1021e33ec.htm EX-10.21 sbbp_Ex_1021

Exhibit 10.21

STRONGBRIDGE BIOPHARMA PLC

2017 INDUCEMENT PLAN

The purpose of the Strongbridge Biopharma plc 2017 Inducement Plan is to assist Strongbridge Biopharma plc and its affiliates and subsidiaries in attracting valued employees by offering them a greater stake in the Company’s success and a closer identity with it, and to encourage ownership of the Company’s stock by such employees.

1. Definitions

As used herein, the following definitions shall apply:

(a) “Award” means a grant of Options, Stock Awards or Restricted Stock Units under the Plan.

(b) “Award Agreement” means the written agreement, instrument or document evidencing an Award.

(d) “Change of Control” means, after the Effective Date, any of the following events:

(i) Any “person” (as such term is used in sections 13(d) and 14(d) of the Exchange Act) (other than persons who are shareholders on the Effective Date) becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than 50% of the voting power of the then outstanding securities of the Company; provided that a Change of Control shall not be deemed to occur as a result of a change of ownership resulting from the death of a shareholder, and a Change of Control shall not be deemed to occur as a result of a transaction in which the Company becomes a subsidiary of another corporation and in which the shareholders of the Company, immediately prior to the transaction, will beneficially own, immediately after the transaction, shares entitling such shareholders to more than 50% of all votes to which all shareholders of the parent corporation would be entitled in the election of directors (without consideration of the rights of any class of stock to elect directors by a separate class vote); or

(ii) The consummation of (i) a merger or consolidation of the Company with another corporation where the shareholders of the Company, immediately prior to the merger or consolidation, will not beneficially own, immediately after the merger or consolidation, shares entitling such shareholders to more than 50% of all votes to which all shareholders of the surviving corporation would be entitled in the election of directors (without consideration of the rights of any class of stock to elect directors by a separate class vote); (ii) a sale or other disposition of all or substantially all of the assets of the Company; or (iii) a liquidation or dissolution of the Company.

(iii) Notwithstanding the foregoing, the following acquisitions shall not constitute a Change of Control: (A) an acquisition by the Company or entity controlled by the

Company, or (B) an acquisition by an employee benefit plan (or related trust) sponsored or maintained by the Company.

(e) “Code” means the Internal Revenue Code of 1986, as amended, and the Treasury regulations promulgated thereunder. A reference to any provision of the Code or the Treasury regulations promulgated thereunder shall include reference to any successor provision of the Code or the Treasury regulations.

(f) “Committee” means the committee designated by the Board to administer the Plan under Section 2. The Committee shall consist of at least two members and each member shall be a Non-Employee Director and an “independent director” within the meaning of Rule 5605(a)(3) of the Nasdaq Stock Market Equity Rules.

(g) “Company” means Strongbridge Biopharma plc.

(h) “Company Stock” means the ordinary shares of the Company, par value US$0.01 per share each.

(i) “Effective Date” has the meaning set forth in Section 17.

(j) “Eligible Individual” means any individual who was not previously an employee or a Non-Employee Director of the Company or any of its subsidiaries (or who had a bona fide period of non-employment with the Company and its subsidiaries) who is hired by the Company or a subsidiary.

(k) “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder. A reference to any provision of the Exchange Act or rule promulgated under the Exchange Act shall include reference to any successor provision or rule.

(l) “Fair Market Value” means: (x) if the principal trading market for the Company Stock is a national securities exchange or the Nasdaq National Market, the last reported sale price thereof on the relevant date or (if there were no trades on that date) the latest preceding date upon which a sale was reported, or (y) if the Company Stock is not principally traded on such exchange or market, the mean between the last reported “bid” and “asked” prices of Company Stock on the relevant date, as reported on Nasdaq or, if not so reported, as reported by the National Daily

-2-

Quotation Bureau, Inc. or as reported in a customary financial reporting service, as applicable and as the Committee determines.

(m) “Grantee” means an Eligible Individual who receives an Award under the Plan.

(n) “Non-Employee Director” means a member of the Board who meets the definition of a “non-employee director” under Rule 16b-3(b)(4) promulgated by the Exchange Act.

(o) “Option” means a right to purchase a specified number of Company Stock at a specified price awarded by the Committee as described in Section 6 of the Plan.

(p) “Plan” means the Strongbridge Biopharma plc 2017 Inducement Plan.

(q) “Restricted Stock Unit” means the right to a payment in Company Stock or in cash, or in a combination thereof, awarded by the Committee under Section 7 of the Plan.

(r) “Stock Award” means the right to payment in Company Stock awarded by the Committee under Section 7 of the Plan.

2. Administration

(a) Administration and Authority. The Plan shall be administered by the Compensation Committee. The Committee shall have the sole authority to (i) determine the Eligible Individuals to whom Awards shall be made under the Plan; (ii) determine the type, size, and terms of the Award to be made to each such Eligible Individual; (iii) determine the time when the Awards will be made and the duration of any applicable exercise or restriction period, including the criteria for exercisability and the acceleration of exercisability; (iv) amend the terms of any previously issued Award; (v) accelerate the vesting, exercisability, or lapse of any forfeiture condition with respect to an Award; and (vi) deal with any other matters arising under the Plan.

(b) Committee Determinations. The Committee shall have full power and authority to administer, construe and interpret the Plan, correct any defect, supply any omission, or reconcile any inconsistency in the Plan or any Award or Award Agreement, make factual determinations and adopt or amend such rules, regulations, agreements, and instruments for implementing the Plan and for the conduct of its business as it deems necessary or advisable, in its sole discretion. The Committee’s interpretations of the Plan and all determinations made by the Committee pursuant to the powers vested in it hereunder shall be conclusive and binding on all persons having any interest in the Plan or in any Awards granted hereunder. All powers of the Committee shall be executed in its sole discretion, in the best interest of the Company, not as a fiduciary, and in keeping with the objectives of the Plan and need not be uniform as to similarly situated individuals.

(c) Limitation of Liability. To the maximum extent permitted by law, no member of the Committee shall be liable for any action taken or decision made in good faith relating to the Plan or any Award thereunder. The Committee may employ counsel, consultants, accountants, appraisers, brokers or other persons. The Committee, the Company, and the officers and directors

-3-

of the Company shall be entitled to rely upon the advice, opinions or valuations of any such persons.

3. Awards

Awards under the Plan may consist of grants of Options as described in Section 6, as Stock Awards as described in Section 7, and Restricted Stock Units as described in Section 7. All Awards shall be subject to the terms and conditions set forth herein and to such other terms and conditions consistent with the Plan as the Committee deems appropriate and as are specified in the Award Agreement. The Committee shall approve the form and provisions of each Award Agreement. Awards under a particular Section of the Plan need not be uniform as among the Grantees.

4. Shares Subject to the Plan

(a) Shares Authorized. Subject to adjustment as described below, the Company Stock available for Awards under the Plan is 1,500,000 (the “Share Pool”). The shares may be authorized but unissued shares of Company Stock or reacquired shares of Company Stock, including shares purchased by the Company on the open market for purposes of the Plan.

(b) Adjustments to Share Pool. The Share Pool shall be reduced, on the date of grant, by one share for each Award granted under the Plan; provided that Awards that are valued by reference to shares of Company Stock but are required to be paid in cash pursuant to their terms shall not reduce the Share Pool. If and to the extent Options terminate, expire, or are canceled, forfeited, exchanged, or surrendered without having been exercised, or if any Stock Awards or Restricted Stock Units (including restricted stock received upon the exercise of Options) are forfeited, the shares of Company Stock subject to such Awards shall again be available for Awards under the Share Pool. Notwithstanding the foregoing, the following shares of Company Stock shall not become available for issuance under the Plan: (A) shares tendered by Grantees, or withheld by the Company, as full or partial payment to the Company upon the exercise of stock options granted under the Plan; and (B) shares withheld by, or otherwise remitted to, the Company to satisfy a Grantee’s tax withholding obligations upon the lapse of restrictions on Stock Awards or the exercise of Options granted under the Plan.

(c) Adjustments. If there is any change in the number or kind of shares of Company Stock outstanding (i) by reason of a stock dividend, spinoff, recapitalization, stock split, or combination or exchange of shares; (ii) by reason of a merger, reorganization, or consolidation; (iii) by reason of a reclassification or change in par value; or (iv) by reason of any other extraordinary or unusual event affecting the outstanding Company Stock as a class without the Company’s receipt of consideration, or if the value of outstanding shares of Company Stock is substantially reduced as a result of a spinoff or the Company’s payment of an extraordinary dividend or distribution, the maximum number of shares of Company Stock available for Awards, the maximum number of shares of Company Stock that any individual participating in the Plan may be granted in any year, the number of shares covered by outstanding Awards, the kind of shares issued under the Plan, and the price per share of such Awards shall be adjusted by the Committee to reflect any increase or decrease in the number of, or change in the kind or value of, issued shares of Company Stock to preclude the enlargement or dilution of rights and benefits under such Awards; provided, however, that any fractional shares resulting from such adjustment

-4-

shall be eliminated. Any adjustments determined by the Committee shall be final, binding, and conclusive.

5. Eligibility for Participation

Any Eligible Individual shall be eligible to participate in the Plan. The Committee shall select the Eligible Individuals to receive Awards and shall determine the number of shares of Company Stock subject to a particular Award in such manner as the Committee determines.

6. Granting of Options

The Company may grant Options to purchase shares of Company Stock to Eligible Individuals. The following provisions are applicable to Options.

(a) Number of Shares. The Committee shall determine the number of shares of Company Stock that shall be subject to each Award of Options.

(b) Price. The purchase price (the “Exercise Price”) of Company Stock subject to an Option shall be determined by the Board and shall be equal to or greater than the Fair Market Value of a share of Company Stock on the date the Option is granted.

(c) Option Term. The Committee shall determine the term of each Option. The term of any Option shall not exceed ten years from the date of grant.

(d) Exercisability of Options. Options shall become exercisable in accordance with such terms and conditions, consistent with the Plan, as may be determined by the Committee and specified in the Award Agreement. The Committee may accelerate the exercisability of any or all outstanding Options at any time for any reason. The Committee may provide in an Award Agreement that the Grantee may elect to exercise part or all of an Option before it otherwise has become exercisable. Any shares so purchased shall be restricted shares and shall be subject to a repurchase right in favor of the Company during a specified restriction period, with the repurchase price equal to the lesser of (A) the Exercise Price, or (B) the Fair Market Value of such shares at the time of repurchase, and (C) any other restrictions determined by the Company.

(e) Termination of Employment, Disability, or Death.

(i) Except as provided below, an Option may only be exercised while the Grantee is employed by, or providing service to, the Employer (as defined below) as an Eligible Individual. In the event that a Grantee ceases to be employed by, or provide service to, the Employer for any reason other than Disability, death, or termination for Cause, any Option which is otherwise exercisable by the Grantee shall terminate unless exercised within 90 days after the date on which the Grantee ceases to be employed by, or provide service to, the Employer (or within such other period of time as may be specified by the Committee), but in any event no later than the date of expiration of the Option term. Except as otherwise provided by the Committee or in the Award Agreement, any of the Grantee’s Options that are not otherwise exercisable as of the date on which the Grantee ceases to be employed by, or provide service to, the Employer shall terminate as of such date.

-5-

(ii) In the event the Grantee ceases to be employed by, or provide service to, the Employer on account of a termination for Cause by the Employer, any Option held by the Grantee shall terminate as of the date the Grantee ceases to be employed by, or provide service to, the Employer. In addition, notwithstanding any other provisions of this Section 6, if the Committee determines that the Grantee has engaged in conduct that constitutes Cause at any time while the Grantee is employed by, or providing service to, the Employer or after the Grantee’s termination of employment or service, any Option held by the Grantee shall immediately terminate, and the Grantee shall automatically forfeit all shares underlying any exercised portion of an Option for which the Company has not yet delivered the share certificates, upon refund by the Company of the Exercise Price paid by the Grantee for such shares. Upon any exercise of an Option, the Company may withhold delivery of share certificates pending resolution of an inquiry that could lead to a finding resulting in a forfeiture.

(iii) In the event the Grantee ceases to be employed by, or provide service to, the Employer because the Grantee is Disabled (as defined below), any Option which is otherwise exercisable by the Grantee shall terminate unless exercised within one year after the date on which the Grantee ceases to be employed by, or provide service to, the Employer (or within such other period of time as may be specified by the Committee), but in any event no later than the date of expiration of the Option term. Except as otherwise provided by the Committee, any of the Grantee’s Options which are not otherwise exercisable as of the date on which the Grantee ceases to be employed by, or provide service to, the Employer shall terminate as of such date.

(iv) If the Grantee dies while employed by, or providing service to, the Employer or within 90 days after the date on which the Grantee ceases to be employed or provide service on account of a termination specified in Section 6(e)(i) above (or within such other period of time as may be specified by the Committee), any Option that is otherwise exercisable by the Grantee shall terminate unless exercised within one year after the date on which the Grantee ceases to be employed by, or provide service to, the Employer (or within such other period of time as may be specified by the Committee), but in any event no later than the date of expiration of the Option term. Except as otherwise provided by the Committee, any of the Grantee’s Options that are not otherwise exercisable as of the date on which the Grantee ceases to be employed by, or provide service to, the Employer shall terminate as of such date.

(v) For purposes of this Plan:

(A) The term “Employer” shall mean the Company and its parent and subsidiary corporations or other entities, as determined by the Committee.

(B) “Employed by, or provide service to, the Employer” shall mean employment or service as an Eligible Individual (so that, for purposes of exercising Options and satisfying conditions with respect to Stock Awards or Restricted Stock Units, a Grantee shall not be considered to have terminated employment or service until the Grantee ceases to be an Eligible Individual, unless the Committee determines otherwise.

(C) “Disability” shall mean a Grantee’s becoming disabled within the meaning of section 22(e)(3) of the Code, within the meaning of the Employer’s long-

-6-

term disability plan applicable to the Grantee, or as otherwise determined by the Committee.

(D) “Cause” shall mean, except to the extent specified otherwise by the Committee or as defined in any other agreement between the Grantee and the Company, a finding by the Committee that the Grantee has (i) been convicted of a felony or crime involving moral turpitude; (ii) disclosed trade secrets or confidential information of the Employer to persons not entitled to receive such information; (iii) breached any written noncompetition or nonsolicitation agreement between the Grantee and the Employer; or (iv) engaged in willful and continued negligence in the performance of the duties assigned to the Grantee by the Employer, after the Grantee has received notice of and failed to cure such negligence.

(f) Exercise of Options. A Grantee may exercise an Option that has become vested and exercisable, in whole or in part, by delivering a notice of exercise to the Company. The Grantee shall pay the Exercise Price for an Option by the Committee (i) in cash; (ii) by delivering shares of Company Stock owned by the Grantee (including Company Stock acquired in connection with the exercise of an Option, subject to such restrictions as the Committee deems appropriate) and having a Fair Market Value on the date of exercise equal to the Exercise Price or by attestation (on a form prescribed by the Committee) to ownership of shares of Company Stock having a Fair Market Value on the date of exercise equal to the Exercise Price; (iii) payment through a broker in accordance with procedures permitted by Regulation T of the Federal Reserve Board; or (iv) by such other method as the Committee may approve. In addition, the Grantee may elect to settle the Option on a “net basis” by taking delivery of the number of Company Stock equal to Fair Market Value of the shares subject to any Option less the exercise price, any tax (or other governmental obligation) or other administration fees due. The Grantee shall pay the Exercise Price and the amount of any withholding tax due (pursuant to Section 8) as specified by the Committee.

7. Stock Awards and Restricted Stock Units

The Company may issue or transfer shares of Company Stock to an Eligible Individual under a Stock Award or Restricted Stock Unit, upon such terms as the Committee deems appropriate. The following provisions are applicable to Stock Awards and Restricted Stock Units:

(a) General Requirements. Shares of Company Stock issued or transferred pursuant to Stock Awards may be issued or transferred for consideration or for no consideration, and subject to restrictions or no restrictions, as determined by the Committee. The Committee shall determine the number of shares of Company Stock subject to a Stock Award and the number of Restricted Stock Units to be granted to a Grantee, the duration of the period during which, and the conditions, if any, under which, the Stock Award and Restricted Stock Units may vest or may be forfeited to the Company and the other terms and conditions of such Awards. The Committee may require different periods of service with respect to different Grantees holding different Stock Awards or Restricted Stock Units or to separate, designated portions of shares constituting Stock Awards.

(b) Transfer Restrictions and Legend on Stock Certificate. Stock Awards and Restricted Stock Units may not be sold, assigned, transferred, pledged or otherwise encumbered

-7-

except as provided in the Plan or as may be provided in the applicable Award Agreement; provided, however, that the Committee may determine that Stock Awards and Restricted Stock Units may be transferred by the Grantee. Each certificate for Stock Awards shall contain a legend giving appropriate notice of the restrictions in the Award. The Grantee shall be entitled to have the legend removed from the stock certificate covering the shares subject to restrictions when all restrictions on such shares have lapsed. The Committee may determine that the Company shall not issue certificates for Stock Awards until all restrictions on such shares have lapsed, or that the Company shall retain possession of certificates for Stock Awards until all restrictions on such shares have lapsed. Upon the lapse of the restrictions applicable to a Stock Award, the Company or other custodian, as applicable, shall deliver such certificates to the Grantee or the Grantee’s legal representative.

(c) Payment/Lapse of Restrictions. Each Restricted Stock Unit shall be granted with respect to one share of Company Stock or shall have a value equal to the Fair Market Value of one share of Company Stock. Restricted Stock Units shall be paid in cash, shares of Company Stock, other securities, other Awards or other property, as determined in the sole discretion of the Committee, upon the lapse of restrictions applicable thereto, or otherwise in accordance with the applicable Award Agreement. The amount payable as a result of the vesting of an Restricted Stock Unit shall be distributed as soon as practicable following the vesting date and in no event later than the fifteenth date of the third calendar month of the year following the vesting date of the Restricted Stock Unit (or as otherwise permitted under Section 409A of the Code); provided, however, that a Grantee may, if and to the extent permitted by the Committee, elect to defer payment of Restricted Stock Units in a manner permitted by Section 409A of the Code.

(d) Termination of Employment or Service. Except as otherwise set forth in the Award Agreement, if the Grantee ceases to be employed by, or provide service to, the Employer (as defined in Section 6(e)), any Stock Award or Restricted Stock Units held by the Grantee that are subject to the transfer restrictions set forth in Section 7(b) above at such time shall be forfeited. The Committee may, however, provide for complete or partial exceptions to this requirement as it deems appropriate.

(e) No Right to Vote and to Receive Dividends. Prior to the lapse of the transfer restrictions set forth in Section 7(b) above, the Grantee shall not have the right to vote shares subject to Stock Awards or to receive any dividends or other distributions paid on such shares, subject to any restrictions deemed appropriate by the Committee.

8. Withholding of Taxes

(a) Required Withholding. All Awards under the Plan shall be subject to applicable federal (including FICA), state, and local tax (or other governmental obligation) withholding requirements or other administration fees due. The Employer may require that the Grantee or other person receiving or exercising Awards pay to the Employer the amount of any federal, state, or local taxes (or other governmental obligations) that the Employer is required to withhold or any administration fees due with respect to such Awards, or the Employer may deduct from other wages paid by the Employer the amount of any withholding taxes, governmental obligations or administration fees due with respect to such Awards.

-8-

(b) Election to Withhold Shares. If the Board so permits, a Grantee may elect to satisfy the Employer’s income tax (or other governmental obligation) withholding requirement and any administration fees due with respect to an Award by having shares withheld up to an amount that does not exceed the Grantee’s minimum applicable withholding rate for federal (including FICA), state, and local tax (and other governmental obligation) liabilities plus any other administration fees due. The election must be in a form and manner prescribed by the Committee and may be subject to the prior approval of the Committee.

9. Transferability of Awards

(a) Nontransferability of Awards. Except as provided below, only the Grantee may exercise rights under an Award during the Grantee’s lifetime. A Grantee may not transfer those rights except by will or by the laws of descent and distribution. When a Grantee dies, the personal representative or other person entitled to succeed to the rights of the Grantee may exercise such rights. Any such successor must furnish proof satisfactory to the Company of his or her right to receive the Award under the Grantee’s will or under the applicable laws of descent and distribution.

(b) Transfer of Stock Options. Notwithstanding the foregoing, the Committee may provide, in an Award Agreement, that a Grantee may transfer Options to family members, or one or more trusts or other entities for the benefit of or owned by family members, consistent with applicable securities laws, according to such terms as the Committee may determine; provided that the Grantee receives no consideration for the transfer of an Option and the transferred Option shall continue to be subject to the same terms and conditions as were applicable to the Option immediately before the transfer.

10. Consequences of a Change of Control

(a) Assumption of Awards. Upon a Change of Control where the Company is not the surviving corporation (or survives only as a subsidiary of another corporation), unless the Committee determines otherwise, all outstanding Awards shall be assumed by, or replaced with comparable Awards by, the surviving corporation (or a parent or subsidiary of the surviving corporation).

(b) Termination of Awards. Upon a Change of Control where the Company is not the surviving corporation (or survives only as a subsidiary of another corporation), in the event the surviving corporation (or a parent or subsidiary of the surviving corporation) does not assume or replace the Awards with comparable Awards, (i) the Company shall provide each Grantee with outstanding Awards written notice of such Change of Control; (ii) all outstanding Options shall automatically accelerate and become fully vested and exercisable; (iii) all outstanding Stock Awards shall become vested and deliverable in accordance with Section 7(b); and (iv) all outstanding Restricted Stock Units shall become vested and deliverable in accordance with Section 7(c).

(c) Other Alternatives. Notwithstanding the foregoing, in the event of a Change of Control, the Committee may take one or both of the following actions: the Committee may (i) require that Grantees surrender their outstanding Options in exchange for a payment by the

-9-

Company, in cash or Company Stock as determined by the Committee, in an amount equal to the amount by which the then Fair Market Value of the shares of Company Stock subject to the Grantee’s unexercised Options exceeds the Exercise Price of the Options; or (ii) after giving Grantees an opportunity to exercise their outstanding Options, terminate any or all unexercised Options at such time as the Committee deems appropriate. Such surrender or termination shall take place as of the date of the Change of Control or such other date as the Committee may specify.

11. Requirements for Issuance or Transfer of Shares

(a) Shareholder’s Agreement. The Committee may require that a Grantee execute a shareholder’s agreement, with such terms as the Committee deems appropriate, with respect to any Company Stock issued or distributed pursuant to the Plan.

(b) Limitations on Issuance or Transfer of Shares. No Company Stock shall be issued or transferred in connection with any Award hereunder unless and until all legal requirements applicable to the issuance or transfer of such Company Stock have been complied with to the satisfaction of the Committee. The Committee shall have the right to condition any Award made to any Grantee hereunder on such Grantee’s undertaking in writing to comply with such restrictions on his or her subsequent disposition of such shares of Company Stock as the Committee shall deem necessary or advisable, and certificates representing such shares may be legended to reflect any such restrictions. Certificates representing shares of Company Stock issued or transferred under the Plan shall be subject to such stop-transfer orders and other restrictions as may be required by applicable laws, regulations, and interpretations, including any requirement that a legend be placed thereon.

(c) Lock-Up Period. If so requested by the Company or any representative of the underwriters (the “Managing Underwriter”) in connection with any underwritten offering of securities of the Company under the Securities Act of 1933, as amended (the “Securities Act”), a Grantee (including any successor or assigns) shall not sell or otherwise transfer any shares or other securities of the Company during the 30-day period preceding and the 180-day period following the effective date of a registration statement of the Company filed under the Securities Act for such underwriting (or such shorter period as may be requested by the Managing Underwriter and agreed to by the Company) (the “Market Standoff Period”). The Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such Market Standoff Period.

12. Amendment and Termination of the Plan

(a) Amendment. The Board may amend or terminate the Plan at any time; provided, however, that the Board shall not amend the Plan without shareholder approval if such approval is required in order to comply with the Code or other applicable laws or to comply with applicable stock exchange requirements.

(b) Termination of Plan. The Plan shall terminate on the day immediately preceding the tenth anniversary of its effective date, unless the Plan is terminated earlier by the Board or is extended by the Board.

-10-

(c) Termination and Amendment of Outstanding Awards. A termination or amendment of the Plan that occurs after an Award is made shall not materially impair the rights of a Grantee unless the Grantee consents or unless the Board acts under Section 20(b). The termination of the Plan shall not impair the power and authority of the Committee with respect to an outstanding Award. Whether or not the Plan has terminated, an outstanding Award may be terminated or amended under Section 20(b) or may be amended by agreement of the Company and the Grantee consistent with the Plan. Notwithstanding the foregoing, any such amendment or termination shall be subject to the approval of the Company’s stockholders if such stockholder approval is required by any federal or state law or regulation or the rules of any stock exchange or automated quotation system on which the Company Stock may then be listed or quoted, in each case.

(d) Governing Document. The Plan shall be the controlling document. No other statements, representations, explanatory materials or examples, oral or written, may amend the Plan in any manner. The Plan shall be binding upon and enforceable against the Company and its successors and assigns.

13. Funding of the Plan

The Plan shall be unfunded. The Company shall not be required to establish any special or separate fund or to make any other segregation of assets to assure the payment of any Awards under the Plan. In no event shall interest be paid or accrued on any Award, including unpaid installments of Awards.

14. Rights of Participants

Nothing in the Plan shall entitle any Eligible Individual or other person to any claim or right to be granted an Award under the Plan. Neither the Plan nor any action taken hereunder shall be construed as giving any individual any rights to be retained by or in the employ of the Employer or any other employment rights.

15. No Fractional Shares

No fractional shares of Company Stock shall be issued or delivered pursuant to the Plan or any Award. The Committee shall determine whether cash, other awards or other property shall be issued or paid in lieu of such fractional shares or whether such fractional shares or any rights thereto shall be forfeited or otherwise eliminated.

16. Headings

Section headings are for reference only. In the event of a conflict between a title and the content of a Section, the content of the Section shall control.

17. Effective Date of the Plan

The Plan shall be effective on February 23, 2017.

-11-

18. Miscellaneous

(a) Awards in Connection with Corporate Transactions and Otherwise. Nothing contained in the Plan shall be construed to (i) limit the right of the Committee to make Awards under the Plan in connection with the acquisition, by purchase, lease, merger, consolidation, or otherwise, of the business or assets of any corporation, firm or association; or (ii) limit the right of the Company to grant stock options or make other awards outside of the Plan.

(b) Compliance with Law. The Plan, exercise of Options, restrictions of Stock Awards and obligations of the Company to issue or transfer shares of Company Stock under Awards shall be subject to all applicable laws and to approvals by any governmental or regulatory agency as may be required. With respect to persons subject to section 16 of the Exchange Act, it is the intent of the Company that the Plan and all transactions under the Plan comply with all applicable provisions of Rule 16b-3 or its successors under the Exchange Act. In addition, it is the intent of the Company that the Plan and applicable Awards under the Plan comply with the applicable provisions of section 409A of the Code. To the extent that any legal requirement of section 16 of the Exchange Act or section 409A of the Code as set forth in the Plan ceases to be required under section 16 of the Exchange Act or section 409A of the Code, that Plan provision shall cease to apply. The Committee may revoke any Award if it is contrary to law or modify an Award to bring it into compliance with any valid and mandatory government regulation. The Committee may also adopt rules regarding the withholding of taxes on payments to Grantees. The Committee may, in its sole discretion, agree to limit its authority under this Section.

(c) Employees Subject to Taxation Outside the United States. With respect to Grantees who are subject to taxation in countries other than the United States, the Committee may make Awards on such terms and conditions as the Committee deems appropriate to comply with the laws of the applicable countries, and the Committee may create such procedures, addenda, and subplans and make such modifications as may be necessary or advisable to comply with such laws.

(d) Governing Law. The validity, construction, interpretation, and effect of the Plan and Award Agreements issued under the Plan shall be governed and construed by and determined in accordance with the laws of the State of Delaware, without giving effect to the conflict of laws provisions thereof.

-12-

EX-10.6 3 sbbp-20170930ex1067f35d6.htm EX-10.6 sbbp_Ex_106

exhibit 10.6

amended and restated EMPLOYMENT AGREEMENT

THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is made by and between Strongbridge U.S. Inc., a Delaware Corporation (the “Company”), and Matthew Pauls (“Executive”) as of October 13, 2017.

W I T N E S S E T H:

WHEREAS, the Company and Executive are parties to an amended and restated employment agreement (such agreement, the “Prior Agreement”);

WHEREAS, the Company desires to continue to retain the services of Executive as set forth in this Agreement, and Executive desires to serve the Company in such capacity, subject to the terms and conditions of this Agreement; and

WHEREAS, the Company and Executive intend for this Agreement to replace the Prior Agreement except as otherwise set forth herein.

NOW, THEREFORE, for and in consideration of the mutual promises, covenants and obligations contained herein, Company and Executive agree as follows:

ARTICLE I

EMPLOYMENT AND DUTIES

Section 1.01 Employment and Term. Subject to the provisions of Article III of this Agreement, the Executive shall be employed by the Company for the period commencing on the date hereof and continuing until terminated as described in Section 3.01 (the “Term”) on the terms and subject to the conditions set forth in this Agreement.

Section 1.02 Position and Duties. Executive shall serve as Chief Executive Officer of the Company, or in such other positions as the parties may agree and shall report directly to the Board of Directors of the Company (the “Board”). Executive shall have the duties and responsibilities customarily associated with such position and will perform such other duties as reasonably directed by the Board consistent with such position(s).

Section 1.03 Scope. Executive will devote substantially all of his business time, attention, skills and efforts to the performance of his duties. Executive acknowledges that his duties and responsibilities require Executive’s full-time business efforts and agrees to not engage in any other business activity or interests which materially interfere or conflict with the performance of Executive’s duties. Notwithstanding the foregoing, Executive may (a) without obtaining approval of the Board, serve on one for profit corporate board that does not compete with the Company, (b) upon receipt of prior written approval by the Board, serve on any other for profit corporate boards that do not compete with the Company, (c) serve on civic or charitable boards or committees of entities that do not compete with the Company, (d) deliver a reasonable number of lectures or fulfill speaking engagements or (e) manage personal investments, so long as such activities do not

significantly interfere with the performance of Executive’s duties and so long as Executive does not own more than five percent (5%) of the voting stock of any publicly held corporation.

ARTICLE II

COMPENSATION AND BENEFITS

Section 2.01 Base Salary. During the Term, the Company will pay Executive a base salary (the “Base Salary”) at an initial rate of $_______ per year in accordance with the Company’s standard payroll practices. Base Salary will be reviewed at least annually by the Board or a committee thereof and may be adjusted (in which case such adjusted amount shall be the “Base Salary”).

Section 2.02 Annual Incentive. During Executive’s employment with the Company, and as determined by the Board in its sole discretion, Executive shall be eligible for an annual cash incentive (the “Annual Incentive”) with a target of 50% of Base Salary (such percentage, the “Target Annual Incentive”). The Annual Incentive shall be based on the achievement of predetermined performance goals as determined annually by Executive and the Board, which shall be provided to the Executive in writing no later than thirty (30) days following the beginning of the year to which they relate. The actual Annual Incentive earned in any particular year may be greater or lower than the Target Annual Incentive, depending on the level of achievement of the applicable performance goals and the discretion of the Board. The Annual Incentive shall be paid to Executive as soon as practicable, but in no event later than the date that is two-and-one-half months following the end of the taxable year (of Executive, or the Company, whichever is later) in which such incentive is earned.

Section 2.03 Long-Term Incentive Plans. Executive shall be eligible to receive grants under the Company’s long-term incentive plans (including stock option, restricted stock and other equity compensation plans and any other long-term incentive plans) at the discretion of the Company’s Board.

Section 2.04 Business and Entertainment Expenses. Subject to the Company’s standard policies and procedures for expense reimbursement as applied to its executive employees generally, the Company shall reimburse Executive for, or pay on behalf of Executive, reasonable out-of-pocket business expenses incurred by Executive on behalf of the Company.

Section 2.05 Other Company Benefits. Executive shall be entitled to participate in all employee benefit plans, practices and programs maintained by the Company and made available to its similarly situated executives, including the Company’s paid time-off policy. Executive shall also be entitled to paid time-off for all holidays in the U.S. in accordance with the applicable Company policy. Executive shall agree to comply with a reasonable application process to permit the Company to insure his life under a standard “key man” insurance policy upon request from the Board.

- 2 -

ARTICLE III

TERMINATION

Section 3.01 General. The Company may terminate Executive’s employment for any reason or no reason, and Executive may terminate his employment for any reason or no reason, in either case subject only to the terms of this Agreement. For purposes of this Agreement, the following terms have the following meanings:

(a) “Accrued Obligations” shall mean: (i) Executive’s earned but unpaid Base Salary through the Termination Date; (ii) payment of any annual, long-term, or other incentive award which relates to a completed fiscal year or performance period, as applicable, and is payable (but not yet paid) on or before the Termination Date; (iii) a lump-sum payment in respect of accrued but unused vacation days at Executive’s per-business-day Base Salary rate in effect as of the Termination Date; and (iv) any unpaid expense or other reimbursements due pursuant to Section 2.04 hereof.

(b) “Cause” shall mean (i) Executive’s conviction of, or plea of guilty or nolo contendere to, any felony or any crime involving theft, embezzlement, dishonesty or moral turpitude; (ii) any act by Executive constituting willful misconduct, deliberate malfeasance, dishonesty, unethical conduct or gross negligence in the performance of his duties; (iii) Executive’s willful and continued failure to perform any of the duties of his position (which has not been cured within thirty (30) days following the first written notice from the Company describing such failure in reasonable detail); or (iv) any material breach (which has not been cured within 30 days following the first written notice from the Company describing such breach in reasonable detail) by Executive of this Agreement or any other agreement between Executive and the Company or any of its affiliates.

(i) any person or group of persons becomes the beneficial owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power of the Company’s then outstanding securities (a “Majority of the Securities”); provided that if the person or group of persons is already deemed to own more than 50% of the total fair market value or total voting power, then the acquisition of additional stock by such person or group of persons shall not constitute an additional Change in Control;

(ii) the stockholders of the Company approve a plan of complete liquidation of the Company;

(iii) the sale or disposition of all or substantially all of the Company’s assets;

(iv) a merger, consolidation or reorganization of the Company with or involving any other entity, other than a merger, consolidation or reorganization that would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting

- 3 -

securities of the surviving entity) at least a 50% of the combined voting power of the Company (or such surviving entity) outstanding immediately after such merger, consolidation or reorganization owned in approximately the same proportion of such ownership by each of the prior shareholders as prior to the transaction.

(v) Notwithstanding the foregoing, the following acquisitions shall not constitute a Change in Control: (A) an acquisition by the Company or entity controlled by the Company, or (B) an acquisition by an employee benefit plan (or related trust) sponsored or maintained by the Company.

(d) “Disability” shall mean Executive’s becoming incapacitated for a period of at least 180 days by accident, sickness or other circumstance that renders Executive mentally or physically incapable of performing the material duties and services required of Executive hereunder on a full-time basis during such period. A termination of Executive’s employment due to a Disability shall be effective only if the party terminating Executive’s employment first gives at least 15 days’ written notice of such termination to the other party.

(e) “Good Reason” shall mean, without Executive’s express written consent, the occurrence of any one or more of the following: (i) a material diminution by the Company of Executive’s Base Salary, other than any diminution that is also applicable in a substantially similar manner and proportion to the other senior executives of the Company; (ii) the assignment to Executive of duties or responsibilities which are materially inconsistent with Executive’s position; (iii) a change in the principal location at which Executive performs his duties for the Company to a new location that is more than fifty (50) miles from the prior location; or (iv) an action or inaction that constitutes a material breach of this Agreement by the Company.

A termination of employment by Executive for Good Reason shall be effectuated by giving the Company written notice (“Notice of Termination for Good Reason”), not later than 30 days following the occurrence of the circumstance that constitutes Good Reason, setting forth in reasonable detail the specific conduct of the Company that constitutes Good Reason and the specific provision(s) of this Agreement on which Executive relied. The Company shall be entitled, during the 45-day period following receipt of a Notice of Termination for Good Reason, to cure the circumstances that gave rise to Good Reason, provided that the Company shall be entitled to waive its right to cure or reduce the cure period by delivery of written notice to that effect to Executive (such 45-day or shorter period, the “Cure Period”). If, during the Cure Period, such circumstance is remedied, Executive will not be permitted to terminate employment for Good Reason as a result of such circumstance. If, at the end of the Cure Period, the circumstance that constitutes Good Reason has not been remedied, Executive will be entitled to terminate employment for Good Reason during the 30-day period that follows the end of the Cure Period. If Executive does not terminate employment during such 30-day period, Executive will not be permitted to terminate employment for Good Reason as a result of such event.

(f) “Pro-Rata Annual Incentive” shall mean an amount equal to (i) the Annual Incentive that Executive would have been entitled to receive for the calendar year that includes the Termination Date if his employment hereunder had continued (as determined by the Board of Directors based upon the actual achievement of the applicable performance goals), multiplied by

- 4 -

(ii) a fraction, the numerator of which is the number of days he was employed hereunder during such year and the denominator of which is the number of days in such year.

(g) “Termination Date” shall mean the date on which Executive’s employment hereunder terminates.

Section 3.02 Termination Without Cause or by Executive with Good Reason or Due to Executive’s Death. If the Company terminates Executive’s employment without Cause, or the Executive terminates for Good Reason, or Executive’s employment is terminated due to Executive’s death, the Term shall expire on the Termination Date and Executive shall be entitled to: (a) the Accrued Obligations; (b) an amount equal to the sum of (i) 18 months of the annual Base Salary as in effect immediately prior to the Termination Date and (ii) the Target Annual Incentive, paid in equal installments on the normal payroll cycle over the 18-month period that begins on the sixtieth (60th) day following the Termination Date; (c) the Pro-Rata Annual Incentive, payable in a cash lump sum to Executive on the date Company pays its annual incentive compensation bonuses for the year that includes the Termination Date if Executive’s employment continued; and (d) medical, dental benefits provided by the Company to Executive and Executive’s spouse and dependents (in each case, as provided in any applicable plan) at least equal to the levels of benefits provided to other similarly situated active employees of the Company and its subsidiaries until the earlier of (i) the 18-month anniversary of the Termination Date or (ii) the date that Executive becomes covered under a subsequent employer’s medical and dental plans.

Section 3.03 Reserved.

Section 3.04 Termination Without Cause, by Executive with Good Reason, or Due to Executive’s Death following a Change in Control of the Company. If the Company terminates Executive’s employment without Cause, or the Executive terminates for Good Reason, or Executive’s employment is terminated due to Executive’s death, in any case, within twenty-four (24) months following the occurrence of Change in Control, the Term shall expire on the Termination Date and, in lieu of the benefits set forth in Section 3.02 or 3.03, Executive shall be entitled to: (a) the Accrued Obligations; (b) an amount equal to the sum of (i) 24 months of the annual Base Salary as in effect immediately prior to the Termination Date and (ii) one (1) times the Target Annual Incentive, paid in equal installments on the normal payroll cycle over the 24-month period that begins on the sixtieth (60th) day following the Termination Date; (c) the Pro-Rata Annual Incentive, payable in a cash lump sum to Executive on the date Company pays its annual incentive compensation bonuses for the year that includes the Termination Date if Executive’s employment continued; (d) medical, dental benefits provided by the Company to Executive and Executive’s spouse and dependents (in each case, as provided in any applicable plan) at least equal to the levels of benefits provided to other similarly situated active employees of the Company and its subsidiaries until the earlier of (i) the 18-month anniversary of the Termination Date or (ii) the date that Executive becomes covered under a subsequent employer’s medical and dental plans; and (e) the acceleration of vesting of all unvested equity or equity-based awards held by Executive as of the Termination Date.

Section 3.05 Other Terminations. If Executive’s employment hereunder is terminated (a) by Executive without Good Reason, (b) by the Company for Cause; or (c) due to Executive’s

- 5 -

Disability, the Term shall expire as of the Termination Date and Executive shall be entitled to the Accrued Obligations.

Section 3.06 Release. Executive’s entitlement to the payments (other than the Accrued Obligations) and benefits described in this Article III is expressly contingent upon Executive providing the Company with a signed release that is attached hereto as Attachment A (the “Release”). To be effective, such Release must be delivered by Executive to the Company no later than 45 days following the Termination Date and must not be revoked during the seven (7) days following such delivery. If such Release is not executed in a timely manner or is revoked, all such payments and benefits shall immediately cease and the Executive shall be required to repay to the Company any such payments that have already been paid to the Executive.

Section 3.07 Resignation from Positions. Upon the termination of Executive’s employment for any reason, Executive shall immediately resign from each position held with the Company and its affiliates as of the Termination Date, including any position on the board of directors, if requested to do so by the Company.

ARTICLE IV

RESTRICTIVE COVENANTS

Section 4.01 Confidentiality.

(a) Company Information. Executive agrees at all times during the Term of this Agreement and thereafter, to hold in strictest confidence, and not to use, except in connection with the performance of Executive's duties, and not to disclose to any person or entity without written authorization of the Company, any Confidential Information of the Company. As used herein, “Confidential Information” means any Company proprietary or confidential information, technical data, trade secrets or know-how, including, but not limited to, research, product plans, products, services, customer lists and customers, markets, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, marketing, distribution and sales methods and systems, sales and profit figures, finances and other business information disclosed to Executive by the Company, either directly or indirectly in writing, orally or by drawings or inspection of documents or other tangible property. However, Confidential Information does not include any of the foregoing items which has become publicly known and made generally available through no wrongful act of Executive.

(b) Executive-Restricted Information. Executive agrees that during the Term of this Agreement Executive will not improperly use or disclose any proprietary or confidential information or trade secrets of any person or entity with whom Executive has an agreement or duty to keep such information or secrets confidential.

- 6 -

connection with the performance of Executive's duties, and not to disclose to any person or entity, or to use it except as necessary in performing the Executive’s duties, consistent with the Company's agreement with such third party.

Section 4.02 Non-Competition.

(a) Executive acknowledges that, during the Term, Executive has had access to information concerning the Company’s critical business strategies, engineering and technology development plans, competitive analyses, organizational structure. Accordingly, in consideration of the compensation provided under this Agreement, Executive agrees that during the Term and for the one (1) year period thereafter, Executive will not directly or indirectly, own, manage, operate, control (including indirectly through a debt or equity investment), provide services to, or be employed by, any person or entity engaged in any business that is (i) located in or provides services or products to a region in which the Company does business, and (ii) competitive with the business activities of the Company as they existed during the period that Executive provided services to the Company.

(b) Executive acknowledges that the restrictions contained under this Section 4.02 are reasonable and necessary to protect the legitimate interests of the Company, that the Company would not have executed this Agreement in the absence of such restrictions, and that any violation of any provision of this paragraph will result in irreparable injury to the Company. In the event the provisions under this Section 4.02 shall ever be deemed to exceed the time, scope or geographic limitations permitted by applicable laws, then such provisions shall be reformed to the maximum time, scope or geographic limitations, as the case may be, permitted by applicable laws.

Section 4.03 Injunctive Relief. Executive agrees that it is impossible to measure in money the damages which will accrue to the Company by reason of a failure by Executive to perform any of Executive’s obligations under this Article IV. Accordingly, if Company or any of its affiliates institutes any action or proceeding to enforce its rights under this Article IV, to the extent permitted by applicable law, Executive hereby waives the claim or defense that the Company or its affiliates has an adequate remedy at law, and Executive shall not claim that any such remedy at law exists.

ARTICLE V

MISCELLANEOUS

Section 5.01 Withholding. The Company shall withhold all applicable federal, state and local taxes, social security and workers’ compensation contributions and other amounts as may be required by law with respect to compensation payable to Executive.

Section 5.02 Modification of Payments.

- 7 -

its assets (a “Payment”) is a “parachute payment” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”) on account of the aggregate value of the Payments due to Executive being equal to or greater than three times the “base amount,” as defined in Section 280G(b)(3) of the Code, (the “Parachute Threshold”) so that Executive would be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”) and the net after-tax benefit that Executive would receive by reducing the Payments to the Parachute Threshold is greater than the net after-tax benefit Executive would receive if the full amount of the Payments were paid to Executive, then the Payments payable to Executive shall be reduced (but not below zero) so that the Payments due to Executive do not exceed the amount of the Parachute Threshold, reducing first any Payments under Section 3.02(b) hereof.

(b) The Company hereby agrees that, for purposes of determining whether any payment and benefits set forth in Section 3.04 above would be subject to the Excise Tax, the non-compete set forth in in Section 4.02 above shall be treated as an agreement for the performance of personal services. The Company hereby agrees to indemnify, defend, and hold harmless Executive from and against any adverse impact, tax, penalty, or excise tax resulting from the Company or accountant’s attribution of a value to the non-compete set forth in in Section 4.02 above that is less than the total compensation amount that would be disclosed under Item 402(c) of Securities and Exchange Commission Regulation S-K in the year prior to year of the event that triggers the Excise Tax, to the extent the use of such lesser amount results in a larger Excise Tax than Executive would have been subject to had the Company or accountant attributed a value to the non-compete set forth in in Section 4.02 above that is at least equal to the total compensation amount disclosed under Item 402(c) of Securities and Exchange Commission Regulation S-K for such year.

Section 5.03 Section 409A.

(a) Notwithstanding anything herein to the contrary, this Agreement is intended to be interpreted and applied so that the payment of the benefits set forth herein either shall either be exempt from the requirements of Section 409A of the Code (“Section 409A”) or shall comply with the requirements of such provision.

(b) Notwithstanding any provision of this Agreement to the contrary, if Executive is a “specified employee” within the meaning of Section 409A, any payments or arrangements due upon a termination of Executive’s employment under any arrangement that constitutes a “nonqualified deferral of compensation” within the meaning of Section 409A and which do not otherwise qualify under the exemptions under Treas. Regs. Section 1.409A-1 (including without limitation, the short-term deferral exemption or the permitted payments under Treas. Regs. Section 1.409A-1(b)(9)(iii)(A)), shall be delayed and paid or provided, without interest, on the earlier of (i) the date which is six months after Executive’s “separation from service” (as such term is defined in Section 409A and the regulations and other published guidance thereunder) for any reason other than death, and (ii) the date of Executive’s death.

(c) After any Termination Date, Executive shall have no duties or responsibilities that are inconsistent with having a “separation from service” within the meaning of Section 409A and, notwithstanding anything in the Agreement to the contrary, distributions upon termination of employment of nonqualified deferred compensation may only be made upon a “separation from service” as determined under Section 409A and such date shall be the

- 8 -

Termination Date for purposes of this Agreement. Each payment under this Agreement or otherwise shall be treated as a separate payment for purposes of Section 409A. In no event may Executive, directly or indirectly, designate the calendar year of any payment to be made under this Agreement which constitutes a “nonqualified deferral of compensation” within the meaning of Section 409A and to the extent an amount is payable within a time period, the time during which such amount is paid shall be in the discretion of the Company.

Section 5.04 Merger Clause. Effective as of the date hereof, this Agreement contains the complete, full, and exclusive understanding of Executive and the Company as to its subject matter and shall, on such date, and supersede any prior employment agreement between Executive and the Company (and its affiliates), including the Prior Agreement. Any amendments to this Agreement shall be effective and binding on Executive and the Company only if any such amendments are in writing and signed by both Parties.

Section 5.05 Assignment.

(a) This Agreement is personal to Executive and, without the prior written consent of the Company, shall not be assigned by Executive otherwise than by will or the laws of descent and distribution, and any assignment in violation of this Agreement shall be void.

(b) Notwithstanding the foregoing Section 5.05(a), this Agreement and all rights of Executive hereunder shall inure to the benefit of, and be enforceable by, Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If Executive should die while any amounts would still be payable to him or her hereunder if he or she had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to Executive’s devisee, legatee or other designee or, should there be no such designee, to Executive’s estate.

(c) The Company may assign this Agreement to any affiliate or subsidiary of the Company without the consent of Executive and shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company (a “Successor”) to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would have been required to perform it if no such succession had taken place. As used in this Agreement, (i) the term “Company” shall mean the Company as hereinbefore defined and any Successor and any permitted assignee to which this Agreement is assigned and (ii) the term “Board” shall mean the Board as hereinbefore defined and the board of directors or equivalent governing body of any Successor and any permitted assignee to which this Agreement is assigned.

Section 5.06 Dispute Resolution. Except for any proceeding brought pursuant to Section 5.05 above, the parties agree that any dispute arising out of or relating to this Agreement or the formation, breach, termination or validity thereof, will be settled by binding arbitration by a panel of three arbitrators in accordance with the commercial arbitration rules of the American Arbitration Association. The arbitration proceedings will be located in Philadelphia, Pennsylvania. The arbitrators are not empowered to award damages in excess of compensatory damages and each party irrevocably waives any damages in excess of compensatory damages. Judgment upon any arbitration award may be entered into any court having jurisdiction thereof and the parties consent

- 9 -

to the jurisdiction of any court of competent jurisdiction located in the Eastern District of Pennsylvania.

Section 5.07 GOVERNING LAW. THIS AGREEMENT SHALL BE DEEMED TO BE MADE IN THE COMMONWEALTH OF PENNSYLVANIA, INTERPRETATION, CONSTRUCTION AND PERFORMANCE OF THIS AGREEMENT IN ALL RESPECT SHALL BE GOVERNED BY THE LAWS OF THE COMMONWEALTH OF PENNSYLVANIA WITHOUT REGARD TO ITS PRINCIPLES OF CONFLICTS OF LAW.

Section 5.08 Amendment; No Waiver. No provision of this Agreement may be amended, modified, waived or discharged except by a written document signed by Executive and duly authorized officer of the Company. The failure of a party to insist upon strict adherence to any term of this Agreement on any occasion shall not be considered as a waiver of such party’s rights or deprive such party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement. No failure or delay by any party in exercising any right or power hereunder will operate as a waiver thereof, nor will any single or partial exercise of any other right or power. No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by any party, which are not set forth expressly in this Agreement.

Section 5.09 Severability. If any term or provision of this Agreement is invalid, illegal or incapable of being enforced by any applicable law or public policy, all other conditions and provisions of this Agreement shall nonetheless remain in full force and effect so long as the economic and legal substance of the transactions contemplated by this Agreement is not affected in any manner materially adverse to any party. Upon any such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible.

Section 5.10 Survival. The rights and obligations of the parties under the provisions of this Agreement that relate to post-termination obligations shall survive and remain binding and enforceable, notwithstanding the expiration of the term of this Agreement, the termination of Executive’s employment with the Company for any reason or any settlement of the financial rights and obligations arising from Executive’s employment hereunder, to the extent necessary to preserve the intended benefits of such provisions.

Section 5.11 Notices. All notices and other communications required or permitted by this Agreement will be made in writing and all such notices and communications will be deemed to have been duly given when delivered or (unless otherwise specified) mailed by United States certified or registered mail, return receipt requested, postage prepaid, addressed, if to the Company, at its principal office, and if to Executive, at Executive’s last address on file with the Company. Either party may change such address from time to time by notice to the other.

Section 5.12 Headings and References. The headings of this Agreement are inserted for convenience only and neither constitute a part of this Agreement nor affect in any way the meaning

- 10 -

or interpretation of this Agreement. When a reference in this Agreement is made to a Section, such reference shall be to a Section of this Agreement unless otherwise indicated.

Section 5.13 Counterparts. This Agreement may be executed in one or more counterparts (including via facsimile), each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

[signature page follows]

- 11 -

IN WITNESS WHEREOF, this Agreement has been executed by the parties as of the date first written above.


	STRONGBRIDGE U.S. INC.

	By:	/s/ A. Brian Davis
	Name: A. Brian Davis
	Title: Chief Financial Officer


	EXECUTIVE

	/s/ Matthew Pauls
	Matthew Pauls

- 12 -

ATTACHMENT A

GENERAL RELEASE

1. Matthew Pauls (“Executive”), for and in consideration of the commitments of Strongbridge U.S. Inc. (the “Company”) as set forth in Article III of the Amended and Restated Employment Agreement dated as of October 13, 2017 (the “Employment Agreement”), and intending to be legally bound, does hereby REMISE, RELEASE AND FOREVER DISCHARGE the Company and its present and former divisions, subsidiaries, parents, predecessor and successor corporations, officers, directors, and their respective successors, predecessors, assigns, heirs, executors, and administrators (collectively, “Releasees”) from all causes of action, suits, debts, claims and demands whatsoever in law or in equity, which Executive ever had, now has, or hereafter may have, whether known or unknown, or which Executive’s heirs, executors, or administrators may have, by reason of any matter, cause or thing whatsoever, up to the date of Executive’s execution of this General Release, particularly, but without limitation of the foregoing general terms, any claims arising from or relating in any way to Executive’s employment relationship with the Company and Releasees, the terms and conditions of that relationship, and the termination of that relationship, including, but not limited to, any claims arising under any applicable Company employee benefit plan(s), the Age Discrimination in Employment Act, the Older Workers’ Benefit Protection Act, Title VII of The Civil Rights Act of 1964, the Civil Rights Act of 1991, Sections 1981 through 1988 of Title 42 of the United States Code, the Americans with Disabilities Act, the Employee Retirement Income Security Act of 1974, the Family and Medical Leave Act, the Worker Adjustment and Retraining Notification Act, Pennsylvania employment laws, and any other federal, state and local employment laws, as amended, and any other claims under any federal, state or local common law, statutory, or regulatory provision, now or hereafter recognized, and any claims for attorneys’ fees and costs. This General Release is effective without regard to the legal nature of the claims raised and without regard to whether any such claims are based upon tort, equity, implied or express contract or discrimination of any sort.

2. To the fullest extent permitted by law, and subject to the provisions of Paragraph 3 below, Executive represents and affirms that (i) Executive has not filed or caused to be filed on Executive’s behalf any claim for relief against the Company or any Releasee and, to the best of Executive’s knowledge and belief, no outstanding claims for relief have been filed or asserted against the Company or any Releasee on Executive’s behalf; and (ii) Executive has no knowledge of any improper, unethical or illegal conduct or activities that Executive has not already reported to any supervisor, manager, department head, human resources representative, agent or other representative of the Company, to any member of the Company’s legal or compliance departments, or to the ethics hotline; and (iii) Executive will not file, commence, prosecute or participate in any judicial or arbitral action or proceeding against the Company or any Releasee based upon or arising out of any act, omission, transaction, occurrence, contract, claim or event existing or occurring on or before the date of execution of this General Release.

3. The release of claims described in Paragraph 1 of this General Release does not preclude Executive from filing a charge with the U.S. Equal Employment Opportunity Commission. However, Executive agrees and hereby waives any and all rights to any monetary relief or other personal recovery from any such charge, including costs and attorneys’ fees.

4. Subject to the provisions of Paragraph 3 of this General Release, in further consideration of the commitments of the Company as described in the Employment Agreement, Executive agrees that Executive will not file, claim, sue or cause or permit to be filed, any civil action,

- 13 -

suit or legal proceeding seeking equitable or monetary relief (including damages, injunctive, declaratory, monetary or other relief) for himself involving any matter released in Paragraph 1. In the event that suit is filed in breach of this release of claims, it is expressly understood and agreed that this release of claims shall constitute a complete defense to any such suit. In the event any Releasee is required to institute litigation to enforce the terms of this paragraph, Releasees shall be entitled to recover reasonable costs and attorneys' fees incurred in such enforcement. Executive further agrees and covenants that should any person, organization, or other entity file, claim, sue, or cause or permit to be filed any civil action, suit or legal proceeding involving any matter occurring at any time in the past, Executive will not seek or accept personal equitable or monetary relief in such civil action, suit or legal proceeding. Nothing in this General Release shall prohibit or restrict Executive from: (i) making any disclosure of information required by law; (ii) providing information to, or testifying or otherwise assisting in any investigation or proceeding brought by any federal regulatory or law enforcement agency or legislative body, any self-regulatory organization, or the Company’s designated legal, compliance or human resources officers; or (iii) filing, testifying, participating in or otherwise assisting in a proceeding relating to an alleged violation of any federal, state or municipal law relating to fraud, or any rule or regulation of the Securities and Exchange Commission or any self-regulatory organization.

5. Executive understands and agrees that the payments, benefits and agreements provided in the Employment Agreement are being provided to Executive in consideration for Executive’s acceptance and execution of, and in reliance upon Executive’s representations in, the Employment Agreement and this General Release, and that they are greater than the payments, benefits and agreements, if any, to which Executive would have received if Executive had not executed the Employment Agreement and this General Release. In addition, Executive acknowledges and agrees that Executive has been paid all amounts owed to Executive as of the date of Executive’s signing of this General Release.

6. Executive and the Company agree and acknowledge that the agreement by the Company described in the Employment Agreement, and the settlement and termination of any asserted or unasserted claims against the Releasees, are not and shall not be construed to be an admission of any violation of any federal, state or local statute or regulation, or of any duty owed by any of the Releasees to Executive.

7. This General Release and the obligations of the parties hereunder shall be construed, interpreted and enforced in accordance with and be governed by the laws of Pennsylvania without reference to its conflicts of laws principles.

8. Executive certifies and acknowledges as follows:

that Executive has read the terms of this General Release, and that Executive understands its terms and effects, including the fact that Executive has agreed to RELEASE AND FOREVER DISCHARGE the Company and each and every one of its affiliated entities from any legal action arising out of Executive’s relationship with the Company and the termination of that relationship;

that Executive has signed this Release voluntarily and knowingly in exchange for the consideration described herein and in the Employment Agreement,

- 14 -

which Executive acknowledges is adequate and satisfactory to Executive and to which Executive acknowledges that Executive would not otherwise be entitled;

that Executive has been and is hereby advised in writing to consult with an attorney prior to signing this General Release;

that Executive does not waive rights or claims that may arise after the date this General Release is executed;

that the Company has provided Executive with at least 21 (twenty-one) days within which to consider this General Release, that any modifications, material or otherwise, made to this General Release have not restarted or affected in any manner the original 21 (twenty-one) day consideration period, and that Executive has signed on the date indicated below after concluding that this General Release is satisfactory to Executive;

that Executive acknowledges that this General Release may be revoked by Executive within seven (7) days after Executive’s execution, and it shall not become effective until the expiration of such seven-day revocation period. If the last day of the revocation period is a Saturday, Sunday, or legal holiday in the state in which Executive resides, then the revocation period shall not expire until the next following day which is not a Saturday, Sunday, or legal holiday. In the event of a timely revocation by Executive, this General Release and the Employment Agreement will be deemed null and void and the Company will have no obligations hereunder; and

that this General Release may not be signed prior to the third calendar day before the last day of the Term of the Employment Agreement. If this General Release is signed prior to the last day of the Term of the Employment Agreement, the Company reserves the right to have Executive ratify the General Release on or after the last day of the Term.

- 15 -

Intending to be legally bound hereby, Executive executed the foregoing General Release on the date indicated below.


	Matthew Pauls

	/s/ Matthew Pauls
	Signature

	Date:	November 13, 2017

- 16 -

EX-10.7 4 sbbp-20170930ex10730aa02.htm EX-10.7 sbbp_Ex_107

Exhibit 10.7

amended and restated EMPLOYMENT AGREEMENT

THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is made by and between Strongbridge U.S. Inc., a Delaware corporation (the “Company”), and [NAME] (“Executive”) as of October 13, 2017.

W I T N E S S E T H:

WHEREAS, the Company and Executive are parties to an amended and restated employment agreement (such agreement, the “Prior Agreement”);

WHEREAS, the Company and Executive intend for this Agreement to replace the Prior Agreement except as otherwise set forth herein.

NOW, THEREFORE, for and in consideration of the mutual promises, covenants and obligations contained herein, Company and Executive agree as follows:

ARTICLE I

EMPLOYMENT AND DUTIES

Section 1.01 Employment and Term. Subject to the provisions of Article III of this Agreement, Executive shall be employed by the Company for the period commencing on the date hereof and continuing until terminated as described in Section 3.01 (the “Term”) on the terms and subject to the conditions set forth in this Agreement.

Section 1.02 Position and Duties. Executive shall serve as the [TITLE] of the Company, or in such other positions as the parties may agree. Executive shall have the duties and responsibilities customarily associated with such position and will perform such other duties as reasonably directed by the Chief Executive Officer of the Company (the “CEO”) consistent with such position(s).

Section 1.03 Scope. Executive will devote substantially all of his business time, attention, skills and efforts to the performance of his duties. Executive acknowledges that his duties and responsibilities require Executive’s full-time business efforts and agrees to not engage in any other business activity or interests which materially interfere or conflict with the performance of Executive’s duties. Notwithstanding the foregoing, Executive may (a) serve on corporate, civic or charitable boards or committees of entities that do not compete with the Company, with the approval of the CEO, (b) deliver a reasonable number of lectures or fulfill speaking engagements, with the approval of the CEO, or (c) manage personal investments, so long as such activities do not significantly interfere with the performance of Executive’s duties.

ARTICLE II

COMPENSATION AND BENEFITS

Section 2.01 Base Salary. During the Term, the Company will pay Executive a base salary (the “Base Salary”) at an initial rate of $_______ per year in accordance with the Company’s standard payroll practices. The Base Salary will be reviewed at least annually by the Board of Directors of the Company (the “Board”) or a committee thereof and may be adjusted (in which case such adjusted amount shall be the “Base Salary”).

Section 2.02 Annual Incentive. During Executive’s employment with the Company, and as determined by the Board in its sole discretion, Executive shall be eligible for an annual cash incentive (the “Annual Incentive”) with a target of _______ percent (__%) of the Base Salary (such percentage, the “Target Annual Incentive”). The Annual Incentive shall be based on the achievement of predetermined performance goals as determined annually by the CEO and the Board, which shall be provided to Executive in writing no later than thirty (30) days following the beginning of the year to which they relate. The actual Annual Incentive earned in any particular year may be greater or lower than the Target Annual Incentive, depending on the level of achievement of the applicable performance goals and the discretion of the Board. The Annual Incentive shall be paid to Executive as soon as practicable, but in no event later than the date that is two-and-one-half months following the end of the taxable year (of Executive, or the Company, whichever is later) in which such incentive is earned.

- 2 -

ARTICLE III

TERMINATION

(a) “Accrued Obligations” shall mean (i) Executive’s earned but unpaid Base Salary through the Termination Date; (ii) payment of any annual, long-term, or other incentive award which relates to a completed fiscal year or performance period, as applicable, and is payable (but not yet paid) on or before the Termination Date; (iii) a lump-sum payment in respect of accrued but unused vacation days at Executive’s per-business-day Base Salary rate in effect as of the Termination Date; and (iv) any unpaid expense or other reimbursements due pursuant to Section 2.04 hereof.

(b) “Cause” shall mean (i) Executive’s conviction of, or plea of guilty or nolo contendere to, any felony or any crime involving theft, embezzlement, dishonesty or moral turpitude; (ii) any act by Executive constituting willful misconduct, deliberate malfeasance, dishonesty, unethical conduct or gross negligence in the performance of his duties; (iii) Executive’s willful and continued failure to perform any of the duties of his position (which has not been cured within thirty (30) days following the first written notice from the Company describing such failure in reasonable detail); or (iv) any material breach (which has not been cured within thirty (30) days following the first written notice from the Company describing such breach in reasonable detail) by Executive of this Agreement or any other agreement between Executive and the Company or any of its affiliates.

(ii) the stockholders of the Company approve a plan of complete liquidation of the Company;

(iii) the sale or disposition of all or substantially all of the Company’s assets;

- 3 -

continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) at least a 50% of the combined voting power of the Company (or such surviving entity) outstanding immediately after such merger, consolidation or reorganization owned in approximately the same proportion of such ownership by each of the prior shareholders as prior to the transaction.

(d) “Disability” shall mean Executive’s becoming incapacitated for a period of at least one hundred eighty (180) days by accident, sickness or other circumstance that renders Executive mentally or physically incapable of performing the material duties and services required of Executive hereunder on a full-time basis during such period. A termination of Executive’s employment due to a Disability shall be effective only if the party terminating Executive’s employment first gives at least fifteen (15) days’ written notice of such termination to the other party.

A termination of employment by Executive for Good Reason shall be effectuated by giving the Company written notice (“Notice of Termination for Good Reason”), not later than thirty (30) days following the occurrence of the circumstance that constitutes Good Reason, setting forth in reasonable detail the specific conduct of the Company that constitutes Good Reason and the specific provision(s) of this Agreement on which Executive relied. The Company shall be entitled, during the forty-five (45) day period following receipt of a Notice of Termination for Good Reason, to cure the circumstances that gave rise to Good Reason, provided that the Company shall be entitled to waive its right to cure or reduce the cure period by delivery of written notice to that effect to Executive (such forty-five (45) day or shorter period, the “Cure Period”). If, during the Cure Period, such circumstance is remedied, Executive will not be permitted to terminate employment for Good Reason as a result of such circumstance. If, at the end of the Cure Period, the circumstance that constitutes Good Reason has not been remedied, Executive will be entitled to terminate employment for Good Reason during the thirty (30) day period that follows the end of the Cure Period. If Executive does not terminate employment during such thirty (30) day period, Executive will not be permitted to terminate employment for Good Reason as a result of such event.

(f) “Pro-Rata Annual Incentive” shall mean an amount equal to (i) the Annual Incentive that Executive would have been entitled to receive for the calendar year that includes the

- 4 -

Termination Date if his employment hereunder had continued (as determined by the Board based upon the actual achievement of the applicable performance goals), multiplied by (ii) a fraction, the numerator of which is the number of days he was employed hereunder during such year and the denominator of which is the number of days in such year.

(g) “Termination Date” shall mean the date on which Executive’s employment hereunder terminates.

Section 3.02 Termination Without Cause or by Executive with Good Reason or Due to Executive’s Death. If the Company terminates Executive’s employment without Cause, or Executive terminates for Good Reason, or Executive’s employment is terminated due to Executive’s death, the Term shall expire on the Termination Date and Executive shall be entitled to: (a) the Accrued Obligations; (b) an amount equal to the sum of (i) twelve (12) months of the annual Base Salary as in effect immediately prior to the Termination Date and (ii) the Target Annual Incentive, paid in equal installments on the normal payroll cycle over the twelve (12) month period that begins on the sixtieth (60th) day following the Termination Date; (c) the Pro-Rata Annual Incentive, payable in a cash lump sum to Executive on the date Company pays its annual incentive compensation bonuses for the year that includes the Termination Date if Executive’s employment continued; and (d) medical, dental benefits provided by the Company to Executive and Executive’s spouse and dependents (in each case, as provided in any applicable plan) at least equal to the levels of benefits provided to other similarly situated active employees of the Company and its subsidiaries until the earlier of (i) the one-year anniversary of the Termination Date or (ii) the date that Executive becomes covered under a subsequent employer’s medical and dental plans.

Section 3.03 Reserved.

Section 3.04 Termination Without Cause, by Executive with Good Reason, or Due to Executive’s Death following a Change in Control of the Company. If the Company terminates Executive’s employment without Cause, Executive terminates for Good Reason, or Executive’s employment is terminated due to Executive’s death, in any case, within twenty four (24) months following the occurrence of Change in Control, the Term shall expire on the Termination Date and, in lieu of the benefits set forth in Section 3.02 or 3.03, Executive shall be entitled to: (a) the Accrued Obligations; (b) an amount equal to the sum of (i) eighteen (18) months of the annual Base Salary as in effect immediately prior to the Termination Date and (ii) the Target Annual Incentive, paid in equal installments on the normal payroll cycle over the eighteen (18) month period that begins on the sixtieth (60th) day following the Termination Date; (c) the Pro-Rata Annual Incentive, payable in a cash lump sum to Executive on the date Company pays its annual incentive compensation bonuses for the year that includes the Termination Date if Executive’s employment continued; (d) medical, dental benefits provided by the Company to Executive and Executive’s spouse and dependents (in each case, as provided in any applicable plan) at least equal to the levels of benefits provided to other similarly situated active employees of the Company and its subsidiaries until the earlier of (i) the one-year anniversary of the Termination Date or (ii) the date that Executive becomes covered under a subsequent employer’s medical and dental plans; and (e) the acceleration of vesting of all unvested equity or equity based awards held by Executive as of the Termination Date.

- 5 -

Section 3.05 Other Terminations. If Executive’s employment hereunder is terminated (a) by Executive without Good Reason; (b) by the Company for Cause; or (c) due to Executive’s Disability, the Term shall expire as of the Termination Date and Executive shall be entitled to the Accrued Obligations.

Section 3.06 Release. Executive’s entitlement to the payments (other than the Accrued Obligations) and benefits described in this Article III is expressly contingent upon Executive providing the Company with a signed release that is attached hereto as Attachment A (the “Release”). To be effective, such Release must be delivered by Executive to the Company no later than forty-five (45) days following the Termination Date and must not be revoked during the seven (7) days following such delivery. If such Release is not executed in a timely manner or is revoked, all such payments and benefits shall immediately cease and Executive shall be required to repay to the Company any such payments that have already been paid to Executive.

ARTICLE IV

RESTRICTIVE COVENANTS

Section 4.01 Confidentiality.

(a) Company Information. Executive agrees at all times during the Term of this Agreement and thereafter, to hold in strictest confidence, and not to use, except in connection with the performance of Executive’s duties, and not to disclose to any person or entity without written authorization of the Company, any Confidential Information of the Company. As used herein, “Confidential Information” means any Company proprietary or confidential information, technical data, trade secrets or know-how, including, but not limited to, research, product plans, products, services, customer lists and customers, markets, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, marketing, distribution and sales methods and systems, sales and profit figures, finances and other business information disclosed to Executive by the Company, either directly or indirectly in writing, orally or by drawings or inspection of documents or other tangible property. However, Confidential Information does not include any of the foregoing items which has become publicly known and made generally available through no wrongful act of Executive.

(c) Third Party Information. Executive recognizes that the Company has received and in the future will receive from third parties their confidential or proprietary information subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. Executive agrees at all times during the Term of this Agreement and thereafter, to hold in strictest confidence, and not to use, except in connection with the performance of Executive’s duties, and not to disclose to any person or entity, or to use it except as necessary in performing Executive’s duties, consistent with the Company’s agreement with such third party.

- 6 -

Section 4.02 Non-Competition.

ARTICLE V

MISCELLANEOUS

Section 5.02 Modification of Payments.

(a) In the event it shall be determined that any payment, right or distribution by the Company or any other person or entity to or for the benefit of Executive pursuant to the terms of this Agreement or otherwise, in connection with, or arising out of, his employment with the Company or a change in ownership or effective control of the Company or a substantial portion of its assets (a “Payment”) is a “parachute payment” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”) on account of the aggregate value of the Payments due to Executive being equal to or greater than three times the “base amount,” as defined

- 7 -

in Section 280G(b)(3) of the Code, (the “Parachute Threshold”) so that Executive would be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”) and the net after-tax benefit that Executive would receive by reducing the Payments to the Parachute Threshold is greater than the net after-tax benefit Executive would receive if the full amount of the Payments were paid to Executive, then the Payments payable to Executive shall be reduced (but not below zero) so that the Payments due to Executive do not exceed the amount of the Parachute Threshold, reducing first any Payments under Section 3.02(b) hereof.

(b) The Company hereby agrees that, for purposes of determining whether any payment and benefits set forth in Section 3.04 above would be subject to the Excise Tax, the non-compete set forth in in Section 4.02 above shall be treated as an agreement for the performance of personal services. The Company hereby agrees to indemnify, defend, and hold harmless Executive from and against any adverse impact, tax, penalty, or excise tax resulting from the Company or accountant’s attribution of a value to the non-compete set forth in in Section 4.02 above that is less than the total compensation amount that would be disclosed under Item 402(c) of Securities and Exchange Commission Regulation S-K if Executive had been a “named executive officer” of the Company in the year prior to year of the event that triggers the Excise Tax, to the extent the use of such lesser amount results in a larger Excise Tax than Executive would have been subject to had the Company or accountant attributed a value to the non-compete set forth in in Section 4.02 above that is at least equal to the total compensation amount disclosed under Item 402(c) of Securities and Exchange Commission Regulation S-K for such year..

Section 5.03 Section 409A.

(b) Notwithstanding any provision of this Agreement to the contrary, if Executive is a “specified employee” within the meaning of Section 409A, any payments or arrangements due upon a termination of Executive’s employment under any arrangement that constitutes a “nonqualified deferral of compensation” within the meaning of Section 409A and which do not otherwise qualify under the exemptions under Treas. Regs. Section 1.409A-1 (including without limitation, the short-term deferral exemption or the permitted payments under Treas. Regs. Section 1.409A-1(b)(9)(iii)(A)), shall be delayed and paid or provided, without interest, on the earlier of (i) the date which is six (6) months after Executive’s “separation from service” (as such term is defined in Section 409A and the regulations and other published guidance thereunder) for any reason other than death, and (ii) the date of Executive’s death.

(c) After any Termination Date, Executive shall have no duties or responsibilities that are inconsistent with having a “separation from service” within the meaning of Section 409A and, notwithstanding anything in the Agreement to the contrary, distributions upon termination of employment of nonqualified deferred compensation may only be made upon a -separation from service” as determined under Section 409A and such date shall be the Termination Date for purposes of this Agreement. Each payment under this Agreement or otherwise shall be treated as a separate payment for purposes of Section 409A. In no event may

- 8 -

Executive, directly or indirectly, designate the calendar year of any payment to be made under this Agreement which constitutes a -nonqualified deferral of compensation” within the meaning of Section 409A and to the extent an amount is payable within a time period, the time during which such amount is paid shall be in the discretion of the Company.

Section 5.05 Assignment.

- 9 -

Section 5.12 Headings and References. The headings of this Agreement are inserted for convenience only and neither constitute a part of this Agreement nor affect in any way the meaning or interpretation of this Agreement. When a reference in this Agreement is made to a Section, such reference shall be to a Section of this Agreement unless otherwise indicated.

- 10 -

[signature page follows]

- 11 -

IN WITNESS WHEREOF, this Agreement has been executed by the parties as of the date first written above.

	STRONGBRIDGE U.S. INC.

	By:
	Name: Matthew Pauls
	Title: President


	EXECUTIVE



	[NAME]

- 12 -

ATTACHMENT A

GENERAL RELEASE

[NAME] (“Executive”), for and in consideration of the commitments of Strongbridge U.S. Inc. (the “Company”) as set forth in Article III of the Amended and Restated Employment Agreement dated as of October 13, 2017 (the “Employment Agreement”), and intending to be legally bound, does hereby REMISE, RELEASE AND FOREVER DISCHARGE the Company and its present and former divisions, subsidiaries, parents, predecessor and successor corporations, officers, directors, and their respective successors, predecessors, assigns, heirs, executors, and administrators (collectively, “Releasees”) from all causes of action, suits, debts, claims and demands whatsoever in law or in equity, which Executive ever had, now has, or hereafter may have, whether known or unknown, or which Executive’s heirs, executors, or administrators may have, by reason of any matter, cause or thing whatsoever, up to the date of Executive’s execution of this General Release, particularly, but without limitation of the foregoing general terms, any claims arising from or relating in any way to Executive’s employment relationship with the Company and Releasees, the terms and conditions of that relationship, and the termination of that relationship, including, but not limited to, any claims arising under any applicable Company employee benefit plan(s), the Age Discrimination in Employment Act, the Older Workers’ Benefit Protection Act, Title VII of The Civil Rights Act of 1964, the Civil Rights Act of 1991, Sections 1981 through 1988 of Title 42 of the United States Code, the Americans with Disabilities Act, the Employee Retirement Income Security Act of 1974, the Family and Medical Leave Act, the Worker Adjustment and Retraining Notification Act, Pennsylvania employment laws, and any other federal, state and local employment laws, as amended, and any other claims under any federal, state or local common law, statutory, or regulatory provision, now or hereafter recognized, and any claims for attorneys’ fees and costs. This General Release is effective without regard to the legal nature of the claims raised and without regard to whether any such claims are based upon tort, equity, implied or express contract or discrimination of any sort.

To the fullest extent permitted by law, and subject to the provisions of Paragraph 3 below, Executive represents and affirms that (i) Executive has not filed or caused to be filed on Executive’s behalf any claim for relief against the Company or any Releasee and, to the best of Executive’s knowledge and belief, no outstanding claims for relief have been filed or asserted against the Company or any Releasee on Executive’s behalf; and (ii) Executive has no knowledge of any improper, unethical or illegal conduct or activities that Executive has not already reported to any supervisor, manager, department head, human resources representative, agent or other representative of the Company, to any member of the Company’s legal or compliance departments, or to the ethics hotline; and (iii) Executive will not file, commence, prosecute or participate in any judicial or arbitral action or proceeding against the Company or any Releasee based upon or arising out of any act, omission, transaction, occurrence, contract, claim or event existing or occurring on or before the date of execution of this General Release.

The release of claims described in Paragraph I of this General Release does not preclude Executive from filing a charge with the U.S. Equal Employment Opportunity Commission. However, Executive agrees and hereby waives any and all rights to any monetary relief or other personal recovery from any such charge, including costs and attorneys’ fees.

- 13 -

Subject to the provisions of Paragraph 3 of this General Release, in further consideration of the commitments of the Company as described in the Employment Agreement, Executive agrees that Executive will not file, claim, sue or cause or permit to be filed, any civil action, suit or legal proceeding seeking equitable or monetary relief (including damages, injunctive, declaratory, monetary or other relief) for himself involving any matter released in Paragraph 1. In the event that suit is filed in breach of this release of claims, it is expressly understood and agreed that this release of claims shall constitute a complete defense to any such suit. In the event any Releasee is required to institute litigation to enforce the terms of this paragraph, Releasees shall be entitled to recover reasonable costs and attorneys’ fees incurred in such enforcement. Executive further agrees and covenants that should any person, organization, or other entity file, claim, sue, or cause or permit to be filed any civil action, suit or legal proceeding involving any matter occurring at any time in the past, Executive will not seek or accept personal equitable or monetary relief in such civil action, suit or legal proceeding. Nothing in this General Release shall prohibit or restrict Executive from: (i) making any disclosure of information required by law; (ii) providing information to, or testifying or otherwise assisting in any investigation or proceeding brought by any federal regulatory or law enforcement agency or legislative body, any self-regulatory organization, or the Company’s designated legal, compliance or human resources officers; or (iii) filing, testifying, participating in or otherwise assisting in a proceeding relating to an alleged violation of any federal, state or municipal law relating to fraud, or any rule or regulation of the Securities and Exchange Commission or any self-regulatory organization.

Executive understands and agrees that the payments, benefits and agreements provided in the Employment Agreement are being provided to Executive in consideration for Executive’s acceptance and execution of, and in reliance upon Executive’s representations in, the Employment Agreement and this General Release, and that they are greater than the payments, benefits and agreements, if any, to which Executive would have received if Executive had not executed the Employment Agreement and this General Release. In addition, Executive acknowledges and agrees that Executive has been paid all amounts owed to Executive as of the date of Executive’s signing of this General Release.

Executive and the Company agree and acknowledge that the agreement by the Company described in the Employment Agreement, and the settlement and termination of any asserted or unasserted claims against the Releasees, are not and shall not be construed to be an admission of any violation of any federal, state or local statute or regulation, or of any duty owed by any of the Releasees to Executive.

This General Release and the obligations of the parties hereunder shall be construed, interpreted and enforced in accordance with and be governed by the laws of Pennsylvania without reference to its conflicts of laws principles.

a. Executive certifies and acknowledges as follows: that Executive has read the terms of this General Release, and that Executive understands its terms and effects, including the fact that Executive has agreed to RELEASE AND FOREVER DISCHARGE the Company and each and every one of its affiliated entities from any legal action arising out of Executive’s relationship with the Company and the termination of that relationship;

- 14 -

b. that Executive has signed this Release voluntarily and knowingly in exchange for the consideration described herein and in the Employment Agreement, which Executive acknowledges is adequate and satisfactory to Executive and to which Executive acknowledges that Executive would not otherwise be entitled;

c. that Executive has been and is hereby advised in writing to consult with an attorney prior to signing this General Release;

d. that Executive does not waive rights or claims that may arise after the date this General Release is executed;

e. that the Company has provided Executive with at least 21 (twenty-one) days within which to consider this General Release, that any modifications, material or otherwise, made to this General Release have not restarted or affected in any manner the original 21 (twenty-one) day consideration period, and that Executive has signed on the date indicated below after concluding that this General Release is satisfactory to Executive;

f. that Executive acknowledges that this General Release may be revoked by Executive within seven (7) days after Executive’s execution, and it shall not become effective until the expiration of such seven-day revocation period. If the last day of the revocation period is a Saturday, Sunday, or legal holiday in the state in which Executive resides, then the revocation period shall not expire until the next following day which is not a Saturday, Sunday, or legal holiday. In the event of a timely revocation by Executive, this General Release and the Employment Agreement will be deemed null and void and the Company will have no obligations hereunder; and

g. that this General Release may not be signed prior to the third calendar day before the last day of the Term of the Employment Agreement. If this General Release is signed prior to the last day of the Term of the Employment Agreement, the Company reserves the right to have Executive ratify the General Release on or after the last day of the Term.

- 15 -

Intending to be legally bound hereby, Executive executed the foregoing General Release on the date indicated below.


	[NAME]


	Signature

	Date:

- 16 -

EX-101.INS 5 sbbp-20170930.xml EX-101.INS 0001634432 us-gaap:MaximumMember us-gaap:CommonStockMember sbbp:EquityDistributionAgreementJmp28April2017Member 2017-01-01 2017-09-30 0001634432 us-gaap:AdditionalPaidInCapitalMember sbbp:SaleOfStockConcurrentWithCrgCreditFacilityBorrowingMember 2017-01-01 2017-09-30 0001634432 us-gaap:AdditionalPaidInCapitalMember sbbp:EquityDistributionAgreementJmp28April2017Member 2017-01-01 2017-09-30 0001634432 sbbp:EquityDistributionAgreementJmp28April2017Member 2017-01-01 2017-09-30 0001634432 us-gaap:CommonStockMember sbbp:SaleOfStockConcurrentWithCrgCreditFacilityBorrowingMember 2017-01-01 2017-09-30 0001634432 us-gaap:CommonStockMember sbbp:EquityDistributionAgreementJmp28April2017Member 2017-01-01 2017-09-30 0001634432 us-gaap:RetainedEarningsMember 2017-09-30 0001634432 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0001634432 us-gaap:RetainedEarningsMember 2016-12-31 0001634432 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001634432 us-gaap:CommonStockMember 2017-09-30 0001634432 sbbp:DeferredSharesMember 2017-09-30 0001634432 us-gaap:CommonStockMember 2016-12-31 0001634432 sbbp:DeferredSharesMember 2016-12-31 0001634432 us-gaap:SubsequentEventMember 2017-10-06 0001634432 sbbp:SaleOfStockConcurrentWithCrgCreditFacilityBorrowingMember 2017-07-14 0001634432 sbbp:VestingBasedOnMarketAppreciationEventMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-09-30 0001634432 sbbp:VestingBasedOnMarketAppreciationEventMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-09-30 0001634432 sbbp:VestingSubjectToAccelerationMember 2017-09-30 0001634432 sbbp:NonEmployeeDirectorEquityCompensationPlanMember 2017-09-30 0001634432 sbbp:InducementPlan2017Member 2017-09-30 0001634432 sbbp:EquityCompensationPlan2015Member 2017-09-30 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0001634432 us-gaap:RetainedEarningsMember 2017-01-01 2017-09-30 0001634432 sbbp:SaleOfStockConcurrentWithCrgCreditFacilityBorrowingMember 2017-01-01 2017-09-30 0001634432 sbbp:SaleOfStockAtMarketFacilityMember 2017-01-01 2017-09-30 0001634432 sbbp:TaroPharmaceuticalIndustriesMember sbbp:AcquiredDevelopedProductRightsMember sbbp:KeveyisMember sbbp:AssetPurchaseAgreementMember 2017-03-01 2017-03-31 0001634432 sbbp:TaroPharmaceuticalIndustriesMember sbbp:AcquiredDevelopedProductRightsMember sbbp:KeveyisMember sbbp:AssetPurchaseAgreementMember 2016-12-01 2016-12-31 0001634432 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0001634432 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001634432 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001634432 sbbp:LeaseArrangementMarch2015Member 2015-03-01 2015-03-31 0001634432 us-gaap:InProcessResearchAndDevelopmentMember 2016-12-31 0001634432 us-gaap:InProcessResearchAndDevelopmentMember 2015-12-31 0001634432 us-gaap:InProcessResearchAndDevelopmentMember 2017-01-01 2017-09-30 0001634432 us-gaap:InProcessResearchAndDevelopmentMember 2016-01-01 2016-12-31 0001634432 sbbp:AcquiredDevelopedProductRightsMember 2016-12-01 2016-12-31 0001634432 sbbp:AcquiredDevelopedProductRightsMember 2017-09-30 0001634432 sbbp:TaroPharmaceuticalIndustriesMember sbbp:AcquiredDevelopedProductRightsMember sbbp:KeveyisMember sbbp:SupplyAgreementMember 2016-12-31 0001634432 sbbp:AcquiredDevelopedProductRightsMember 2016-01-01 2016-12-31 0001634432 sbbp:EquityDistributionAgreementJmp28April2017Member 2017-07-01 2017-09-30 0001634432 us-gaap:EmployeeStockOptionMember 2017-09-30 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2017-09-30 0001634432 2016-07-01 2016-09-30 0001634432 sbbp:WarrantsIssuedCrgCreditFacilityMember 2017-07-14 0001634432 2016-01-01 2016-09-30 0001634432 2016-09-30 0001634432 2015-12-31 0001634432 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0001634432 us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0001634432 sbbp:LeaseArrangementMarch2015Member 2015-03-31 0001634432 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-09-30 0001634432 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0001634432 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001634432 2017-07-01 2017-09-30 0001634432 sbbp:AcquiredDevelopedProductRightsMember 2017-01-01 2017-09-30 0001634432 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-07-01 2017-09-30 0001634432 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-01 2017-09-30 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2017-07-01 2017-09-30 0001634432 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0001634432 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-09-30 0001634432 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-09-30 0001634432 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001634432 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-07-01 2016-09-30 0001634432 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2016-07-01 2016-09-30 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2016-07-01 2016-09-30 0001634432 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0001634432 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-09-30 0001634432 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0001634432 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001634432 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-09-30 0001634432 us-gaap:MaximumMember us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-09-30 0001634432 sbbp:WarrantsIssuedLoanAgreementOneMember us-gaap:CommonStockMember 2017-07-01 2017-09-30 0001634432 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0001634432 us-gaap:SubsequentEventMember 2017-10-06 2017-10-06 0001634432 sbbp:VestingSubjectToAccelerationMember sbbp:GranteeTwoMember 2017-01-01 2017-09-30 0001634432 sbbp:VestingBasedOnMarketAppreciationEventMember sbbp:GranteeFourMember 2017-01-01 2017-09-30 0001634432 sbbp:VestingBasedOnMarketAppreciationEventMember sbbp:GranteeFiveMember 2017-01-01 2017-09-30 0001634432 sbbp:VestingBasedOnMarketAppreciationEventMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-01-01 2017-09-30 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2016-02-26 2016-02-26 0001634432 sbbp:VestingBasedOnMarketAppreciationEventMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-01-01 2017-09-30 0001634432 sbbp:SaleOfStockConcurrentWithCrgCreditFacilityBorrowingMember 2017-07-14 2017-07-14 0001634432 2016-01-01 2016-12-31 0001634432 sbbp:CreditFacility2017Member 2017-07-14 0001634432 sbbp:CreditFacility2017Member 2017-07-14 2017-07-14 0001634432 sbbp:EquityDistributionAgreementJmp28April2017Member 2017-04-28 2017-04-28 0001634432 sbbp:TaroPharmaceuticalIndustriesMember sbbp:AcquiredDevelopedProductRightsMember sbbp:KeveyisMember sbbp:SupplyAgreementMember 2016-12-01 2016-12-31 0001634432 sbbp:TaroPharmaceuticalIndustriesMember sbbp:AcquiredDevelopedProductRightsMember sbbp:KeveyisMember sbbp:AssetPurchaseAgreementMember 2016-12-31 0001634432 sbbp:WarrantsIssuedPrivateEquityPlacementFacilityMember 2017-09-30 0001634432 sbbp:WarrantsIssuedLoanAgreementOneMember 2017-09-30 0001634432 sbbp:WarrantsIssuedCrgCreditFacilityMember 2017-09-30 0001634432 sbbp:WarrantsIssuedLoanAgreementOneMember 2017-01-01 2017-09-30 0001634432 sbbp:WarrantsIssuedCrgCreditFacilityMember 2017-07-14 2017-07-14 0001634432 sbbp:WarrantsIssuedCrgCreditFacilityMember 2017-07-01 2017-09-30 0001634432 sbbp:AcquiredDevelopedProductRightsMember 2016-12-31 0001634432 2017-09-30 0001634432 2016-12-31 0001634432 2017-01-01 2017-09-30 utr:sqft sbbp:pharmacy sbbp:payment sbbp:item sbbp:product iso4217:USD xbrli:shares xbrli:pure xbrli:shares iso4217:USD false --12-31 Q3 2017 2017-09-30 6-K 0001634432 Non-accelerated Filer Strongbridge Biopharma plc 7500000 4207000 3432000 25078000 25063000 2400000 P7Y P7Y 58291 7822860 394289 428571 7000000 7500000 P6Y 40000000 1600000 0.05 P6Y P3Y 0.040 1.098 1.098 40000 40000 40000 40000 40000 40000 44000 44000 24490000 40177000 10000000 6522000 13530000 2 2 2 1 0.50 0.03 3000000 P12M <div> <div> 3. Revenue recognition Product Revenue, Net   We sell Keveyis to one specialty pharmacy provider (the “Customer”), who is the exclusive distributor of Keveyis in the United States.  The Customer subsequently resells Keveyis to patients, which are covered by payors that may provide for government-mandated or privately negotiated rebates with respect to the purchase of Keveyis.  Revenues from sales of Keveyis are recognized when we satisfy a performance obligation by transferring control of Keveyis to the Customer. Transfer of control occurs upon receipt of Keveyis by the Customer.  We expense incremental costs related to the set-up of the contract with the Customer when incurred, as these costs did not meet the criteria for capitalization. Reserves for Variable Consideration   Revenues from sales of Keveyis are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from rebates, co-pay assistance and other allowances that are offered between us and the patients’ payors.  There is no variable consideration reserve for returns as we do not accept returns of Keveyis.  These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than the Customer). Where appropriate, these estimates may take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. We reassess our estimates on an ongoing basis. If actual results in the future vary from our estimates, we will adjust our estimates. Any such adjustments would affect net product revenue and earnings in the period such variances become known. Trade Discount: We provide the Customer with a discount that is explicitly stated in our contract and is recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from the Customer. To the extent, the services received are distinct from our sale of Keveyis to the Customer, these payments are classified in selling, general and administrative expenses in our consolidated statement of operations and comprehensive loss. Funded Co-pay Assistance Program: We contract with a third-party to manage the co-pay assistance program intended to provide financial assistance to qualified insured patients. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that we expect to receive associated with Keveyis that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. These payments are consideration payable to the customer and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet. Government Rebates: We are subject to discount obligations under state Medicaid programs and Medicare. We estimate our Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated patient mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet. For Medicaid, accruals are based on estimates of future Medicaid beneficiary utilization applied to the Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. Effective January 1, 2011, manufacturers of pharmaceutical products are responsible for 50% of the patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap. In order to estimate the cost to us of this Medicare coverage gap responsibility, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program. Our liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for Keveyis that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. Temporary Supply and Patient Assistance Programs: We provide free Keveyis to uninsured patients who satisfy pre-established criteria for either the Temporary Supply Program or the Patient Assistance Program.  Patients who meet the Temporary Supply Program eligibility criteria may receive a temporary supply of free Keveyis for no more than sixty days while we are determining the patient’s third-party insurance, prescription drug benefit or other third-party coverage for Keveyis.  The Patient Assistance Program provides free Keveyis for up to twelve months to patients that satisfy pre-established criteria for financial need.  We do not recognize any revenue related to these free products and the associated costs are classified in selling, general and administrative expenses in our consolidated statements of operations and comprehensive loss.   <div /></div> </div> P60D P1Y 1 P20D P20D 33.66 30.14 31.46 4000000 37219 37219 23400000 1000 1000 1000

1089000

1422000

979000

14868000

8793000

1110000

3202000

195975000

204081000

3864000

1192000

3521000

197000

401000

3120000

1102000

84000

205000

897000

3864000

309000

822000

3042000

1331000

124000

324000

1007000

371000

3767000

1256000

3264927

170000

6176647

274250

7764569

14743

137531000

92105000

67601000

48035000

43756000

51623000

25469000

66837000

44366000

43756000

-26154000

-22471000

7.37

2.45

2.50

394289

7764569

394289

370280

7000000

<div> <div> 8. Commitments and contingencies (a)  Lease obligations In March 2015, we entered into a 52‑month building sublease agreement for 14,743 square feet of office space in Trevose, Pennsylvania. The lease has annual rent escalations and is recognized on a straight‑line basis over the term of the lease.  As of September 30, 2017, future minimum commitments under facility operating leases were as follows (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Operating </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> leases </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 80 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 319 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 184 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total minimum lease payments </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 583 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   Rent expense recognized under our operating lease, including additional rent charges for utilities, parking, maintenance and real estate taxes, was approximately $226,000 and $206,000 for the nine months ended September 30, 2017 and 2016, respectively. (b) Commitments to Taro Pharmaceuticals Industries Ltd. In December 2016, we acquired the United States marketing rights to Keveyis® (dichlorphenamide) from a subsidiary of Taro.  Keveyis is approved in the United States to treat hyperkalemic, hypokalemic and related variants of primary periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.  Keveyis has received orphan drug exclusivity status in the United States through August 7, 2022.  Under the terms of the asset purchase agreement, we paid Taro an upfront payment in two installments of $1 million in December 2016 and $7.5 million in March 2017, and will pay an aggregate of $7.5 million in potential milestones upon the achievement of certain product sales targets. Taro has agreed to continue to manufacture Keveyis for us under an exclusive supply agreement through the orphan exclusivity period. We are obligated to purchase certain annual minimum amounts of product totaling approximately $29 million over a six-year period. The supply agreement may extend beyond the orphan exclusivity period unless terminated by either party pursuant to the terms of the agreement. If terminated by Taro at the conclusion of the orphan exclusivity period, we have the right to manufacture the product on our own or have the product manufactured by a third party on our behalf. <div /></div> </div>

0.01

600000000

35335026

35812344

35335026

35812344

353000

358000

<div> <div> As of September 30, 2017, future minimum commitments under facility operating leases were as follows (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Operating </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> leases </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 80 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 319 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 184 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total minimum lease payments </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 583 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

968000

591000

32370000

7633000

63639000

35558000

<div> <div> 7. Long-Term debt On July 14, 2017, we entered into a $50 million senior credit facility with CRG LP (“CRG”), a healthcare-focused investment firm, to retire our prior credit facility with Oxford Finance LLC and Horizon Technology Finance Corporation and provide additional capital to us. We initially borrowed $40 million under the term loan agreement and have the option to borrow an additional $10 million based upon the achievement of a certain revenue milestone on or prior to June 30, 2018. Concurrent with the initial borrowing, CRG purchased $3 million of our ordinary shares at a price of $6.98 per share. As a condition to the new credit facility, we issued warrants with a seven-year term to CRG to purchase 394,289 of our ordinary shares at an exercise price of $7.37 per share The term loan agreement has a six-year term with three years of interest-only payments. The interest-only period may be extended to six years based upon the achievement of certain milestones during the first three years of the loan term. The loan agreement provides for interest payable at an annual rate of 12.5% and a final payment fee of 5% of the principal balance. The loan agreement includes a payment-in-kind <a name="exp"></a>(PIK) provision, which allows us to defer 4.0% of the 12.5% annual interest payable under the loan during the first three years of the term of the loan (which may be extended for the entire term of the loan, subject to the satisfaction of certain conditions) by adding such amount to the principal loan amount. We have granted a security interest in substantially all of our existing assets and assets acquired by us in the future, including intellectual property. The loan agreement contains facility and prepayment fees, and customary affirmative and negative covenants, including a financial covenant regarding minimum amounts of net revenue and restrictions on our ability to pay cash dividends, and a list of events that will constitute “events of default” under the loan agreement, and permit the lenders to declare all amounts under the loan agreement immediately due and payable, including a material adverse change in our business, operations or financial condition. We incurred $2.5 million in debt discounts and $0.8 million of debt issuance costs relating to this loan agreement which have been recorded as a reduction to the long-term debt. These amounts will be amortized over the outstanding period of the debt to interest expense using the effective interest rate method. In connection with the retirement of our prior credit facility we incurred a final payment fee of $1.6 million and a loss on early extinguishment of debt of $3.5 million. Future principal payments due under the loan agreement are as follows (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Principal </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Payments </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,765 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13,530 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2022 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 13,530 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2023 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,522 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total future payments </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,347 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>     <div /></div> </div>

0.125

P6Y

2500000

800000

-926000

804000

1599000

8000

<div> <div> 11. Stock‑based compensation Our board of directors has adopted the 2017 Inducement Plan (the “Inducement Plan”). The Inducement Plan provides for the grant of equity-based awards to new employees. The purpose of the Inducement Plan is to attract valued employees by offering them a greater stake in our success and a closer identity with us, and to encourage ownership of our ordinary shares by such employees. The Inducement Plan is effective as of February 23, 2017. As of September 30, 2017, 52,850 shares are available for issuance pursuant to the Inducement Plan. Our board of directors has adopted, and our shareholders have approved, the 2015 Equity Compensation Plan (the “2015 Plan”). The 2015 Plan provides for the grant of incentive stock options to our employees and any parent or subsidiary corporations’ employees, and for the grant of nonstatutory stock options, stock awards, and restricted stock units to our employees, directors and consultants and our parent or subsidiary corporations’ employees and consultants. The 2015 Plan is effective as of September 3, 2015.  As of September 30, 2017, 374,289 shares are available for issuance pursuant to the 2015 Plan. Our board of directors has adopted, and our shareholders have approved, the Non‑Employee Director Equity Compensation Plan (the “Non‑Employee Director Plan”). The Non‑Employee Director Plan provides for the grant of nonstatutory stock options, stock awards, and restricted stock units to our non‑employee directors. The Non‑Employee Director Plan is effective as of September 3, 2015.  As of September 30, 2017, 792 shares are available for issuance pursuant to the Non‑Employee Director Plan. A summary of our outstanding stock options as of September 30, 2017 is as follows: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="9" valign="bottom" style="width:41.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options Outstanding </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Term </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Years) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic Value </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding—January 1, 2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,249,784 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11.00 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.89 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,991,850 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.50 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Forfeited and cancelled </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (64,987) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.37 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding—September 30, 2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,176,647 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.41 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.78 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13,287 </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested and exercisable—September 30, 2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,034,974 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10.38 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.61 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,249 </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div> Included in the stock options outstanding at September 30, 2017 are unvested stock options to purchase 88,908 shares at a weighted average exercise price of $18.80 per share for which the vesting of certain tranches will accelerate if the fair value per share of our stock reaches $31.46. In addition, the options outstanding include 97,652 shares that vest upon a market appreciation event, so long as it occurs prior to the date specified in the applicable award agreement and 97,652 shares that will vest upon the one year anniversary of the market appreciation event. The market appreciation event, which had not yet occurred as of September 30, 2017, is defined as the last trading day in the period in which our closing stock price on each of 20 consecutive trading days reported on NASDAQ has been at least $30.14 or $33.66 for the respective grantee. Stock‑based compensation expense We recognized stock‑based compensation expense for employees and directors for stock options and RSUs in the accompanying unaudited consolidated statements of operations as follows (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:54.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:54.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="6" valign="bottom" style="width:21.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine Months Ended </td> </tr> <tr> <td valign="bottom" style="width:54.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="5" valign="bottom" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="6" valign="bottom" style="width:21.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> </tr> <tr> <td valign="bottom" style="width:54.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:54.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Selling, general and administrative </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 1,007 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 897 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 3,042 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 3,120 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:54.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 324 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 205 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 822 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 401 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:54.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total stock-based compensation </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,331 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,102 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,864 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,521 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div> As of September 30, 2017, the total unrecognized compensation expense related to unvested stock options, net of estimated forfeitures, is $10.3 million, which we expect to recognize over an estimated weighted‑average period of 2.77 years. In determining the estimated fair value of our service-based awards, we use the Black‑Scholes option‑pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment. The fair value of our service-based awards that were granted during the years was estimated with the following assumptions: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.20%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:60.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:37.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine Months Ended </td> </tr> <tr> <td valign="bottom" style="width:60.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:37.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> </tr> <tr> <td valign="bottom" style="width:60.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> <td valign="bottom" style="width:16.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> </tr> <tr> <td valign="bottom" style="width:60.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term (in years) </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.96 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.87 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.78% - 2.26% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.3% - 1.6% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 78.2% - 105.9% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 78.1% - 83.6% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Dividend rate </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> —% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> —% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   Restricted Stock Units On February 26, 2016, our board of directors approved grants of restricted stock units (“RSUs”) to employees.  These RSUs vest two years from the date of issuance, provided that the employee is employed by us on such vesting date. All RSUs will fully vest upon a change of control of our company.  If and when the RSUs vest, we will issue one ordinary share for each whole RSU that has vested, subject to satisfaction of the executive’s tax withholding obligations. The RSUs will cease to be outstanding upon such issuance of ordinary shares.  We recorded expense, which is included in the stock-based compensation table above, of $124,000 and $84,000 for the three months ended September 30, 2017 and 2016, respectively, and $309,000 and $197,000 for the nine months ended September 30, 2017 and 2016, respectively. As of September 30, 2017, the total unrecognized compensation expense related to unvested RSUs is $0.6 million, which we expect to recognize over an estimated weighted‑average period of 1.49 years. A summary of our unvested RSUs as of September 30, 2017 is as follows: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested—January 1, 2017 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 184,000 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 92,250 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (2,000) </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested—September 30, 2017 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 274,250 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

-1.54

-0.36

-2.67

-0.98

1554000

2006000

P2Y9M7D

P1Y5M27D

600000

10300000

2000

28194000

-1953000

<div> <div> The following table presents our assets and liabilities that are measured at fair value on a recurring basis for the periods presented (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:33.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:65.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of September 30, 2017 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level I </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level II </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level III </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 43,756 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 43,756 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total assets </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 43,756 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 43,756 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrant liability </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 39,284 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 39,284 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total liabilities </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 39,284 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 39,284 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:64.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of December 31, 2016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level I </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level II </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level III </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrant liability </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,090 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,090 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total liabilities </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,090 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,090 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> 4. Fair value measurement We follow FASB accounting guidance on fair value measurements for financial assets and liabilities measured on a recurring basis. Because of their short-term nature, the amounts reported in the balance sheet for cash and cash equivalents, and accounts payable approximate fair value. The guidance requires fair value measurements to maximize the use of “observable inputs.” The three-level hierarchy of inputs to measure fair value are as follows:  Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Because of their short-term nature, the amounts reported in the balance sheet for cash and cash equivalents, and accounts payable approximate fair value. Level 2: Significant observable inputs other than Level 1 prices such as quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). The fair values of the outstanding warrants were measured using the Black-Scholes option-pricing model. Inputs used to determine estimated fair value of the warrant liabilities include the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends and the expected volatility of the underlying stock. The significant unobservable inputs used in the fair value measurement of the warrant liabilities were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement. The following table presents our assets and liabilities that are measured at fair value on a recurring basis for the periods presented (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:33.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:65.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of September 30, 2017 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level I </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level II </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level III </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 43,756 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 43,756 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total assets </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 43,756 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 43,756 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrant liability </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 39,284 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 39,284 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total liabilities </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 39,284 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 39,284 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:64.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of December 31, 2016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level I </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level II </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level III </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrant liability </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,090 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,090 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total liabilities </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,090 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,090 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

40177000

29300000

36410000

P8Y

-64000

-20000

-36000

-11000

-3545000

3500000

7256000

15828000

<div> <div> 5. Intangible assets and goodwill The gross carrying amount of in‑process research and development (IPR&D), acquired developed product rights and goodwill is as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:33.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:19.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:63.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of September 30, 2017 </td> <td valign="bottom" style="width:00.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning of Period </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Additions </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:21.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortization/Impairment </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End of Period </td> <td valign="bottom" style="width:00.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;"> IPR&D </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;">      </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;"> 20,723 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;">      </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;">  — </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;">      </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:19.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;"> (20,723) </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;">      </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;">  — </td> <td valign="bottom" style="width:00.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Acquired developed product rights </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:14.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,177 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:19.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3,767) </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 36,410 </td> <td valign="bottom" style="width:00.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,256 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:19.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,256 </td> <td valign="bottom" style="width:00.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 68,156 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:19.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (24,490) </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 43,666 </td> <td valign="bottom" style="width:00.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:35.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:61.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of December 31, 2016 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:17.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning of Period </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Additions </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Impairment </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End of Period </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> IPR&D </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 36,551 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (15,828) </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,723 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Acquired developed product rights </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,177 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,177 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,256 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,256 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 43,807 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,177 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (15,828) </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 68,156 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   Our finite lived intangible asset consists of acquired developed product rights obtained from the asset acquisition of Keveyis® (dichlorphenamide) from a subsidiary of Taro Pharmaceutical Industries Ltd. (“Taro”).  Keveyis is approved in the United States to treat hyperkalemic, hypokalemic and related variants of primary periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.  Keveyis has received orphan drug exclusivity status in the United States through August 7, 2022. In connection with the Asset Purchase Agreement and Supply Agreement we entered into with Taro, we paid Taro an upfront payment in two installments of $1 million in December 2016 and $7.5 million in March 2017.  We concluded that the supply price payable by us exceeds fair value and, therefore, used a discounted cash flow method with a probability assumption to value the payments in excess of fair value at $29.3 million, for which we have recorded an intangible asset and corresponding liability. This liability will be reduced as we purchase inventory over the term of the Supply Agreement.  In addition, we incurred transaction costs of $2.4 million, which were recorded in our Statement of Operations during the year ended December 31, 2016. The overall recording of the transaction resulted in the recording of an intangible asset of $40.2 million. This asset is being amortized over an eight-year period using the straight-line method.  We recorded amortization expense of $3.8 million and $0 for the nine months ended September 30, 2017 and 2016, respectively.  We recorded a $20.7 million impairment charge related to the in-process research and development of veldoreotide, which we acquired from Aspireo Pharmaceuticals, Ltd. in 2015. The factors considered in determining the fair value measurement were future revenues expected to be generated, estimated development timeline, increased costs and, an appropriate risk-adjusted discount rate. The decrease in the valuation of our intangible asset related to veldoreotide is due to a longer estimated development timeline, as well as increased costs above those previously estimated. <div /></div> </div>

5228000

20723000

15828000

20723000

-33645000

-7618000

-94083000

-35910000

255000

-926000

652000

-850000

-1781000

333000

979000

543000

1410000

1003000

-931000

237000

97000

923000

36551000

20723000

60900000

36410000

43807000

68156000

43666000

2838000

1364000

2059000

1003000

<div> <div> Inventory Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Our inventory consists of only finished goods.  <div /></div> </div>

P52M

70559000

111757000

137531000

92105000

15957000

10215000

11090000

39284000

50000000

40347000

13530000

6765000

18434000

37195000

<div> <div> 1. Organizatio<a name="a1Organization_719123"></a>n Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Our first commercial product is Keveyis® (dichlorphenamide), the first and only treatment approved by the U.S. Food and Drug Administration ("FDA") for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Keveyis has orphan drug exclusivity status in the United States through August 7, 2022. In addition to this neuromuscular disease product, we have two clinical-stage product candidates for rare endocrine diseases, Recorlev™ and veldoreotide. Recorlev (levoketoconazole) is a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome. Veldoreotide is a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both Recorlev and veldoreotide have received orphan designation from the FDA and the European Medicines Agency ("EMA"). Given the well-identified and concentrated prescriber base addressing our target markets, we intend to use a small, focused sales force to effectively market Keveyis and our other products and product candidates, if approved, in the United States, the European Union and other key global markets. We believe that our ability to execute on this strategy is enhanced by the significant commercial and clinical development experience of key members of our management team. We will continue to identify and evaluate the potential acquisition of other products and product candidates that would be complementary to our existing rare neuromuscular and endocrine franchises or that would form the basis for new rare disease franchises. We believe this approach will enable us to maximize our commercial potential by further leveraging our existing resources and expertise. Liquidity As of September 30, 2017, we held cash and cash equivalents of $44.4 million. On April 28, 2017, we entered into an equity distribution agreement with JMP Securities LLC (“JMP”), pursuant to which we may sell, at our option, from time to time, up to an aggregate of $40 million in ordinary shares of the Company through JMP, as the sales agent (the “ATM Facility”). On July 14, 2017, we entered into a $50 million senior credit facility with CRG LP (“CRG”), a healthcare-focused investment firm, to retire our prior credit facility with Oxford Finance LLC and Horizon Technology Finance Corporation and provide additional capital to us. We initially borrowed $40 million under the term loan agreement and have the option to borrow an additional $10 million based upon the achievement of a certain revenue milestone on or prior to June 30, 2018. Concurrent with the initial borrowing, CRG purchased $3 million of our ordinary shares at a price of $6.98 per share. The loan and security agreement contains financial and non-financial covenants including minimum amounts of net revenue we must achieve in 2017 and beyond. Failure to comply with the covenants could result in the lenders declaring the loan immediately due and payable. Our liquidity requirements are predicated on maintaining compliance with the debt covenants and repaying outstanding borrowings in accordance with the loan agreement. On October 6, 2017, we sold 4,000,000 ordinary shares in a public offering at a price to the public of $6.25 per ordinary share for net proceeds of approximately $23.4 million, after deducting underwriting discounts and commissions and offering expenses payable by us.   We may never achieve profitability, and unless and until we do, we will continue to need to raise additional capital. We believe the combination of our existing cash resources as of September 30, 2017 and the net proceeds from our October 2017 public offering, will enable us to fund future cash requirements for at least the next twelve months from the date of issuance of these unaudited consolidated financial statements. We expect our funding requirements for operating expenses to increase due to expenses associated with the commercialization of Keveyis, the execution of the Recorlev SONICS and LOGICS Phase 3 clinical trials, and our selling, general and administrative expenses. Our funding requirements will also increase to the extent we pursue potential in-licenses, acquisitions or similar transactions as part of our strategy. These expenses may be offset only in part by sales of Keveyis. To the extent our sales of Keveyis are less than we anticipate, or our expenses are higher than we anticipate, we may be required to fund our operations and capital needs through additional equity or debt financings. There can be no assurances, however, that additional funding will be available on terms acceptable to us. <div /></div> </div>

-1412000

19479000

-7500000

-24742000

-34450000

-32597000

-7601000

-94735000

-35060000

-122000

-17000

-32597000

-7601000

-94735000

-35060000

<div> <div> Recent accounting pronouncements In January 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-04, Intangibles - Goodwill and Other:  Simplifying the Accounting for Goodwill Impairment. ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. This standard, which will be effective for the us beginning in the first quarter of fiscal year 2021, is required to be applied prospectively. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact this standard will have on our financial statements.   In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments, which clarifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows in order to reduce diversity in practice. The guidance is effective for us beginning in the first quarter of fiscal year 2018. Early adoption is permitted. We are currently evaluating the impact of adopting this guidance on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Improvements to Employee Share-Based Payment Accounting,  which affects all entities that issue share-based payment awards to their employees. The amendments in this ASU cover such areas as the recognition of excess tax benefits and deficiencies, the classification of those excess tax benefits on the statement of cash flows, an accounting policy election for forfeitures, the amount an employer can withhold to cover income taxes and still qualify for equity classification and the classification of those taxes paid on the statement of cash flows. This ASU is effective for annual and interim periods beginning after December 15, 2016. This guidance can be applied either prospectively, retrospectively or using a modified retrospective transition method. Early adoption is permitted. We have adopted the standard effective January 1, 2017 and have elected to account for forfeitures as they occur as opposed to estimating forfeitures. The adoption of this standard did not have a material impact on our financial statements.  In February 2016, the FASB issued ASU No. 2016-02, Leases, that discusses how an entity should account for lease assets and lease liabilities. The guidance specifies that an entity who is a lessee under lease agreements should recognize lease assets and lease liabilities for those leases classified as operating leases under previous FASB guidance. Accounting for leases by lessors is largely unchanged under the new guidance. The guidance is effective for the us beginning in the first quarter of fiscal year 2019. Early adoption is permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. We are currently evaluating the impact of adopting this guidance on our consolidated financial statements. In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities,  that modifies certain aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The accounting standard update is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, and early adoption is permitted.  We are currently assessing the impact that adopting this new accounting guidance will have on our consolidated financial statements. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU No. 2015-11 applies only to inventory for which cost is determined by methods other than last in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. We adopted this standard on April 1, 2017. The adoption of this standard had no impact on the Company’s consolidated financial statements, there was no accounting impact to previously issued financial statements based on our adoption. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The new guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. We adopted this new standard on April 1, 2017 in conjunction with the launch of Keveyis. As we did not record revenue prior to adopting this standard, there was no accounting impact to previously issued financial statements based on our adoption of ASC Topic 606.  <div /></div> </div>

-1275000

15000

-34506000

-2885000

-32370000

-7633000

-59577000

-33025000

583000

184000

319000

80000

206000

226000

<div> <div> 2. Summary of significant accounting policies and basis of presentation Basis of presentation These unaudited consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (U.S. GAAP). The unaudited consolidated financial statements reflect all adjustments, which include only normal recurring adjustments that are, in the opinion of management, necessary to present a fair statement of the operating results and financial position for the periods presented. The preparation of the unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures in the consolidated financial statements.  Actual results could differ from those estimates. These unaudited consolidated financial statements should be read in conjunction with the accounting policies and notes to the audited consolidated financial statements included in our 2016 Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2017.  Operating results for the nine months ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. Revenue recognition Prior to the April 2017 launch of Keveyis, we did not generate any revenue. Therefore, we adopted Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers, effective April 1, 2017.  Topic 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.  Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services.  To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We apply the five-step model to contracts only when it is probable that we will collect the consideration we are entitled to receive in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For a complete discussion of accounting for net product revenue, see Note 3, "Revenue Recognition". Inventory Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Our inventory consists of only finished goods.  Foreign currency translation The consolidated financial statements are reported in United States dollars, which is our functional currency, including each of our consolidated subsidiaries. Transactions in foreign currencies are remeasured into our functional currency at the rate of exchange prevailing at the date of the transaction. Any monetary assets and liabilities arising from these transactions are remeasured into our functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded in foreign exchange loss in our consolidated statements of operations. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. We must apply significant judgment in this process. Actual results could materially differ from those estimates. Net loss per share Basic net loss per share is calculated by dividing the net loss attributable to shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted net loss per share is calculated by dividing the net loss attributable to shareholders by the weighted‑average number of ordinary shares outstanding for the period, including any dilutive effect from outstanding stock options or other equity-based awards. Shares used in the diluted net loss per share calculations exclude anti‑dilutive ordinary share equivalents, which currently consist of outstanding stock options, unvested restricted stock units and warrants. The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of September 30, 2017 and 2016, as they would be anti-dilutive: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:00.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:25.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine Months Ended </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:25.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,764,569 </td> <td valign="middle" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:00.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options issued and outstanding </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,176,647 </td> <td valign="middle" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td valign="middle" style="width:00.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,264,927 </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested restricted stock units </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 274,250 </td> <td valign="middle" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:00.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 170,000 </td> </tr> </table></div>   Recent accounting pronouncements In January 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-04, Intangibles - Goodwill and Other:  Simplifying the Accounting for Goodwill Impairment. ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. This standard, which will be effective for the us beginning in the first quarter of fiscal year 2021, is required to be applied prospectively. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact this standard will have on our financial statements.   In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments, which clarifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows in order to reduce diversity in practice. The guidance is effective for us beginning in the first quarter of fiscal year 2018. Early adoption is permitted. We are currently evaluating the impact of adopting this guidance on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Improvements to Employee Share-Based Payment Accounting,  which affects all entities that issue share-based payment awards to their employees. The amendments in this ASU cover such areas as the recognition of excess tax benefits and deficiencies, the classification of those excess tax benefits on the statement of cash flows, an accounting policy election for forfeitures, the amount an employer can withhold to cover income taxes and still qualify for equity classification and the classification of those taxes paid on the statement of cash flows. This ASU is effective for annual and interim periods beginning after December 15, 2016. This guidance can be applied either prospectively, retrospectively or using a modified retrospective transition method. Early adoption is permitted. We have adopted the standard effective January 1, 2017 and have elected to account for forfeitures as they occur as opposed to estimating forfeitures. The adoption of this standard did not have a material impact on our financial statements.  In February 2016, the FASB issued ASU No. 2016-02, Leases, that discusses how an entity should account for lease assets and lease liabilities. The guidance specifies that an entity who is a lessee under lease agreements should recognize lease assets and lease liabilities for those leases classified as operating leases under previous FASB guidance. Accounting for leases by lessors is largely unchanged under the new guidance. The guidance is effective for the us beginning in the first quarter of fiscal year 2019. Early adoption is permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. We are currently evaluating the impact of adopting this guidance on our consolidated financial statements. In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities,  that modifies certain aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The accounting standard update is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, and early adoption is permitted.  We are currently assessing the impact that adopting this new accounting guidance will have on our consolidated financial statements. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU No. 2015-11 applies only to inventory for which cost is determined by methods other than last in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. We adopted this standard on April 1, 2017. The adoption of this standard had no impact on the Company’s consolidated financial statements, there was no accounting impact to previously issued financial statements based on our adoption. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The new guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. We adopted this new standard on April 1, 2017 in conjunction with the launch of Keveyis. As we did not record revenue prior to adopting this standard, there was no accounting impact to previously issued financial statements based on our adoption of ASC Topic 606.    <div /></div> </div>

497000

153000

150000

387000

-1211000

35000

107000

82000

550000

408000

7500000

1000000

7500000

1412000

764000

1687000

73000

2981000

38686000

40000000

-32719000

-7618000

-94735000

-35060000

25000

17000

29000000

22261000

15882000

4516000

12113000

4504000

-129400000

-224135000

4062000

2533000

4062000

2533000

<div> <div> Accrued liabilities consist of the following (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Consulting and professional fees </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,202 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,110 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued payable due Taro Pharmaceuticals Industries Ltd. </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,500 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Supply agreement - current portion </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,432 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,207 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Employee compensation </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,006 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,554 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 153 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 497 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total accrued liabilities </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 8,793 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 14,868 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:00.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:25.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine Months Ended </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:25.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,764,569 </td> <td valign="middle" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:00.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options issued and outstanding </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,176,647 </td> <td valign="middle" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td valign="middle" style="width:00.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,264,927 </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested restricted stock units </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 274,250 </td> <td valign="middle" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:00.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 170,000 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> We recognized stock‑based compensation expense for employees and directors for stock options and RSUs in the accompanying unaudited consolidated statements of operations as follows (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:54.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:54.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="6" valign="bottom" style="width:21.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine Months Ended </td> </tr> <tr> <td valign="bottom" style="width:54.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="5" valign="bottom" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="6" valign="bottom" style="width:21.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> </tr> <tr> <td valign="bottom" style="width:54.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:54.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Selling, general and administrative </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 1,007 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 897 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 3,042 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 3,120 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:54.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 324 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 205 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 822 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 401 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:54.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total stock-based compensation </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,331 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,102 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,864 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,521 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The gross carrying amount of in‑process research and development (IPR&D), acquired developed product rights and goodwill is as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:33.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:19.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:63.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of September 30, 2017 </td> <td valign="bottom" style="width:00.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning of Period </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Additions </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:21.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortization/Impairment </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End of Period </td> <td valign="bottom" style="width:00.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;"> IPR&D </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;">      </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;"> 20,723 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;">      </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;">  — </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;">      </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:19.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;"> (20,723) </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;">      </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;">  — </td> <td valign="bottom" style="width:00.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:14.80pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Acquired developed product rights </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:14.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,177 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:19.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3,767) </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 36,410 </td> <td valign="bottom" style="width:00.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,256 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:19.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,256 </td> <td valign="bottom" style="width:00.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 68,156 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:19.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (24,490) </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 43,666 </td> <td valign="bottom" style="width:00.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:35.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:61.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of December 31, 2016 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:17.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning of Period </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Additions </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Impairment </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End of Period </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> IPR&D </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 36,551 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (15,828) </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,723 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Acquired developed product rights </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,177 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,177 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,256 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,256 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 43,807 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,177 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (15,828) </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 68,156 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Future principal payments due under the loan agreement are as follows (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Principal </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Payments </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,765 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13,530 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2022 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 13,530 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2023 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,522 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total future payments </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,347 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested—January 1, 2017 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 184,000 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 92,250 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (2,000) </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested—September 30, 2017 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 274,250 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="9" valign="bottom" style="width:41.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options Outstanding </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Term </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Years) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic Value </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding—January 1, 2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,249,784 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11.00 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.89 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,991,850 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.50 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Forfeited and cancelled </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (64,987) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.37 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding—September 30, 2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,176,647 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.41 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.78 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13,287 </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested and exercisable—September 30, 2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,034,974 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10.38 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.61 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,249 </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.20%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:60.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:37.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine Months Ended </td> </tr> <tr> <td valign="bottom" style="width:60.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:37.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> </tr> <tr> <td valign="bottom" style="width:60.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> <td valign="bottom" style="width:16.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> </tr> <tr> <td valign="bottom" style="width:60.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term (in years) </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.96 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.87 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.78% - 2.26% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.3% - 1.6% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 78.2% - 105.9% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 78.1% - 83.6% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Dividend rate </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> —% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> —% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:34.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:34.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:06.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Expiration </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:34.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Classification </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Date </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Issued </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:34.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants in connection with private equity placement </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Liability </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.50 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6/28/2022 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,000,000 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,000,000 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:34.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrants in connection with Horizon and Oxford loan agreement </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Equity </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.45 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12/28/2026 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 428,571 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (58,291) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 370,280 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:34.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants in connection with CRG loan agreement </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Equity </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.37 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7/14/2024 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 394,289 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 394,289 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:34.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,822,860 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,764,569 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

11260000

3117000

26068000

8484000

3521000

3864000

P2Y

2000

92250

184000

274250

P5Y10M13D

P5Y11M16D

0.836

1.059

0.781

0.782

0.016

0.0226

0.013

0.0178

374289

52850

792

2249000

2034974

10.38

P5Y7M10D

64987

2991850

13287000

3249784

6176647

88908

97652

11.00

7.41

18.80

P6Y10M21D

P7Y9M11D

7.37

3.50

6.98

6.25

40000

35335026

40000

35812344

66972000

44000

195975000

353000

-129400000

-19652000

44000

204081000

358000

-224135000

10300

429799

10300

429799

73000

2981000

73000

2977000

4000

1000

73000

<div> <div>                                 12. Subsequent Events On October 6, 2017, we sold 4,000,000 ordinary shares in a public offering at a price to the public of $6.25 per ordinary share for net proceeds of approximately $23.4 million, after deducting underwriting discounts and commissions and offering expenses payable by us.                   <div /></div> </div>

11090000

39284000

21205382

35463496

35716247

EX-101.SCH 6 sbbp-20170930.xsd EX-101.SCH 00100 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Consolidated Statements of Cash Flow link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Fair value measurement (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Intangible assets and goodwill - Components (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Accrued liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Long Term Debt - Future principal payments (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Commitments and contingencies - Lease (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Consolidated Statement of Stockholders’ (Deficit) Equity link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of significant accounting policies and basis of presentation link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Revenue recognition link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Fair value measurement link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Intangible assets and goodwill link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Accrued liabilities link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Long Term Debt link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Ordinary shares link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of significant accounting policies and basis of presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Summary of significant accounting policies and basis of presentation (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Fair value measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Intangible assets and goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Accrued liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Long Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Commitments and contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Ordinary shares (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Organization - Products (Details) link:presentationLink link:calculationLink link:definitionLink 40102 - Disclosure - Organization - Cash (Details) link:presentationLink link:calculationLink link:definitionLink 40103 - Disclosure - Organization - Equity distribution agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40104 - Disclosure - Organization - Credit facility (Details) link:presentationLink link:calculationLink link:definitionLink 40105 - Disclosure - Organization - Public offering (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of significant accounting policies and basis of presentation - Antidilutive securities (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Revenue recognition - General (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Revenue recognition - Allowance and Reserve (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Intangible assets and goodwill - Asset purchase (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Long Term Debt - Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Commitments and contingencies - Commitments to Taro (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Ordinary shares - Equity transactions (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Ordinary shares - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Stock-based compensation - General (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Stock-based compensation - Stock options (Details) link:presentationLink link:calculationLink link:definitionLink 41103 - Disclosure - Stock-based compensation - Options outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 41104 - Disclosure - Stock-based compensation - Stock-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 41105 - Disclosure - Stock-based compensation - Fair value assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 41106 - Disclosure - Stock-based compensation - Restricted stock units (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Subsequent events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 sbbp-20170930_cal.xml EX-101.CAL EX-101.DEF 8 sbbp-20170930_def.xml EX-101.DEF EX-101.LAB 9 sbbp-20170930_lab.xml EX-101.LAB No definition available. Document and Entity Information [Abstract] Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Document Fiscal Year Focus Document Fiscal Period Focus Consolidated Balance Sheets Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents—end of period Cash and cash equivalents—beginning of period Cash and cash equivalents Accounts Receivable, Net, Current Accounts receivable Inventory, Net Inventory Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Deferred Tax Assets, Net, Noncurrent Deferred tax asset Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Goodwill Goodwill, End of Period Goodwill, Beginning of Period Goodwill Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY Accrued Liabilities, Current [Abstract] Current liabilities: Accounts Payable Accounts payable Accrued Liabilities, Current Accrued liabilities Total accrued liabilities Liabilities, Current Total current liabilities Long-term Debt, Excluding Current Maturities Long-term debt Warrants and Rights Outstanding Warrant liabilities Warrant liability Carrying value as of the balance sheet date of obligations incurred through that date and due beyond one year (or beyond one operating cycle if longer) in connection with supply agreement. Accrued Liabilities, Supply Agreement, Noncurrent Supply agreement liability, noncurrent Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note 8) Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders’ (deficit) equity: Aggregate par or state value of deferred shares issued in order to satisfy legislative requirement to maintain a minimum level of issued share capital denominated in euro. Deferred Shares, Value Deferred shares, $1.098 par value, 40,000 shares authorized, issued and outstanding at September 30, 2017 and December 31, 2016 Common Stock, Value, Issued Ordinary shares, $0.01 par value, 600,000,000 shares authorized at September 30, 2017 and December 31, 2016; 35,812,344 and 35,335,026 shares issued and outstanding at September 30, 2017 and December 31, 2016 Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Balance at end of period Balance at beginning of period Total stockholders’ (deficit) equity Liabilities and Equity Total liabilities and stockholders’ (deficit) equity Face amount or stated value per share of deferred shares. Deferred Shares, Par Or Stated Value Per Share Deferred shares, par value (in dollars per share) The maximum number of deferred shares permitted to be issued by an entity's charter and bylaws. Deferred Shares , Shares Authorized Deferred shares, shares authorized Total number of deferred shares of an entity that have been sold or granted to shareholders (includes related deferred shares that were issued, repurchased, and remain in the treasury). Deferred Shares , Shares Issued Deferred shares, shares issued Number of deferred stock of stock outstanding. Deferred Shares, Shares Outstanding Deferred shares, shares outstanding Common Stock, Par or Stated Value Per Share Ordinary shares, par value (in dollars per share) Common Stock, Shares Authorized Ordinary shares, shares authorized Common Stock, Shares, Issued Ordinary shares, shares issued Common Stock, Shares, Outstanding Ordinary shares, shares outstanding Consolidated Statements of Operations and Comprehensive Loss Revenues [Abstract] Revenues: Revenue, Net Net product sales Revenues Total revenues Operating Expenses [Abstract] Cost and expenses: Cost of Goods Sold Cost of sales (excluding amortization of intangible asset) Selling, General and Administrative Expense Selling, general and administrative Research and Development Expense Research and development Amortization of Intangible Assets Acquired product rights, Amortization Amortization of intangible asset Impairment of Intangible Assets (Excluding Goodwill) Impairment of intangible asset Costs and Expenses Total cost and expenses Operating Income (Loss) Operating loss Nonoperating Income (Expense) [Abstract] Other income (expense), net: Fair Value Adjustment of Warrants Unrealized gain (loss) on fair value of warrants Change in fair value of warrant liability Interest Expense Interest expense Foreign Currency Transaction Gain (Loss), before Tax Foreign exchange loss Gain (Loss) on Extinguishment of Debt Loss on early extinguishment of debt Loss on early extinguishment of debt Other Nonoperating Income (Expense) Other income (expense), net Nonoperating Income (Expense) Total other income (expense), net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Income Tax Expense (Benefit) Income tax (expense) benefit Income tax expense Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net loss Net Income (Loss) Attributable to Noncontrolling Interest Net loss attributable to non-controlling interest Net Income (Loss) Attributable to Parent Net loss attributable to Strongbridge Biopharma No definition available. Net Income (Loss) Available to Common Stockholders, Basic and Diluted [Abstract] Net loss attributable to ordinary shareholders: Net Income (Loss) Available to Common Stockholders, Basic Basic Earnings Per Share, Basic and Diluted [Abstract] Net loss per share attributable to ordinary shareholders: Earnings Per Share, Basic and Diluted Basic and diluted (in dollars per share) Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Weighted-average shares used in computing net loss per share attributable to ordinary shareholders: Weighted Average Number of Shares Outstanding, Basic and Diluted Basic and diluted Consolidated Statements of Shareholders’ Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Shares, Outstanding Balance (in shares) Balance (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation Stock Issued During Period, Value, New Issues Issuance of shares, net of offering costs Stock Issued During Period, Shares, New Issues Issuance of shares (in shares) Value of stock issued as a result of the exercise of warrants. Stock Issued During Period, Value, Warrants Exercised Exercise of warrants Number of shares issued in exercise of warrants during the current period. Stock Issued During Period, Shares, Warrants Exercised Exercise of warrants (shares) Shares issued in exercise of warrants Adjustments to Additional Paid in Capital, Warrant Issued Issuance of warrants related to the loan agreement, net Consolidated Statements of Cash Flow Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-based Compensation Stock-based compensation Paid-in-Kind Interest Interest paid in kind Amortization of Debt Issuance Costs and Discounts Amortization of debt discounts and debt issuance costs Deferred Income Tax Expense (Benefit) Deferred income tax expense (benefit) Depreciation Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net Impairment/loss on investment in Antisense Therapeutics Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventory Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Other Noncurrent Assets Other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued liabilities and other liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Businesses and Interest in Affiliates Payment for acquisition Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Proceeds from Issuance of Debt Proceeds from long-term debt Repayments of Debt Payment of long-term debt Proceeds from Issuance of Common Stock Proceeds from issuance of ordinary shares Payments to Noncontrolling Interests Acquisition of non-controlling interest Net Cash Provided by (Used in) Financing Activities Net cash provided by (used in) financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net decrease in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental disclosures of cash flow information - Cash paid during the year for: Interest Paid, Net Interest Income Taxes Paid, Net Income taxes other, net of refunds Organization Nature of Operations [Text Block] Organization Summary of significant accounting policies and basis of presentation Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Summary of significant accounting policies and basis of presentation Revenue recognition Disclosure pertaining to revenue. Revenues Disclosure [Text Block] Revenue recognition Fair value measurement Fair Value Disclosures [Text Block] Fair value measurement Intangible assets and goodwill Goodwill and Intangible Assets Disclosure [Text Block] Intangible assets and goodwill Accrued liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued liabilities Debt Disclosure Debt Disclosure [Text Block] Long Term Debt Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and contingencies Income taxes Income Tax Disclosure [Text Block] Income taxes Ordinary shares. Stockholders' Equity Note Disclosure [Text Block] Ordinary shares Stock-based compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock based compensation Subsequent events Subsequent Events [Text Block] Subsequent events Basis of Accounting, Policy [Policy Text Block] Basis of presentation Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Inventory, Policy [Policy Text Block] Inventory Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign currency translation Use of Estimates, Policy [Policy Text Block] Use of estimates Earnings Per Share, Policy [Policy Text Block] Net loss per share New Accounting Pronouncements, Policy [Policy Text Block] Recent accounting pronouncements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potentially dilutive securities excluded from computations of diluted weighted average shares outstanding Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Schedule of fair value of financial assets by level Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of gross carrying amount of in process research and development and goodwill Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued liabilities Schedule of Maturities of Long-term Debt [Table Text Block] Future principal payments Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Schedule of future minimum commitments under facility operating leases Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of warrants Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of summary of outstanding stock options activity Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of stock-based compensation Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of assumptions for estimating fair value of stock option awards Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Schedule of summary of unvested RSUs Number of clinical-stage product candidates. Number of Clinical-Stage Product Candidates Number of clinical-stage product candidates Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] No definition available. Equity Distribution [Abstract] Equity distribution agreement Maximum aggregate amount of common shares issuable under the agreement. Common Stock, Aggregate Issue Amount Aggregate shares issuable (in dollars) Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Debt No definition available. Liquidity [Abstract] Liquidity Line of Credit Facility, Maximum Borrowing Capacity Maximum borrowing capacity The additional borrowing capacity available under the credit facility, upon achievement of certain specified milestones. Line Of Credit Facility, Contingent Additional Borrowing Capacity Additional borrowing capacity on achievement of milestones The gross proceeds from the additional capital contribution to the entity. Proceeds From Issuance Of Common Stock, Gross Gross proceeds from stock issuance Shares Issued, Price Per Share Price per share (in dollars per share) No definition available. Public Offering [Abstract] Public offering Number of new stock issued n a public offering during the period. Stock Issued During Period, Shares, New Issues, Public Offering Issuance of shares in public offering (in shares) Equity impact of the value of new stock issued in a public offering during the period. Stock Issued During Period, Value, New Issues, Public Offering Issuance of shares in public offering Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities Earnings Per Share [Abstract] Net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive shares of common stock (in shares) Represents the number of specialty pharmacy providers. Number of Specialty Pharmacy Provider Number of specialty pharmacy providers Revenue Recognition, Sales Returns, Reserve for Sales Returns Reserve for returns Represents the percentage of patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap. Percentage of Patient’s Cost of Branded Prescription Drugs Related to the Medicare Part D Coverage Gap Percentage of patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap for which manufacturers of pharmaceutical products are responsible Represents maximum period over which entity may provide free product to patient while determining insurance coverage, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Revenue, Temporary Supply Temporary supply period Represent maximum period over which entity may provide free product to patient due to financial need, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Revenue, Financial Need Financial need period Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets, Fair Value Disclosure [Abstract] Assets Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Assets, Fair Value Disclosure Total Assets Liabilities, Fair Value Disclosure [Abstract] Liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Total liabilities EX-101.PRE 10 sbbp-20170930_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	Strongbridge Biopharma plc
Entity Central Index Key	0001634432
Document Type	6-K
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3

XML 12 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 44,366	$ 66,837
Accounts receivable	979
Inventory	1,003
Prepaid expenses and other current assets	1,687	764
Total current assets	48,035	67,601
Property and equipment, net	17	25
Deferred tax asset		1,599
Intangible assets, net	36,410	60,900
Goodwill	7,256	7,256
Other assets	387	150
Total assets	92,105	137,531
Current liabilities:
Accounts payable	1,422	1,089
Accrued liabilities	8,793	14,868
Total current liabilities	10,215	15,957
Long-term debt	37,195	18,434
Warrant liability	39,284	11,090
Supply agreement liability, noncurrent	25,063	25,078
Total liabilities	111,757	70,559
Commitments and contingencies (Note 8)
Stockholders’ (deficit) equity:
Deferred shares, $1.098 par value, 40,000 shares authorized, issued and outstanding at September 30, 2017 and December 31, 2016	44	44
Ordinary shares, $0.01 par value, 600,000,000 shares authorized at September 30, 2017 and December 31, 2016; 35,812,344 and 35,335,026 shares issued and outstanding at September 30, 2017 and December 31, 2016	358	353
Additional paid-in capital	204,081	195,975
Accumulated deficit	(224,135)	(129,400)
Total stockholders’ (deficit) equity	(19,652)	66,972
Total liabilities and stockholders’ (deficit) equity	$ 92,105	$ 137,531

XML 13 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Consolidated Balance Sheets
Deferred shares, par value (in dollars per share)	$ 1.098	$ 1.098
Deferred shares, shares authorized	40,000	40,000
Deferred shares, shares issued	40,000	40,000
Deferred shares, shares outstanding	40,000	40,000
Ordinary shares, par value (in dollars per share)	$ 0.01	$ 0.01
Ordinary shares, shares authorized	600,000,000	600,000,000
Ordinary shares, shares issued	35,812,344	35,335,026
Ordinary shares, shares outstanding	35,812,344	35,335,026

XML 14 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues:
Net product sales	$ 2,533		$ 4,062
Total revenues	2,533		4,062
Cost and expenses:
Cost of sales (excluding amortization of intangible asset)	591		968
Selling, general and administrative	8,484	$ 3,117	26,068	$ 11,260
Research and development	4,504	4,516	12,113	15,882
Amortization of intangible asset	1,256		3,767
Impairment of intangible asset	20,723		20,723	5,228
Total cost and expenses	35,558	7,633	63,639	32,370
Operating loss	(33,025)	(7,633)	(59,577)	(32,370)
Other income (expense), net:
Unrealized gain (loss) on fair value of warrants	1,953		(28,194)
Interest expense	(1,364)		(2,838)
Foreign exchange loss	(11)	(20)	(36)	(64)
Loss on early extinguishment of debt	(3,545)		(3,545)
Other income (expense), net	82	35	107	(1,211)
Total other income (expense), net	(2,885)	15	(34,506)	(1,275)
Loss before income taxes	(35,910)	(7,618)	(94,083)	(33,645)
Income tax (expense) benefit	850		(652)	926
Net loss	(35,060)	(7,618)	(94,735)	(32,719)
Net loss attributable to non-controlling interest		17		122
Net loss attributable to Strongbridge Biopharma	(35,060)	(7,601)	(94,735)	(32,597)
Net loss attributable to ordinary shareholders:
Basic	$ (35,060)	$ (7,601)	$ (94,735)	$ (32,597)
Net loss per share attributable to ordinary shareholders:
Basic and diluted (in dollars per share)	$ (0.98)	$ (0.36)	$ (2.67)	$ (1.54)
Weighted-average shares used in computing net loss per share attributable to ordinary shareholders:
Basic and diluted	35,716,247	21,205,382	35,463,496	21,205,382

XML 15 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Stockholders’ (Deficit) Equity - 9 months ended Sep. 30, 2017 - USD ($) $ in Thousands	Concurrent with CRG credit facility borrowing Ordinary Shares	Concurrent with CRG credit facility borrowing Additional Paid-In Capital	Concurrent with CRG credit facility borrowing	ATM Facility Ordinary Shares Maximum	ATM Facility Ordinary Shares	ATM Facility Additional Paid-In Capital	ATM Facility	Ordinary Shares	Deferred Shares	Additional Paid-In Capital Maximum	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at beginning of period at Dec. 31, 2016								$ 353	$ 44		$ 195,975	$ (129,400)	$ 66,972
Balance (in shares) at Dec. 31, 2016								35,335,026	40,000
Increase (Decrease) in Stockholders' Equity
Net loss												(94,735)	(94,735)
Stock-based compensation											3,864		3,864
Issuance of shares, net of offering costs	$ 4	$ 2,977	$ 2,981	$ 1		$ 73	$ 73
Issuance of shares (in shares)	429,799				10,300
Exercise of warrants								$ 1		$ 1			1
Exercise of warrants (shares)								37,219
Issuance of warrants related to the loan agreement, net											1,192		1,192
Balance at end of period at Sep. 30, 2017								$ 358	$ 44		$ 204,081	$ (224,135)	$ (19,652)
Balance (in shares) at Sep. 30, 2017								35,812,344	40,000

XML 16 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flow - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (94,735)	$ (32,719)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liability	28,194
Impairment of intangible asset	20,723	5,228
Stock-based compensation	3,864	3,521
Amortization of intangible asset	3,767
Loss on early extinguishment of debt	3,545
Interest paid in kind	408
Amortization of debt discounts and debt issuance costs	371
Deferred income tax expense (benefit)	804	(926)
Depreciation	8	8
Impairment/loss on investment in Antisense Therapeutics		550
Changes in operating assets and liabilities:
Accounts receivable	(979)
Inventory	(1,003)
Prepaid expenses and other current assets	(923)	(97)
Other assets	(237)	931
Accounts payable	333	(1,781)
Accrued liabilities and other liabilities	1,410	543
Net cash used in operating activities	(34,450)	(24,742)
Cash flows from investing activities:
Payment for acquisition	(7,500)
Net cash used in investing activities	(7,500)
Cash flows from financing activities:
Proceeds from long-term debt	38,686
Payment of long-term debt	(22,261)
Acquisition of non-controlling interest		(1,412)
Net cash provided by (used in) financing activities	19,479	(1,412)
Net decrease in cash and cash equivalents	(22,471)	(26,154)
Cash and cash equivalents—beginning of period	66,837	51,623
Cash and cash equivalents—end of period	44,366	$ 25,469
Supplemental disclosures of cash flow information - Cash paid during the year for:
Interest	2,059
Income taxes other, net of refunds	255
Concurrent with CRG credit facility borrowing
Cash flows from financing activities:
Proceeds from issuance of ordinary shares	2,981
At-the-market facility
Cash flows from financing activities:
Proceeds from issuance of ordinary shares	$ 73

XML 17 R7.htm IDEA: XBRL DOCUMENT

Organization	9 Months Ended
Organization	Sep. 30, 2017
Organization
Organization	1. Organization Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Our first commercial product is Keveyis® (dichlorphenamide), the first and only treatment approved by the U.S. Food and Drug Administration ("FDA") for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Keveyis has orphan drug exclusivity status in the United States through August 7, 2022. In addition to this neuromuscular disease product, we have two clinical-stage product candidates for rare endocrine diseases, Recorlev™ and veldoreotide. Recorlev (levoketoconazole) is a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome. Veldoreotide is a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both Recorlev and veldoreotide have received orphan designation from the FDA and the European Medicines Agency ("EMA"). Given the well-identified and concentrated prescriber base addressing our target markets, we intend to use a small, focused sales force to effectively market Keveyis and our other products and product candidates, if approved, in the United States, the European Union and other key global markets. We believe that our ability to execute on this strategy is enhanced by the significant commercial and clinical development experience of key members of our management team. We will continue to identify and evaluate the potential acquisition of other products and product candidates that would be complementary to our existing rare neuromuscular and endocrine franchises or that would form the basis for new rare disease franchises. We believe this approach will enable us to maximize our commercial potential by further leveraging our existing resources and expertise. Liquidity As of September 30, 2017, we held cash and cash equivalents of $44.4 million. On April 28, 2017, we entered into an equity distribution agreement with JMP Securities LLC (“JMP”), pursuant to which we may sell, at our option, from time to time, up to an aggregate of $40 million in ordinary shares of the Company through JMP, as the sales agent (the “ATM Facility”). On July 14, 2017, we entered into a $50 million senior credit facility with CRG LP (“CRG”), a healthcare-focused investment firm, to retire our prior credit facility with Oxford Finance LLC and Horizon Technology Finance Corporation and provide additional capital to us. We initially borrowed $40 million under the term loan agreement and have the option to borrow an additional $10 million based upon the achievement of a certain revenue milestone on or prior to June 30, 2018. Concurrent with the initial borrowing, CRG purchased $3 million of our ordinary shares at a price of $6.98 per share. The loan and security agreement contains financial and non-financial covenants including minimum amounts of net revenue we must achieve in 2017 and beyond. Failure to comply with the covenants could result in the lenders declaring the loan immediately due and payable. Our liquidity requirements are predicated on maintaining compliance with the debt covenants and repaying outstanding borrowings in accordance with the loan agreement. On October 6, 2017, we sold 4,000,000 ordinary shares in a public offering at a price to the public of $6.25 per ordinary share for net proceeds of approximately $23.4 million, after deducting underwriting discounts and commissions and offering expenses payable by us. We may never achieve profitability, and unless and until we do, we will continue to need to raise additional capital. We believe the combination of our existing cash resources as of September 30, 2017 and the net proceeds from our October 2017 public offering, will enable us to fund future cash requirements for at least the next twelve months from the date of issuance of these unaudited consolidated financial statements. We expect our funding requirements for operating expenses to increase due to expenses associated with the commercialization of Keveyis, the execution of the Recorlev SONICS and LOGICS Phase 3 clinical trials, and our selling, general and administrative expenses. Our funding requirements will also increase to the extent we pursue potential in-licenses, acquisitions or similar transactions as part of our strategy. These expenses may be offset only in part by sales of Keveyis. To the extent our sales of Keveyis are less than we anticipate, or our expenses are higher than we anticipate, we may be required to fund our operations and capital needs through additional equity or debt financings. There can be no assurances, however, that additional funding will be available on terms acceptable to us.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies and basis of presentation

9 Months Ended

Sep. 30, 2017

Summary of significant accounting policies and basis of presentation

Summary of significant accounting policies and basis of presentation

2. Summary of significant accounting policies and basis of presentation

Basis of presentation

Revenue recognition

Inventory

Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Our inventory consists of only finished goods.

Foreign currency translation

The consolidated financial statements are reported in United States dollars, which is our functional currency, including each of our consolidated subsidiaries. Transactions in foreign currencies are remeasured into our functional currency at the rate of exchange prevailing at the date of the transaction. Any monetary assets and liabilities arising from these transactions are remeasured into our functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded in foreign exchange loss in our consolidated statements of operations.

Use of estimates

Net loss per share


	Nine Months Ended
	September 30,
	2017		2016
Warrants		7,764,569		—
Stock options issued and outstanding		6,176,647		3,264,927
Unvested restricted stock units		274,250		170,000

Recent accounting pronouncements

XML 19 R9.htm IDEA: XBRL DOCUMENT

Revenue recognition	9 Months Ended
Revenue recognition	Sep. 30, 2017
Revenue recognition
Revenue recognition	3. Revenue recognition Product Revenue, Net We sell Keveyis to one specialty pharmacy provider (the “Customer”), who is the exclusive distributor of Keveyis in the United States. The Customer subsequently resells Keveyis to patients, which are covered by payors that may provide for government-mandated or privately negotiated rebates with respect to the purchase of Keveyis. Revenues from sales of Keveyis are recognized when we satisfy a performance obligation by transferring control of Keveyis to the Customer. Transfer of control occurs upon receipt of Keveyis by the Customer. We expense incremental costs related to the set-up of the contract with the Customer when incurred, as these costs did not meet the criteria for capitalization. Reserves for Variable Consideration Revenues from sales of Keveyis are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from rebates, co-pay assistance and other allowances that are offered between us and the patients’ payors. There is no variable consideration reserve for returns as we do not accept returns of Keveyis. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than the Customer). Where appropriate, these estimates may take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. We reassess our estimates on an ongoing basis. If actual results in the future vary from our estimates, we will adjust our estimates. Any such adjustments would affect net product revenue and earnings in the period such variances become known. Trade Discount: We provide the Customer with a discount that is explicitly stated in our contract and is recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from the Customer. To the extent, the services received are distinct from our sale of Keveyis to the Customer, these payments are classified in selling, general and administrative expenses in our consolidated statement of operations and comprehensive loss. Funded Co-pay Assistance Program: We contract with a third-party to manage the co-pay assistance program intended to provide financial assistance to qualified insured patients. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that we expect to receive associated with Keveyis that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. These payments are consideration payable to the customer and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet. Government Rebates: We are subject to discount obligations under state Medicaid programs and Medicare. We estimate our Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated patient mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet. For Medicaid, accruals are based on estimates of future Medicaid beneficiary utilization applied to the Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. Effective January 1, 2011, manufacturers of pharmaceutical products are responsible for 50% of the patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap. In order to estimate the cost to us of this Medicare coverage gap responsibility, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program. Our liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for Keveyis that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. Temporary Supply and Patient Assistance Programs: We provide free Keveyis to uninsured patients who satisfy pre-established criteria for either the Temporary Supply Program or the Patient Assistance Program. Patients who meet the Temporary Supply Program eligibility criteria may receive a temporary supply of free Keveyis for no more than sixty days while we are determining the patient’s third-party insurance, prescription drug benefit or other third-party coverage for Keveyis. The Patient Assistance Program provides free Keveyis for up to twelve months to patients that satisfy pre-established criteria for financial need. We do not recognize any revenue related to these free products and the associated costs are classified in selling, general and administrative expenses in our consolidated statements of operations and comprehensive loss.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Fair value measurement

9 Months Ended

Sep. 30, 2017

Fair value measurement

Fair value measurement

4. Fair value measurement

The guidance requires fair value measurements to maximize the use of “observable inputs.” The three-level hierarchy of inputs to measure fair value are as follows:

The following table presents our assets and liabilities that are measured at fair value on a recurring basis for the periods presented (in thousands):


	As of September 30, 2017
	Level I		Level II		Level III		Total
Cash equivalents		43,756		—		—		43,756
Total assets	$	43,756	$	—	$	—	$	43,756
Warrant liability		—		—		39,284		39,284
Total liabilities	$	—	$	—	$	39,284	$	39,284


	As of December 31, 2016
	Level I		Level II		Level III		Total
Warrant liability		—		—		11,090		11,090
Total liabilities	$	—	$	—	$	11,090	$	11,090

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Intangible assets and goodwill

9 Months Ended

Sep. 30, 2017

Intangible assets and goodwill

Intangible assets and goodwill

5. Intangible assets and goodwill

The gross carrying amount of in‑process research and development (IPR&D), acquired developed product rights and goodwill is as follows (in thousands):


	As of September 30, 2017
	Beginning of Period		Additions		Amortization/Impairment		End of Period
IPR&D	$	20,723	$	—	$	(20,723)	$	—
Acquired developed product rights		40,177		—		(3,767)		36,410
Goodwill		7,256		—		—		7,256
Total	$	68,156	$	—	$	(24,490)	$	43,666


	As of December 31, 2016
	Beginning of Period		Additions		Impairment		End of Period
IPR&D	$	36,551	$	—	$	(15,828)	$	20,723
Acquired developed product rights		—		40,177		—		40,177
Goodwill		7,256		—		—		7,256
Total	$	43,807	$	40,177	$	(15,828)	$	68,156

We recorded amortization expense of $3.8 million and $0 for the nine months ended September 30, 2017 and 2016, respectively.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 22 R12.htm IDEA: XBRL DOCUMENT

Accrued liabilities

9 Months Ended

Sep. 30, 2017

Accrued liabilities

Accrued liabilities

6. Accrued liabilities

Accrued liabilities consist of the following (in thousands):


	September 30,		December 31,
	2017		2016
Consulting and professional fees	$	3,202	$	1,110
Accrued payable due Taro Pharmaceuticals Industries Ltd.		—		7,500
Supply agreement - current portion		3,432		4,207
Employee compensation		2,006		1,554
Other		153		497
Total accrued liabilities	$	8,793	$	14,868

XML 23 R13.htm IDEA: XBRL DOCUMENT

Long Term Debt

9 Months Ended

Sep. 30, 2017

Debt Disclosure

Long Term Debt

7. Long-Term debt

On July 14, 2017, we entered into a $50 million senior credit facility with CRG LP (“CRG”), a healthcare-focused investment firm, to retire our prior credit facility with Oxford Finance LLC and Horizon Technology Finance Corporation and provide additional capital to us. We initially borrowed $40 million under the term loan agreement and have the option to borrow an additional $10 million based upon the achievement of a certain revenue milestone on or prior to June 30, 2018. Concurrent with the initial borrowing, CRG purchased $3 million of our ordinary shares at a price of $6.98 per share. As a condition to the new credit facility, we issued warrants with a seven-year term to CRG to purchase 394,289 of our ordinary shares at an exercise price of $7.37 per share

In connection with the retirement of our prior credit facility we incurred a final payment fee of $1.6 million and a loss on early extinguishment of debt of $3.5 million.

Future principal payments due under the loan agreement are as follows (in thousands):


	Principal
	Payments

2017	$	—
2018		—
2019		—
2020		6,765
2021		13,530
2022		13,530
2023		6,522
Total future payments	$	40,347

XML 24 R14.htm IDEA: XBRL DOCUMENT

Commitments and contingencies

9 Months Ended

Sep. 30, 2017

Commitments and contingencies

Commitments and contingencies

8. Commitments and contingencies

(a) Lease obligations

As of September 30, 2017, future minimum commitments under facility operating leases were as follows (in thousands):


	Operating
	leases

2017	$	80
2018		319
2019		184
Total minimum lease payments	$	583

(b) Commitments to Taro Pharmaceuticals Industries Ltd.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Income taxes	9 Months Ended
Income taxes	Sep. 30, 2017
Income taxes
Income taxes	9. Income taxes Deferred tax assets and liabilities are recognized for the future tax consequences of differences between the carrying amounts and tax bases of assets and liabilities and operating loss carryforwards and other attributes using enacted rates expected to be in effect when those differences reverse. Valuation allowances are provided against deferred tax assets that are not more likely than not to be realized. We assess our ability to realize deferred tax assets. Changes in future earnings projections, among other factors, may cause us to adjust our valuation allowance on deferred tax assets. Any such adjustments would impact our income tax expense in the period in which it is determined that these factors have changed. For the nine months ended September 30, 2017, we recorded full valuation allowances against our deferred tax asset and deferred tax liability, resulting in income tax expense of $0.7 million.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Ordinary shares

9 Months Ended

Sep. 30, 2017

Ordinary shares.

Ordinary shares

10. Ordinary shares

Equity Transactions

Concurrent with the CRG credit facility, CRG purchased 429,799 shares of our ordinary shares at a price of $6.98 per share for total proceeds to us of approximately $3.0 million.

Warrants


		Exercise		Expiration	Warrants	Warrants	September 30,
	Classification	Price		Date	Issued	Exercised	2017
Warrants in connection with private equity placement	Liability	$	2.50	6/28/2022	7,000,000	—	7,000,000
Warrants in connection with Horizon and Oxford loan agreement	Equity	$	2.45	12/28/2026	428,571	(58,291)	370,280
Warrants in connection with CRG loan agreement	Equity	$	7.37	7/14/2024	394,289	—	394,289
					7,822,860		7,764,569

XML 27 R17.htm IDEA: XBRL DOCUMENT

Stock-based compensation

9 Months Ended

Sep. 30, 2017

Stock-based compensation

Stock based compensation

11. Stock‑based compensation

A summary of our outstanding stock options as of September 30, 2017 is as follows:


	Options Outstanding
				Weighted-
				Average
		Weighted-		Remaining
		Average		Contractual
	Number of	Exercise		Term	Aggregate
	Shares	Price		(Years)	Intrinsic Value
					(in thousands)
Outstanding—January 1, 2017	3,249,784	$	11.00	6.89	$	—
Granted	2,991,850	$	3.50
Forfeited and cancelled	(64,987)	$	7.37
Exercised	—		—
Outstanding—September 30, 2017	6,176,647	$	7.41	7.78	$	13,287
Vested and exercisable—September 30, 2017	2,034,974	$	10.38	5.61	$	2,249

Stock‑based compensation expense

We recognized stock‑based compensation expense for employees and directors for stock options and RSUs in the accompanying unaudited consolidated statements of operations as follows (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Selling, general and administrative	$	1,007	$	897	$	3,042	$	3,120
Research and development		324		205		822		401
Total stock-based compensation	$	1,331	$	1,102	$	3,864	$	3,521

The fair value of our service-based awards that were granted during the years was estimated with the following assumptions:


	Nine Months Ended
	September 30,
	2017	2016
Expected term (in years)	5.96	5.87
Risk-free interest rate	1.78% - 2.26%	1.3% - 1.6%
Expected volatility	78.2% - 105.9%	78.1% - 83.6%
Dividend rate	—%	—%

Restricted Stock Units

A summary of our unvested RSUs as of September 30, 2017 is as follows:


		Number of
		Shares
Unvested—January 1, 2017		184,000
Granted		92,250
Forfeited		(2,000)
Vested		—
Unvested—September 30, 2017		274,250

XML 28 R18.htm IDEA: XBRL DOCUMENT

Subsequent events	9 Months Ended
Subsequent events	Sep. 30, 2017
Subsequent events
Subsequent events	12. Subsequent Events On October 6, 2017, we sold 4,000,000 ordinary shares in a public offering at a price to the public of $6.25 per ordinary share for net proceeds of approximately $23.4 million, after deducting underwriting discounts and commissions and offering expenses payable by us.

XML 29 R19.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies and basis of presentation (Policies)

9 Months Ended

Sep. 30, 2017

Summary of significant accounting policies and basis of presentation

Basis of presentation

Revenue Recognition

Revenue recognition

Inventory

Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Our inventory consists of only finished goods.

Foreign currency translation

Use of estimates

Net loss per share


	Nine Months Ended
	September 30,
	2017		2016
Warrants		7,764,569		—
Stock options issued and outstanding		6,176,647		3,264,927
Unvested restricted stock units		274,250		170,000

Recent accounting pronouncements

XML 30 R20.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies and basis of presentation (Tables)

9 Months Ended

Sep. 30, 2017

Summary of significant accounting policies and basis of presentation

Schedule of potentially dilutive securities excluded from computations of diluted weighted average shares outstanding


	Nine Months Ended
	September 30,
	2017		2016
Warrants		7,764,569		—
Stock options issued and outstanding		6,176,647		3,264,927
Unvested restricted stock units		274,250		170,000

XML 31 R21.htm IDEA: XBRL DOCUMENT

Fair value measurement (Tables)

9 Months Ended

Sep. 30, 2017

Fair value measurement

Schedule of fair value of financial assets by level

The following table presents our assets and liabilities that are measured at fair value on a recurring basis for the periods presented (in thousands):


	As of September 30, 2017
	Level I		Level II		Level III		Total
Cash equivalents		43,756		—		—		43,756
Total assets	$	43,756	$	—	$	—	$	43,756
Warrant liability		—		—		39,284		39,284
Total liabilities	$	—	$	—	$	39,284	$	39,284


	As of December 31, 2016
	Level I		Level II		Level III		Total
Warrant liability		—		—		11,090		11,090
Total liabilities	$	—	$	—	$	11,090	$	11,090

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

XML 32 R22.htm IDEA: XBRL DOCUMENT

Intangible assets and goodwill (Tables)

9 Months Ended

Sep. 30, 2017

Intangible assets and goodwill

Schedule of gross carrying amount of in process research and development and goodwill

The gross carrying amount of in‑process research and development (IPR&D), acquired developed product rights and goodwill is as follows (in thousands):


	As of September 30, 2017
	Beginning of Period		Additions		Amortization/Impairment		End of Period
IPR&D	$	20,723	$	—	$	(20,723)	$	—
Acquired developed product rights		40,177		—		(3,767)		36,410
Goodwill		7,256		—		—		7,256
Total	$	68,156	$	—	$	(24,490)	$	43,666


	As of December 31, 2016
	Beginning of Period		Additions		Impairment		End of Period
IPR&D	$	36,551	$	—	$	(15,828)	$	20,723
Acquired developed product rights		—		40,177		—		40,177
Goodwill		7,256		—		—		7,256
Total	$	43,807	$	40,177	$	(15,828)	$	68,156

XML 33 R23.htm IDEA: XBRL DOCUMENT

Accrued liabilities (Tables)

9 Months Ended

Sep. 30, 2017

Accrued liabilities

Schedule of accrued liabilities

Accrued liabilities consist of the following (in thousands):


	September 30,		December 31,
	2017		2016
Consulting and professional fees	$	3,202	$	1,110
Accrued payable due Taro Pharmaceuticals Industries Ltd.		—		7,500
Supply agreement - current portion		3,432		4,207
Employee compensation		2,006		1,554
Other		153		497
Total accrued liabilities	$	8,793	$	14,868

XML 34 R24.htm IDEA: XBRL DOCUMENT

Long Term Debt (Tables)

9 Months Ended

Sep. 30, 2017

Debt Disclosure

Future principal payments

Future principal payments due under the loan agreement are as follows (in thousands):


	Principal
	Payments

2017	$	—
2018		—
2019		—
2020		6,765
2021		13,530
2022		13,530
2023		6,522
Total future payments	$	40,347

XML 35 R25.htm IDEA: XBRL DOCUMENT

Commitments and contingencies (Tables)

9 Months Ended

Sep. 30, 2017

Commitments and contingencies

Schedule of future minimum commitments under facility operating leases

As of September 30, 2017, future minimum commitments under facility operating leases were as follows (in thousands):


	Operating
	leases

2017	$	80
2018		319
2019		184
Total minimum lease payments	$	583

XML 36 R26.htm IDEA: XBRL DOCUMENT

Ordinary shares (Tables)

9 Months Ended

Sep. 30, 2017

Ordinary shares.

Schedule of warrants


		Exercise		Expiration	Warrants	Warrants	September 30,
	Classification	Price		Date	Issued	Exercised	2017
Warrants in connection with private equity placement	Liability	$	2.50	6/28/2022	7,000,000	—	7,000,000
Warrants in connection with Horizon and Oxford loan agreement	Equity	$	2.45	12/28/2026	428,571	(58,291)	370,280
Warrants in connection with CRG loan agreement	Equity	$	7.37	7/14/2024	394,289	—	394,289
					7,822,860		7,764,569

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 37 R27.htm IDEA: XBRL DOCUMENT

Stock-based compensation (Tables)

9 Months Ended

Sep. 30, 2017

Stock-based compensation

Schedule of summary of outstanding stock options activity


	Options Outstanding
				Weighted-
				Average
		Weighted-		Remaining
		Average		Contractual
	Number of	Exercise		Term	Aggregate
	Shares	Price		(Years)	Intrinsic Value
					(in thousands)
Outstanding—January 1, 2017	3,249,784	$	11.00	6.89	$	—
Granted	2,991,850	$	3.50
Forfeited and cancelled	(64,987)	$	7.37
Exercised	—		—
Outstanding—September 30, 2017	6,176,647	$	7.41	7.78	$	13,287
Vested and exercisable—September 30, 2017	2,034,974	$	10.38	5.61	$	2,249

Schedule of stock-based compensation

We recognized stock‑based compensation expense for employees and directors for stock options and RSUs in the accompanying unaudited consolidated statements of operations as follows (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Selling, general and administrative	$	1,007	$	897	$	3,042	$	3,120
Research and development		324		205		822		401
Total stock-based compensation	$	1,331	$	1,102	$	3,864	$	3,521

Schedule of assumptions for estimating fair value of stock option awards


	Nine Months Ended
	September 30,
	2017	2016
Expected term (in years)	5.96	5.87
Risk-free interest rate	1.78% - 2.26%	1.3% - 1.6%
Expected volatility	78.2% - 105.9%	78.1% - 83.6%
Dividend rate	—%	—%

Schedule of summary of unvested RSUs


		Number of
		Shares
Unvested—January 1, 2017		184,000
Granted		92,250
Forfeited		(2,000)
Vested		—
Unvested—September 30, 2017		274,250

XML 38 R28.htm IDEA: XBRL DOCUMENT

Organization - Products (Details)	Sep. 30, 2017 product
Organization
Number of clinical-stage product candidates	2

XML 39 R29.htm IDEA: XBRL DOCUMENT

Organization - Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Organization
Cash and cash equivalents	$ 44,366	$ 66,837	$ 25,469	$ 51,623

XML 40 R30.htm IDEA: XBRL DOCUMENT

Organization - Equity distribution agreement (Details) $ in Millions	Apr. 28, 2017 USD ($)
ATM Facility
Equity distribution agreement
Aggregate shares issuable (in dollars)	$ 40

XML 41 R31.htm IDEA: XBRL DOCUMENT

Organization - Credit facility (Details) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended
	Jul. 14, 2017	Sep. 30, 2017
Liquidity
Proceeds from long-term debt		$ 38,686
CRG credit facility
Liquidity
Maximum borrowing capacity	$ 50,000
Proceeds from long-term debt	40,000
Additional borrowing capacity on achievement of milestones	10,000
Concurrent with CRG credit facility borrowing
Liquidity
Gross proceeds from stock issuance	$ 3,000
Price per share (in dollars per share)	$ 6.98

XML 42 R32.htm IDEA: XBRL DOCUMENT

Organization - Public offering (Details) - Subsequent event $ / shares in Units, $ in Millions	Oct. 06, 2017 USD ($) $ / shares shares
Public offering
Issuance of shares in public offering (in shares) \| shares	4,000,000
Price per share (in dollars per share) \| $ / shares	$ 6.25
Issuance of shares in public offering \| $	$ 23.4

XML 43 R33.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies and basis of presentation - Antidilutive securities (Details) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Warrants
Net loss per share
Anti-dilutive shares of common stock (in shares)	7,764,569
Stock options
Net loss per share
Anti-dilutive shares of common stock (in shares)	6,176,647	3,264,927
RSUs
Net loss per share
Anti-dilutive shares of common stock (in shares)	274,250	170,000

XML 44 R34.htm IDEA: XBRL DOCUMENT

Revenue recognition - General (Details)	9 Months Ended
Revenue recognition - General (Details)	Sep. 30, 2017 pharmacy
Revenue recognition
Number of specialty pharmacy providers	1

XML 45 R35.htm IDEA: XBRL DOCUMENT

Revenue recognition - Allowance and Reserve (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2017 USD ($)
Revenue recognition
Reserve for returns	$ 0
Percentage of patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap for which manufacturers of pharmaceutical products are responsible	50.00%
Temporary supply period	60 days
Financial need period	12 months

XML 46 R36.htm IDEA: XBRL DOCUMENT

Fair value measurement (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Liabilities
Warrant liabilities	$ 39,284	$ 11,090
Recurring
Assets
Cash equivalents	43,756
Total Assets	43,756
Liabilities
Warrant liabilities	39,284	11,090
Total liabilities	39,284	11,090
Recurring \| Level I
Assets
Cash equivalents	43,756
Total Assets	43,756
Recurring \| Level III
Liabilities
Warrant liabilities	39,284	11,090
Total liabilities	$ 39,284	$ 11,090

XML 47 R37.htm IDEA: XBRL DOCUMENT

Intangible assets and goodwill - Components (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Sep. 30, 2017	Dec. 31, 2016
In-process research and development and Goodwill
Acquired product rights, Amortization	$ (1,256)	$ (3,767)
Goodwill, Beginning of Period		7,256	$ 7,256
Goodwill, End of Period	7,256	7,256	7,256
Total, Beginning of Period		68,156	43,807
Total, Additions			40,177
Amortization/Impairment		(24,490)
Total Impairment			(15,828)
Total, End of Period	43,666	43,666	68,156
Acquired product rights
In-process research and development and Goodwill
Acquired product rights, Beginning of Period		40,177
Acquired product rights, Additions			40,177
Acquired product rights, Amortization		(3,767)
Acquired product rights, End of Period	$ 36,410	36,410	40,177
IPR&D
In-process research and development and Goodwill
IPR&D, Beginning of Period		20,723	36,551
IPR&D, Impairment		$ (20,723)	(15,828)
IPR&D, End of Period			$ 20,723

XML 48 R38.htm IDEA: XBRL DOCUMENT

Intangible assets and goodwill - Asset purchase (Details) $ in Thousands	1 Months Ended		3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) payment	Sep. 30, 2017 USD ($)	Sep. 30, 2017 USD ($)	Dec. 31, 2016 USD ($) payment	Dec. 31, 2016 item	Dec. 31, 2016 USD ($)
In-process research and development and Goodwill
Amortization of intangible asset			$ 1,256	$ 3,767
Acquired product rights
In-process research and development and Goodwill
Acquired product rights			$ 36,410	36,410			$ 40,177
Transaction costs							2,400
Estimated life		8 years
Amortization of intangible asset				3,767
IPR&D
In-process research and development and Goodwill
IPR&D, Impairment				$ (20,723)	$ (15,828)
Asset Purchase Agreement \| Keveyis \| Taro \| Acquired product rights
In-process research and development and Goodwill
Number of installment payments		2			2	2
Installment payment	$ 7,500	$ 1,000
Supply Agreement \| Keveyis \| Taro \| Acquired product rights
In-process research and development and Goodwill
Acquired product rights							$ 29,300

XML 49 R39.htm IDEA: XBRL DOCUMENT

Accrued liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Accrued liabilities
Consulting and professional fees	$ 3,202	$ 1,110
Accrued payable due Taro Pharmaceuticals Industries Ltd		7,500
Supply agreement - current portion	3,432	4,207
Employee compensation	2,006	1,554
Other	153	497
Total accrued liabilities	$ 8,793	$ 14,868

XML 50 R40.htm IDEA: XBRL DOCUMENT

Long Term Debt - Agreements (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	9 Months Ended
	Jul. 14, 2017	Sep. 30, 2017	Sep. 30, 2017
Loan agreement
Proceeds from long-term debt			$ 38,686
Loss on early extinguishment of debt		$ (3,545)	$ (3,545)
CRG credit facility
Loan agreement
Maximum borrowing capacity	$ 50,000
Proceeds from long-term debt	40,000
Additional borrowing capacity on achievement of milestones	$ 10,000
Credit facility term	6 years
Interest-only payment period	3 years
Interest payment only extension period	6 years
Fixed interest rate (as a percent)	12.50%
Final payment fee (as a percent)	5.00%
Deferral percentage	4.00%
Debt discounts	$ 2,500
Debt issuance costs	800
Final payment fee	1,600
Loss on early extinguishment of debt	3,500
Concurrent with CRG credit facility borrowing
Loan agreement
Gross proceeds from stock issuance	$ 3,000
Price per share (in dollars per share)	$ 6.98
Warrants in connection with CRG credit facility
Loan agreement
Warrant term	7 years	7 years
Securities that warrants may purchase (in shares)	394,289	394,289	394,289
Warrant exercise price (in dollars per share)	$ 7.37	$ 7.37	$ 7.37

XML 51 R41.htm IDEA: XBRL DOCUMENT

Long Term Debt - Future principal payments (Details) $ in Thousands	Sep. 30, 2017 USD ($)
Future principal payments
2020	$ 6,765
2021	13,530
2022	13,530
2023	6,522
Total future payments	$ 40,347

XML 52 R42.htm IDEA: XBRL DOCUMENT

Commitments and contingencies - Lease (Details)	1 Months Ended	9 Months Ended
Commitments and contingencies - Lease (Details)	Mar. 31, 2015 ft²	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)
Future minimum commitments under facility operating leases
2017		$ 80,000
2018		319,000
2019		184,000
Total minimum lease payments		583,000
Rent expense		$ 226,000	$ 206,000
Building lease, March 2015
Lease
Lease term	52 months
Amount of space leased (in square feet) \| ft²	14,743

XML 53 R43.htm IDEA: XBRL DOCUMENT

Commitments and contingencies - Commitments to Taro (Details) - Acquired product rights - Taro - Keveyis $ in Millions	1 Months Ended
	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) payment	Dec. 31, 2016 item	Dec. 31, 2016 USD ($)
Asset Purchase Agreement
Other Commitments
Number of installment payments		2	2
Installment payment	$ 7.5	$ 1.0
Potential milestone payments				$ 7.5
Supply Agreement
Other Commitments
Minimum amount of purchases obligated				$ 29.0
Purchase obligation period		6 years

XML 54 R44.htm IDEA: XBRL DOCUMENT

Income taxes (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
Income taxes (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016
Components of income tax (benefit) provision
Income tax expense	$ (850)	$ 652	$ (926)

XML 55 R45.htm IDEA: XBRL DOCUMENT

Ordinary shares - Equity transactions (Details) - USD ($)			3 Months Ended	9 Months Ended
	Jul. 14, 2017	Apr. 28, 2017	Sep. 30, 2017	Sep. 30, 2017
Concurrent with CRG credit facility borrowing
Equity transactions
Price per share (in dollars per share)	$ 6.98
Gross proceeds from stock issuance	$ 3,000,000
Issuance of shares (in shares)	429,799
Issuance of shares, net of offering costs				$ 2,981,000
ATM Facility
Equity transactions
Aggregate shares issuable (in dollars)		$ 40,000,000
Sales commission (as a percent)		3.00%
Issuance of shares (in shares)			10,300
Issuance of shares, net of offering costs			$ 73,000	$ 73,000
Fees paid			$ 2,000

XML 56 R46.htm IDEA: XBRL DOCUMENT

Ordinary shares - Warrants (Details) - $ / shares		3 Months Ended	9 Months Ended
Ordinary shares - Warrants (Details) - $ / shares	Jul. 14, 2017	Sep. 30, 2017	Sep. 30, 2017
Warrants
Warrants Issued (in shares)		7,822,860	7,822,860
Warrants Outstanding (in shares)		7,764,569	7,764,569
Ordinary Shares
Warrants
Shares issued in exercise of warrants			37,219
Warrants in connection with private equity placement
Warrants
Exercise Price (in dollars per share)		$ 2.50	$ 2.50
Warrants Issued (in shares)		7,000,000	7,000,000
Warrants Outstanding (in shares)		7,000,000	7,000,000
Warrants in connection with Horizon and Oxford loan agreement
Warrants
Exercise Price (in dollars per share)		$ 2.45	$ 2.45
Warrants Issued (in shares)		428,571	428,571
Warrants Exercised (in shares)			(58,291)
Warrants Outstanding (in shares)		370,280	370,280
Warrants in connection with Horizon and Oxford loan agreement \| Ordinary Shares
Warrants
Shares issued in exercise of warrants		37,219
Warrants in connection with CRG credit facility
Warrants
Warrant term	7 years	7 years
Securities that warrants may purchase (in shares)	394,289	394,289	394,289
Exercise Price (in dollars per share)	$ 7.37	$ 7.37	$ 7.37
Warrants Issued (in shares)		394,289	394,289
Warrants Outstanding (in shares)		394,289	394,289

XML 57 R47.htm IDEA: XBRL DOCUMENT

Stock-based compensation - General (Details)	Sep. 30, 2017 shares
Inducement Plan
Stock-based compensation
Number of shares available for issuance	52,850
2015 Plan
Stock-based compensation
Number of shares available for issuance	374,289
Non-Employee Director Plan
Stock-based compensation
Number of shares available for issuance	792

XML 58 R48.htm IDEA: XBRL DOCUMENT

Stock-based compensation - Stock options (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Summary of outstanding stock options
Outstanding at beginning of period (in shares)	3,249,784
Granted (in shares)	2,991,850
Forfeited and cancelled (in shares)	(64,987)
Outstanding at end of period (in shares)	6,176,647	3,249,784
Vested and exercisable at end of period (in shares)	2,034,974
Weighted-Average Exercise Price
Granted (in dollars per share)	$ 3.50
Forfeited and cancelled (in dollars per share)	7.37
Outstanding (in dollars per share)	7.41	$ 11.00
Vested and exercisable at end of period (in dollars per share)	$ 10.38
Additional Disclosures - Options
Weighted Average Remaining Contractual Term, Outstanding	7 years 9 months 11 days	6 years 10 months 21 days
Weighted Average Remaining Contractual Term, Vested and exercisable	5 years 7 months 10 days
Aggregate Intrinsic Value, Outstanding (in dollars)	$ 13,287
Aggregate Intrinsic Value, Vested and exercisable at end of the period (in dollars)	$ 2,249

XML 59 R49.htm IDEA: XBRL DOCUMENT

Stock-based compensation - Options outstanding (Details) - $ / shares	9 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Stock options
Options outstanding (in shares)	6,176,647	3,249,784
Options outstanding, weighted-average exercise price (in dollars per share)	$ 7.41	$ 11.00
Vesting subject to acceleration
Stock options
Options outstanding (in shares)	88,908
Options outstanding, weighted-average exercise price (in dollars per share)	$ 18.80
Vesting subject to acceleration \| Grantee, Two
Stock options
Share price threshold	31.46
Vesting based on market appreciation event \| Grantee, Four
Stock options
Share price threshold	30.14
Vesting based on market appreciation event \| Grantee, Five
Stock options
Share price threshold	$ 33.66
Vesting based on market appreciation event \| Vesting at market appreciation event
Stock options
Options outstanding (in shares)	97,652
Consecutive trading days threshold	20 days
Vesting based on market appreciation event \| Vesting at one year anniversary of market appreciation event
Stock options
Options outstanding (in shares)	97,652
Vesting period following event	1 year
Consecutive trading days threshold	20 days

XML 60 R50.htm IDEA: XBRL DOCUMENT

Stock-based compensation - Stock-based compensation expense (Details) - Stock options - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Stock-based compensation expense
Total stock-based compensation	$ 1,331	$ 1,102	$ 3,864	$ 3,521
Total unrecognized compensation expense	10,300		$ 10,300
Estimated weighted average period over which expense is expected to be recognized			2 years 9 months 7 days
Selling, general and administrative
Stock-based compensation expense
Total stock-based compensation	1,007	897	$ 3,042	3,120
Research and development
Stock-based compensation expense
Total stock-based compensation	$ 324	$ 205	$ 822	$ 401

XML 61 R51.htm IDEA: XBRL DOCUMENT

Stock-based compensation - Fair value assumptions (Details)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Fair value assumptions
Expected term (in years)	5 years 11 months 16 days	5 years 10 months 13 days
Minimum Risk-free interest rate (as a percent)	1.78%	1.30%
Maximum Risk-free interest rate (as a percent)	2.26%	1.60%
Minimum Expected volatility (as a percent)	78.20%	78.10%
Maximum Expected volatility (as a percent)	105.90%	83.60%

XML 62 R52.htm IDEA: XBRL DOCUMENT

Stock-based compensation - Restricted stock units (Details) - RSUs - USD ($)		3 Months Ended		9 Months Ended
	Feb. 26, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Stock-based compensation
Vesting period	2 years
Number of shares issued for each stock award vested	1
Stock-based compensation		$ 124,000	$ 84,000	$ 309,000	$ 197,000
Total unrecognized compensation expense		$ 600,000		$ 600,000
Estimated weighted average period over which expense is expected to be recognized				1 year 5 months 27 days
Summary of unvested RSUs
Unvested - Beginning of period (in shares)				184,000
Granted (in shares)				92,250
Forfeited (in shares)				(2,000)
Unvested - End of period (in shares)		274,250		274,250

XML 63 R53.htm IDEA: XBRL DOCUMENT

Subsequent events (Details) - Subsequent event $ / shares in Units, $ in Millions	Oct. 06, 2017 USD ($) $ / shares shares
Subsequent events
Issuance of shares in public offering (in shares) \| shares	4,000,000
Price per share (in dollars per share) \| $ / shares	$ 6.25
Issuance of shares in public offering \| $	$ 23.4

EXCEL 64 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 66 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 102 221 1 false 40 0 false 9 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.strongbridgebio.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Consolidated Balance Sheets Sheet http://www.strongbridgebio.com/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.strongbridgebio.com/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.strongbridgebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00300 - Statement - Consolidated Statement of Stockholders??? (Deficit) Equity Sheet http://www.strongbridgebio.com/role/StatementConsolidatedStatementOfStockholdersDeficitEquity Consolidated Statement of Stockholders??? (Deficit) Equity Statements 5 false false R6.htm 00400 - Statement - Consolidated Statements of Cash Flow Sheet http://www.strongbridgebio.com/role/StatementConsolidatedStatementsOfCashFlow Consolidated Statements of Cash Flow Statements 6 false false R7.htm 10101 - Disclosure - Organization Sheet http://www.strongbridgebio.com/role/DisclosureOrganization Organization Notes 7 false false R8.htm 10201 - Disclosure - Summary of significant accounting policies and basis of presentation Sheet http://www.strongbridgebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation Summary of significant accounting policies and basis of presentation Notes 8 false false R9.htm 10301 - Disclosure - Revenue recognition Sheet http://www.strongbridgebio.com/role/DisclosureRevenueRecognition Revenue recognition Notes 9 false false R10.htm 10401 - Disclosure - Fair value measurement Sheet http://www.strongbridgebio.com/role/DisclosureFairValueMeasurement Fair value measurement Notes 10 false false R11.htm 10501 - Disclosure - Intangible assets and goodwill Sheet http://www.strongbridgebio.com/role/DisclosureIntangibleAssetsAndGoodwill Intangible assets and goodwill Notes 11 false false R12.htm 10601 - Disclosure - Accrued liabilities Sheet http://www.strongbridgebio.com/role/DisclosureAccruedLiabilities Accrued liabilities Notes 12 false false R13.htm 10701 - Disclosure - Long Term Debt Sheet http://www.strongbridgebio.com/role/DisclosureLongTermDebt Long Term Debt Notes 13 false false R14.htm 10801 - Disclosure - Commitments and contingencies Sheet http://www.strongbridgebio.com/role/DisclosureCommitmentsAndContingencies Commitments and contingencies Notes 14 false false R15.htm 10901 - Disclosure - Income taxes Sheet http://www.strongbridgebio.com/role/DisclosureIncomeTaxes Income taxes Notes 15 false false R16.htm 11001 - Disclosure - Ordinary shares Sheet http://www.strongbridgebio.com/role/DisclosureOrdinaryShares Ordinary shares Notes 16 false false R17.htm 11101 - Disclosure - Stock-based compensation Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensation Stock-based compensation Notes 17 false false R18.htm 11201 - Disclosure - Subsequent events Sheet http://www.strongbridgebio.com/role/DisclosureSubsequentEvents Subsequent events Notes 18 false false R19.htm 20202 - Disclosure - Summary of significant accounting policies and basis of presentation (Policies) Sheet http://www.strongbridgebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies Summary of significant accounting policies and basis of presentation (Policies) Policies 19 false false R20.htm 30203 - Disclosure - Summary of significant accounting policies and basis of presentation (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables Summary of significant accounting policies and basis of presentation (Tables) Tables http://www.strongbridgebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation 20 false false R21.htm 30403 - Disclosure - Fair value measurement (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureFairValueMeasurementTables Fair value measurement (Tables) Tables http://www.strongbridgebio.com/role/DisclosureFairValueMeasurement 21 false false R22.htm 30503 - Disclosure - Intangible assets and goodwill (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureIntangibleAssetsAndGoodwillTables Intangible assets and goodwill (Tables) Tables http://www.strongbridgebio.com/role/DisclosureIntangibleAssetsAndGoodwill 22 false false R23.htm 30603 - Disclosure - Accrued liabilities (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureAccruedLiabilitiesTables Accrued liabilities (Tables) Tables http://www.strongbridgebio.com/role/DisclosureAccruedLiabilities 23 false false R24.htm 30703 - Disclosure - Long Term Debt (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureLongTermDebtTables Long Term Debt (Tables) Tables http://www.strongbridgebio.com/role/DisclosureLongTermDebt 24 false false R25.htm 30803 - Disclosure - Commitments and contingencies (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and contingencies (Tables) Tables http://www.strongbridgebio.com/role/DisclosureCommitmentsAndContingencies 25 false false R26.htm 31003 - Disclosure - Ordinary shares (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureOrdinarySharesTables Ordinary shares (Tables) Tables http://www.strongbridgebio.com/role/DisclosureOrdinaryShares 26 false false R27.htm 31103 - Disclosure - Stock-based compensation (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationTables Stock-based compensation (Tables) Tables http://www.strongbridgebio.com/role/DisclosureStockBasedCompensation 27 false false R28.htm 40101 - Disclosure - Organization - Products (Details) Sheet http://www.strongbridgebio.com/role/DisclosureOrganizationProductsDetails Organization - Products (Details) Details 28 false false R29.htm 40102 - Disclosure - Organization - Cash (Details) Sheet http://www.strongbridgebio.com/role/DisclosureOrganizationCashDetails Organization - Cash (Details) Details 29 false false R30.htm 40103 - Disclosure - Organization - Equity distribution agreement (Details) Sheet http://www.strongbridgebio.com/role/DisclosureOrganizationEquityDistributionAgreementDetails Organization - Equity distribution agreement (Details) Details 30 false false R31.htm 40104 - Disclosure - Organization - Credit facility (Details) Sheet http://www.strongbridgebio.com/role/DisclosureOrganizationCreditFacilityDetails Organization - Credit facility (Details) Details 31 false false R32.htm 40105 - Disclosure - Organization - Public offering (Details) Sheet http://www.strongbridgebio.com/role/DisclosureOrganizationPublicOfferingDetails Organization - Public offering (Details) Details 32 false false R33.htm 40201 - Disclosure - Summary of significant accounting policies and basis of presentation - Antidilutive securities (Details) Sheet http://www.strongbridgebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAntidilutiveSecuritiesDetails Summary of significant accounting policies and basis of presentation - Antidilutive securities (Details) Details 33 false false R34.htm 40301 - Disclosure - Revenue recognition - General (Details) Sheet http://www.strongbridgebio.com/role/DisclosureRevenueRecognitionGeneralDetails Revenue recognition - General (Details) Details 34 false false R35.htm 40302 - Disclosure - Revenue recognition - Allowance and Reserve (Details) Sheet http://www.strongbridgebio.com/role/DisclosureRevenueRecognitionAllowanceAndReserveDetails Revenue recognition - Allowance and Reserve (Details) Details 35 false false R36.htm 40401 - Disclosure - Fair value measurement (Details) Sheet http://www.strongbridgebio.com/role/DisclosureFairValueMeasurementDetails Fair value measurement (Details) Details http://www.strongbridgebio.com/role/DisclosureFairValueMeasurementTables 36 false false R37.htm 40501 - Disclosure - Intangible assets and goodwill - Components (Details) Sheet http://www.strongbridgebio.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails Intangible assets and goodwill - Components (Details) Details 37 false false R38.htm 40502 - Disclosure - Intangible assets and goodwill - Asset purchase (Details) Sheet http://www.strongbridgebio.com/role/DisclosureIntangibleAssetsAndGoodwillAssetPurchaseDetails Intangible assets and goodwill - Asset purchase (Details) Details 38 false false R39.htm 40601 - Disclosure - Accrued liabilities (Details) Sheet http://www.strongbridgebio.com/role/DisclosureAccruedLiabilitiesDetails Accrued liabilities (Details) Details http://www.strongbridgebio.com/role/DisclosureAccruedLiabilitiesTables 39 false false R40.htm 40701 - Disclosure - Long Term Debt - Agreements (Details) Sheet http://www.strongbridgebio.com/role/DisclosureLongTermDebtAgreementsDetails Long Term Debt - Agreements (Details) Details 40 false false R41.htm 40702 - Disclosure - Long Term Debt - Future principal payments (Details) Sheet http://www.strongbridgebio.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails Long Term Debt - Future principal payments (Details) Details 41 false false R42.htm 40801 - Disclosure - Commitments and contingencies - Lease (Details) Sheet http://www.strongbridgebio.com/role/DisclosureCommitmentsAndContingenciesLeaseDetails Commitments and contingencies - Lease (Details) Details 42 false false R43.htm 40802 - Disclosure - Commitments and contingencies - Commitments to Taro (Details) Sheet http://www.strongbridgebio.com/role/DisclosureCommitmentsAndContingenciesCommitmentsToTaroDetails Commitments and contingencies - Commitments to Taro (Details) Details 43 false false R44.htm 40901 - Disclosure - Income taxes (Details) Sheet http://www.strongbridgebio.com/role/DisclosureIncomeTaxesDetails Income taxes (Details) Details http://www.strongbridgebio.com/role/DisclosureIncomeTaxes 44 false false R45.htm 41001 - Disclosure - Ordinary shares - Equity transactions (Details) Sheet http://www.strongbridgebio.com/role/DisclosureOrdinarySharesEquityTransactionsDetails Ordinary shares - Equity transactions (Details) Details 45 false false R46.htm 41002 - Disclosure - Ordinary shares - Warrants (Details) Sheet http://www.strongbridgebio.com/role/DisclosureOrdinarySharesWarrantsDetails Ordinary shares - Warrants (Details) Details 46 false false R47.htm 41101 - Disclosure - Stock-based compensation - General (Details) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationGeneralDetails Stock-based compensation - General (Details) Details 47 false false R48.htm 41102 - Disclosure - Stock-based compensation - Stock options (Details) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationStockOptionsDetails Stock-based compensation - Stock options (Details) Details 48 false false R49.htm 41103 - Disclosure - Stock-based compensation - Options outstanding (Details) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails Stock-based compensation - Options outstanding (Details) Details 49 false false R50.htm 41104 - Disclosure - Stock-based compensation - Stock-based compensation expense (Details) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails Stock-based compensation - Stock-based compensation expense (Details) Details 50 false false R51.htm 41105 - Disclosure - Stock-based compensation - Fair value assumptions (Details) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationFairValueAssumptionsDetails Stock-based compensation - Fair value assumptions (Details) Details 51 false false R52.htm 41106 - Disclosure - Stock-based compensation - Restricted stock units (Details) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails Stock-based compensation - Restricted stock units (Details) Details 52 false false R53.htm 41201 - Disclosure - Subsequent events (Details) Sheet http://www.strongbridgebio.com/role/DisclosureSubsequentEventsDetails Subsequent events (Details) Details http://www.strongbridgebio.com/role/DisclosureSubsequentEvents 53 false false All Reports Book All Reports sbbp-20170930.xml sbbp-20170930.xsd sbbp-20170930_cal.xml sbbp-20170930_def.xml sbbp-20170930_lab.xml sbbp-20170930_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 70 0001558370-17-008889-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-17-008889-xbrl.zip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
MA"IVD!Y6R9['4P-YMD+6U_VG6(2=O.:IP!;^S0N[%ADL[[R]JO)S3$I@MT;F M"+U/"<)O'!J&!WDQ79L*CHX9+D@@FH:B/DD)0]=KT.YFR'F MI!WSX832AH9K(1E=4^Y',6'IRQ%Q0*@GH8,I.9)RBJ=G'-_X@9]-7\GO_"!6 MYYW@>4NUB!6?[!MU1"HZ1#&#PTZ.A.U0?D[1=TM]'[0(-"-%4E(GJ=*X9#Y; M\5C9*]K#T1?);^(I#L=HS:8[,.+QC*AM!F'.-'22ORQL<,**DQJ"37G]W/XAD=_;L3$ M*N92H'Y/#[+,5!D.UC='ZJRFBIX\\5/2%GN0:B+ZX,_Z\)P9V27<+#WG,X;> M^7,V&G62DK?X@L^XRI9]57NA1JK@4Y#D*!I6]&WZ(<6MUJKK$49C)\3AA;GL MG>OR)QQ@P9;P&'NY87IY?7SE;TX=>\"(0@HI18]DZN\II'Y$Y=H:7F,H#2L, M^B#UT58J9P%&4P?L48:Q_/TW*USA 4XL4SM1FF^2"15"<_Y)!@E24)X(W+V% M^*,#%,1O5'UJE7Q25$3C?1BJ;(WXM-%^NTTS2'&NR,0!S/@FE4;3."R(QD,^ M_V(CEAE=;UU)ITQ)#,>.?XK8:N_=\E5E 6NSKDA1LHL!S(X@Y_T0QS.MQ!_E M*/*"*$X$6-F):R8QPE44\ZV\ENR5*#IAD3S'"??PXE2P8E$DMPZN&8LN8-ZI M?NR]J1-R[S93NE SK[8'8H\V%+S[X4I)GNCT"3!8D(2%I3?2QU7[ H(QM=L( M,=M.UW[%!JW$DVBBU1(Z#D1*@Q637DB]M*7:^5JEL0OZU8JY!MW+LR8[X,^R M1!;-EBI+ZLF#4M&&B>C;A74&/*2S]/A:RJNO1C9AL%]O8(<\:2F=@!YD]0UX MLP<6*_!T-DW6/*<+H:D7+>-;-H7"0C6RD[6,C87+=+JG8P">>GJB89 ^(Y^\ MYAC!Q=-]%(?P8L!M/.1!U%,EU7MKY^N0R<=(RB.:MGWG!9GU)J@!SO*.\X// M!CWP@BB'%(#O,Y4-D)6+DN?^:*K,M[!2DJDAX1<>I)[DR2*E(H%B2,GI%'EV M2GNJXPUX)Y!,BA[!0VE0^2CYE=PQ@_I)'@EV$L*%HL[! :E6Q O\-0N_L0[? M(WW94A!7O$C&;-S8MN;>U+2V>#P:<.3L>'396[9>;7=><& L>1A9,T;]RM6D M'U*,;ZVZOGYM[(1X"6LN>^=D3,+A+'W#NN#^5A>RTRD/MQS@&"NUZ]EWL/]Q MBG'U;MW8";E/FRFM.W1]#\3>;"AXU]$LR9/2:=RJ'T^AMCVGO63+&#;K0QF@ M1PU/.%2W1NZF#6KJ_EG1%+%C-DG<=6@"7:(1MO[HPEB*W@;4SZ/E 7,;%QZ- MHKO5SV+52?WX+GR @97GW=@OO)V^XOBC%9,A$:,K@\Q$*'1S)!(=,6-&L2A*JL!EPPXB',ME_0 ML^[3?"?)!:SPHSS)/8X14=R'+UN)+DV6ZIF>='^&Q6Q7< M4<]C[H=#TBY*&E8= .Y/%2F.#VRVPEN5_4@B#L>&TFP$N,E/WN=R$"4(61[2 M#E'6P]+Y9-L6U(PC9\N7U"Y;>B [H>X&*E"\$1-EM*'" B=5>"P#VI6:[ME] MR!V6_3&S3U55NJZTY@A>IB9JA*PF0G,#*F-]1HF&%&\BF6MM<"+2Z*9*+<12 MN^RD70!XW,#S:!A!>0 %0N-4 C,H!6C'-$=#Q[8@3R4K'QMYLT&TNPB9"Q5(J /Y\$/G95U%XJPH\8TO MR+,HOO.]0XDOF?5 ZE0MU,UR9/7-L2?'#*7OF153-7HD:1((VNDU1/$/XH)K M\DP$L@S",'B!>C\R^_6%)+]&_@XG^)=R(,#" AI.H71*\*PPY'9#%^^LUN+J M<\Q\.,_>'B>/N\X3,$L-8("D59UWLV*TTC)8:'"&"W((HAR3EB6)V.:I%K_ED6XTS,$,*F^1L:$0HP 4PZ MI8R,@K1K[E,O*;QRS5BEV[?LBM3ANQB@(DBK[#>O(*U9C<[5)T1TM&(,"JQ# MQ 172_0A+5AD14U4R1,5F(EF>]^5Y7+9<>RV(/M=H"Z40*UV+YULYA ;O@[U"=+0$7%50-*#XZ*PI*5DFC''+[B<'E6KC%0 M+#1',E93*)FRQ 23HYL$2 )<5JIL:Y7YDT]5&6_F7O)(5BDSBKW+^R&%SM:J M5R\E2SK-9@59)_M@WJXQ(2D7#(O%T91W$VH6*[FED'4M'TMBLE)=WW1 MNW"#JD77K6B,VF6;9.[GJE&TE]4+).$QGX0V\,]1->6IIIW++'9)UK1>DN%U M.7-ES=(Q\UI25 G?OX;LZF3EG#XME-4-*:D,HC:V8AZJ,@V"CE,\5X,IX3)! MFL7ZFF%HE4\2*O;BB=O 7\..&RC\X?"1QG#$_=!PX;>Q$U*8:Z>T'E[4]T < M8Q@*WOV.K+\^@U-^!!B [T;PT-G?H011RLSZ!>&1;7"]%P3E*6S?X;O=8NE*Z]5ABV:B?M@B M"+TJ;-'UL8(M0H"Y8,L0MA+8\F[ !$IK)1[YY[+U6$3ILR 4[( K]V43>:(?XXWHK-<;\F2KZO \^3):K4E#;UBO<&WY.IS\MRUW-?F6TF>^OY>[5?* M%Z5?-LS/_I[^4LF?'+4.X)EJ\2D]62Y_MPL#ZFP6JN!,PO6T;N[$*2LK8ZC/ M/"/X6TAS63&3F&*^MSK%L&WU13T.KU3S9T%2=' MG"+0_%\SSH SSB!#J=>< Q+,8M89Q%1BWGF/(VUBL.+#.ZO4*525NYA)2F)@ M;QS'M8*8>J9Y@_ZW"(";F(74#H?U?8U'9\/*GV V MJS"+85?D3M?& +HSFO1#[*2MQ.]ID'W/"E3?J1%9=4 M+49_< ./@1!"PW,H>[96Z[FBVA%,W'>KB\"O/7[3E1AR-^]GI$+LV8D28ECH MJ5!WKP&VB^/I4%4M@WDRY61IB\R65:#0:VRU9/5YR.C=ZH%1[RJ"^_#W(3SN M%A\J+%73'#DH-"E:>-6YHBUBQVX4N7..41 &#P721-$F*7%+;SB/IFJ63HUV MU&'$4Z&-K,3\CSUD$E>,=;NF/$;0'JD#@Q^YS[?[;7*L.+K:\$P/X$=$<$5ZL'=JFR46VB86%;X-']I58*1Q929B8T>V)9R4.!NI;XS?.8>-J^B]PKPJ-94;9&IE-C, M,:I>I]'1"G:]$@$@(-!@"R]$C6,RP /@E 7;/4I1F=5P SI:;I M$/CD1&8.*^6Z3 G@C%LF O6$D4L7:">WD3"K_\X!_@07-DP *)3>C40 M;B"2D7D5,'*JS81 LSG 27#F4EX^0_HP:2?O5X-:/0 BOF#P[1I%3L'A*8R MA3H[E"9+9!X$P1&B(^T?A#17JB;')V:8>3WI,R_'+U>YQMV+'>;CY!5R#^?: MP( D'!9$\$ QHP^LME0R*5N#X>3?!3SHM@Q XV>F;_J>^^XGX0P5?WX2/T54 M5MDQ/"<94-2&Z:/9/ M1 Y@W]N&\Y,#LT".!F,8M/!@[H#T$2/ *&IV]?T!_?VV^J3HA%$\7("[R/=? MFXY.5#='[HQ-BA;"]HJVB)VD4>3.P;J\(:E1MG]883)5![Q<705B'[G'HCCP M69HPN ]B\1].2R_\=:*"U#%[FB6[4-V>!/;+U#TTZKXV+;P&2+.#@+N4199Q M2IYP"/:>"X\X["C7'W H3GYT'3(I^L1WB"U8L#(P6)",:YZSS/A:N#5LP3@9 M);+-;&$_@WDO[+H1\MTM/;XN\\;:ADAAM5DY/=(Y;84XQJD1MO/ 3$B2G*:= MH&8$W=*-$@W,$R81"10;-N2KR56XHEX,OULUNEMW*DA]L:=9&D.<:A)S#7$, M-!HHQ,E?7([YEB6QRW9'_0/AFG^0.,C!R9N$[S<+DK,F.6_K:2@;=KH0 M,Y18.R6%J+BR6BRL]F:96 OFJ&<>E:!NC\CNZA]['A_4FT-"L2JL:&J+% V, M5,QBL:J&V".N1KF[CLE/ 3SD*=8:2?2, MM2VJ 1$D?QCT;O5(/2:3[%%4,59K6V-&D68U,QRI;HH=20PD[QQ#%QX-C@1Q M=3=44E>I9K$>D[\7;?RXZB7V-3R)!U.APY@;30Q%MNQC 8U&5!7(1?K7[_]4 M^C!KJB3<>V!0,-5]"BZY0&"^W(.[W(6/+'SF@,SGOOL3I E>H"BGO[YFK.I0 M3"^"2-%P.&/I"ZWNU!"OMP90JO.Q'4G<6L[( >09F4+)^(J6R,& .A M.^<+@#2$"@EQ\&A)'L%ITS*M;YO.CS9UFN-H/E&Z<43?SN'4IIG@(XSL6]L5 M.$=6/:$[Z.FT,HE3/C?R283271:C;DA]LJWB^6YL?]S,8VY9C?Z^]-'CAF#F[+\_GY/XHA1:'@= MA[BM+_F
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
!]U00ZRKGW?'7[VC4++&2:&OQQS@Q <,X M#Y;"'T_SNY0:&F<0I*IXP[_"Q[NR>N8[, ;)AVX6Y7GE1# :C8ORY#0?QV7SD8]*GJF)UN/VG-7 O5D^EM)M5:V;@U$UFOa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end